var title_f14_42_15008="Pressures mitral stenosis I";
var content_f14_42_15008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pressure tracings in mitral stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 182px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pressures in a patient with mitral stenosis are recorded simultaneously from the left atrium (LA) and left ventricle (LV). There is a persistent pressure gradient throughout all of diastole (shaded area) as LA pressure is higher than that in the LV due to significant mitral stenosis. The pressure gradient is greatest during the initial part of diastole, is reduced during diastole as blood flows from LA into LV, and then increases at the end of diastole as a result of atrial contaction (A wave).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Kern MJ (Ed). Hemodynamic Rounds: Interpretation of Cardiac Pathophysiology from Pressure Waveform Analysis. Wiley-Liss, New York, 1993.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_42_15008=[""].join("\n");
var outline_f14_42_15008=null;
var title_f14_42_15009="Removal of vulvar skin";
var content_f14_42_15009=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skinning vulvectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The vulva skin is dissected off the underlying fat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_42_15009=[""].join("\n");
var outline_f14_42_15009=null;
var title_f14_42_15010="Abdomen CT of child with B henselae";
var content_f14_42_15010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography of the abdomen in a child with visceral involvement of Bartonella henselae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography of the abdomen showing multiple hypodense lesions in the liver and spleen of a child with prolonged fever, abdominal pain, and positive B. henselae serology.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sheldon L Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_42_15010=[""].join("\n");
var outline_f14_42_15010=null;
var title_f14_42_15011="CT locally advanced bladder CA";
var content_f14_42_15011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Locally advanced bladder cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDy3xP45F9pcllc+H7uK7naOVb2YbpVbcrFYwRtVdoyNoHXpiue03VbuHwRrttDba0wvW8wzq3+jCHeM7128kso+bPGMDGTVzxH8TrzXNKtdNu7JVgtVgSNo52DJ5UcceVP8JIjycf3jVe3+I9zD4Vh0YaZaZhspLGOcZ+65bLlTkb8OwDLtPPOelAHC72/vH86N7f3j+dNooAdvb+8fzo3t/eP502igB29v7x/Oje394/nTaKAHb2/vH86N7f3j+dNooAdvb+8fzo3t/eP502igB29v7x/Oje394/nTaKAHb2/vH86N7f3j+dNooAdvb+8fzo3t/eP50gGelSrbTt92GU59ENAEe9v7x/Oje394/nVkadesCRaz4HX5DTv7Kvyu4WdwR6iM0AVCzEck/nSDjpVptOvlGWs7kD3ib/Cq7xSRnDoyn3GKAG5PqaMn1pKKAFyfU0ZPrSUUALmjcfU0lFAC7j6mjJ9TSUUALk+poyfU0lFAGp4X/5GbSf+vyH/ANDFfo144/5Jp4g/7BFx/wCiWr85PC//ACM2kf8AX5D/AOhiv0b8cf8AJM/EH/YIuP8A0S1AH5p7m9T+dG9v7x/Om0UAO3t/eP50b2/vH86bRQA7e394/nRvb+8fzptFADt7f3j+dG9v7x/Om0UAO3t/eP50b2/vH86bRQA7e394/nRvb+8fzptFADt7f3j+dG9v7x/Om0UAa+jyulnfkMc7V/nVS+md2Qlj0qfSv+PG++ifzqpd9V+lAEO9v7x/Oje394/nTaKAHb2/vH86N7f3j+dNooAdvb+8fzo3t/eP502igB29v7x/Oje394/nTaKAHb2/vH86N7f3j+dNooAdvb+8fzo3t/eP502igB6M29fmPX1opE++v1ooAH++31ptOf77fWm0AFFFFABRRRQAUUUUAFFFFABRV3StMvdWu1ttOt3nmPZRwB6k9APc11KeH9I0cgatcnULsdYLVsRr7F+p/DFAHFojSMFjVmY9ABk1fi0TU5F3JYXJX1MZFdW+uSRERaXb29jF2EMYBP1PU1n3F9cys3mXMpJ9XNAGXa+H7yQk3Ci3jAyWk/oKvRWmm2m3MT3cnq52rn6CmuZDkvISO+T0qucnHzjjpQBrJqskIYQw28KDgBIxmlbUb113yXDK5xhRxWaoyck49BTsEDdn1GaALi30jW2C8vml+X3nkfSo0vbkD5Z5Rg4xuOKrl8RE4xT4lCxjHU8k+1AF+DUb6KQFbubv/ETU66/qCKy+dvXn5XUMPpzVBWwdzevA9aiY5BAONxz+FAGhJqVrcEC+0mxm9WRPLbH1Wqz6d4dvD+7kvNPc/wB7EqD+Rqg5IbkYB6imMwbCnigDP1ayWwvWgjuI7lAAVkjzggj3qlVm/wD+Pk/QVWoAKKKKACiiigAooooA0/C//IzaR/1+Q/8AoYr9G/HH/JM/EH/YIuP/AES1fnJ4X/5GbSP+vyH/ANDFfo344/5Jn4g/7BFx/wCiWoA/NGiiigAooooAKKKKACiiigAooooAKKKKACiiigDV0hHeyv8AYpbaqk47DPWqd4CCuQRXU/C/wnrPjLWp9L8PSRJcmEyP5smxSg6ip/ip4G1zwLf2Nr4ia3aa5iaWPyZN42g45oA4aiiigAooooAKKKKACiiigAooooAKKKKAHJ99frRQn31+tFAA/wB9vrTac/32+tNoAKKKKACiiigAoorY8N+H77xBeGGyQCOMbpp3OEiX1Y/070AZltBLdTpDbxvLM5wqIMkn6V2Vn4UsdLMb+J7rEx5+w25y4H+23QfQc1sm80vwpZyWeiQi4v5F2vfPw3P930HtXKF2kkLOSZCdxY80AbeoeIHW1+w6NDFp1hnmOEcv7s3U/jWEDuIJJxRjIOO9Ki4GxepPP/1qAHxse2Ovf602WPDE9V9jQwSMDcct2A6Ggyg8sMj2oAZJGc5c/J2qAgK5yOo4+taCJHJy+QT+IxTJYMghV6c5HegCpFkuN3IxzVhVDEBRwemelVipQEOCpFW9PHmvhjgfw/WgA2dAwXGBUhboikD1NPmQxxszKcnjBqtuYydRnuaAJ8KFLAcjjNQSc545HaraDgcAg849TVWYrHncdzdvagCI5CNJIwzziotoIyAT7Ujtvbn/APVUig4yRQBl6nj7UcdNo/lVSrep/wDH23OeBVSgAooooAKKKKACiiigDT8L/wDIzaR/1+Q/+hiv0b8cf8kz8Qf9gi4/9EtX5yeF/wDkZtI/6/If/QxX6N+OP+SaeIP+wRcf+iWoA/NGivp74Q+DfDOp/D+xu9S0Gwu7pzJumlVixwxx0NeFatbWEerzon2eOJJXXYEb5ecAdaAOWorclNqyMVhtwykgBVIz+tUPKT+6KAKVFXfKT+6KPKT+6KAKVFXfKT+6KPKT+6KAKVXrNQlneXDAHCiJM/3mP/xIb86Tyk/uirtzGkVhaw7R8+ZmH14H6DP41E+i7nVhlbmqP7Kf3vRfde/yMWirvlJ/dFSQrCkqtJEHUdVzjNWcpnUVrZtPOZvso2Hom7p+NS6fDbOXDWySHPG5yOKAPWP2Q5xb/Ei6kK7sWMnH4itX9sy5+0+KfDjbduLJx1/6aGs79nbZaeNZJbaJYy1pMCBk/wAQrS/aXnW51bSTcGAOLZwrOmf4u1AHztRXQq9tHGiD7K5YYYmI5X8apXHll8IiYXgEDrQBl0Vf2r/dH5UbV/uj8qAKFFX9q/3R+VG1f7o/KgChVy7jSG0tF2jzXUyse+CcAfkM/jU0MPmypGijc7BRx3NTai0cl5KYwDGp2Jx/CowP0FQ3eSR000o0ZzfWyX5t/KyXzMeir+1f7o/Kjav90flVnMUKK12e3NuqC3AkBGXz1o3W5ljYQAKD8y54NAGUn31+tFdTbRQG4jX7LEpw3IO7PymigDln++31ptOf77fWm0AFFFFABRRWt4Z0O417U0tbfCRj5ppm+7Endif85oAs+EfDc3iC7fMgttPtwHubp/uxr7erHsK6bW9ZhSwXRtBQ22lRHns87d3c9yaTXNWgjso9E0NWi0u3zlj96d+7se5NYAXK57Edu1ACkBjk5IHenIqk88A+tPRSEDNxnr7U0HLYbkCgBp2HHbnvQ/KYHQ0RRNNMFRSzngDFdRp/hN2h8/UZPKh7Lnk0AcgyscAZY+3etGx0O5mQS3JFvF0G/qfwrSvdRs9MkMdrboGTgZOfzrI1DWbq/wCZWwvTA6AUAbSWOjxoqTXMryZ+bZ/IUwz6HHuEUV5IqnJLNgCue/tk6daiO0VTevy8zrnyx2C57+9Zt5qd1d2+2Y/KzZdgMbz70AdO2saZdzrDDYRYzgF5OTVy31GCwkSSXR7bhvuksK4Swh+0XkMRdYwzAF2OAo9c16tfPoGojyZL23V1XapzksQMDn0NAFTXdc0vWI4530VIWC7G8uYjpVHQ7jQHuG+3WUoXsd+cY9a5y4B0y7ls7kYJ4UjoR2IqxbQBIjIPnU8k9MCgDt3t9BvHLW1zEiAcKykEGqdx4TtpYpJLeeOQdQqNgn865m1sb3UUZrWBjAn3pWO1R9SeKuQrBYOok1+yiY4JETtLgfVQRQBNL4RuIwzISABuAYf1FZN3YXFsC00ZCddw5FdPZeL7OGMwfbknBON0iMn9KW51BL5fMghMgb5d0RDDH4UAeaX5zcE+wqvXoNxoOn3yl4SsdyeWU8D6YrBu9Haxk23Vthf7wzg/SgDnKK3BaW7t+7jXnpkn86BZwYC+WNwHJ9TQBh0Vtizh27jEPTvStaW4YjyxgfWgDDoru/DemaTqsM2lXkMdveTDNrdgn5H7K3Yg1x+qWFxpeoT2V7GY7iByjr7/AOFAFjwv/wAjNpH/AF+Q/wDoYr9G/HH/ACTTxB/2CLj/ANEtX5yeF/8AkZtI/wCvyH/0MV+jfjj/AJJp4g/7BFx/6JagD54+D87x/DzTwshUZk4z/tGvDdQltnvr7zJLZXEj8MnJOfX1r1n4ZyqngewDOAcPx/wI14VqZzqV2f8Apq/8zQBJLPHE8YjWOUIByVwCarzyLK4KxrHgYwvemIpc4FW4IBvCoN7npQBWSF35AwPU8VMtsvG6Tn0Aq4IZI5yrpudDgr15/CrFvp1xcNkREnPbAoAoC3gGfvt+OKDDEeBGR7lq2zo06XSw3BihYjPzN0H4VoP4XnMLSW7rPgAnYjcUAc7pWnwXl+sEu7aQeUPoKf4hsoYb8pHMSQijaV+6AAAPyFbllpUtghv98TqgIKg4ZSRjkelY91aOJt05JeT5t3rmuflm63Nf3UvxPXdfDRyxUVG9WU737RSVvvbf4+RiPC6DJGR6jmo63YbGSSYxJjeAT9fpUWoaeInKsjK4OM9D+VdB5Bj0VJLE0TYb86joA9Y+BDtHrysrbT9lm5/4EK0fjtcK2raZ57xn9w2C4zjk9Kwfg84TVFLHA+zy8/8AAhR8bXD6jppDbv3Td/egDiLt7dJJHjeB/lACovB96pm4QweX9njzjAfnP1qvU0MBfluB/OgCIAngVKtu5+9hR71fhtG8oyBQsS9WJ5pTGJG/dI2O2e9AFNLVSTukP4Cn/Z4u5c1oRWU7glIWYAcn0rRtNDu5496iJV/2moAr6JoyzI11HIVZCyqG6Z28HPtmsSW1RXZVkzg4zjINdhBY3sWnT2kEWZWkJYr0C4HQ1gXFo0DbZxsbpgiuekp88pS26Hr5hPCrDUKVBe8leTv1dtPuSv8A8OZDwuvOMj1FRVsC2ckBcNn7uO9F1YFThwCQMkqcEe1dB5Bj0VNNbvH7j1qGgC9o3/H+v+4//oJoo0b/AI/1/wBx/wD0E0UAYb/fb602nP8Afb602gAooqSCKSeZIoUZ5XIVVUZJJ6AUAT6Xp9zql9FaWUe+aQ8dgB3JPYD1rt9QvLfRtM/sHR3DLnN3dqMG4f0/3R2qEhPDGmvp9sQdUnGLyb+4P+eSn09T3rD2A+ufT1FADwdjc81IuVy+AOwNIpWPG77x7ntSqwJJcFi2DgdM/SgAVmLcjj9KuWls07HoATjP9KfFpzIqS3pKB/uRj7z/AP1q0leHSrb7ZfAsp6RqcAgdFH+NAF20e30yNpS8cYT/AFkzjofRfesPxP45e7xDpSvHGBgzSfeb6DtXLavqlxqk++dgI14jiXhUHoB/Ws+gCxNeTStl2yfpV3TZEmPlvneffrWVU9iSLuLHXdigDq9R8OzXvh4apbDL242yr6p2I9xUlzaWlx8PbV4x5U9tId/y8SMx6k9+MCvTvC8anwWkEMImnmY5UgHd9aq6zpVjcaRFozqqSZLM0XVWPpQB4MevFJXov/Cp9bmmKWTxy+7KV/xrbtP2ffF80e+ebSbVPWa5IP5AE0AeX20r3ca2kiNKRzGwBLL6/hW3qLJ4dMUG6G9neJZeT8se4ZAYevtXpnhv9nbxNdaj+51zTLZoufOiMjbfU/dFesT/AAA8Lo8K6i0mo3LRgz3PntG8smBnABwPYUAfHl9qV5fYF1O7oOiZwq/QDgVTr7DuP2bvCkjFrKW9PUmF58EewOKwdT/Z10VFIjutQtpPQurhf05oA+Wqs2N9dWEvmWVxLA+MEo2M/Wvo+3/Z90bycXV/qAlYcGMrgenUc1m3X7O8X2hfsutz+SRyJIBuJ/A0AeUaZ4itLlGTWUKT4wLiNfvH1YDv7iumhLWKxxajG1xp8oBw3LAHup/pXqGifAnw+GhW9FxcCM/vG8wqW9sDpV/4l+AbS08MPLo8UoNumcOxYhR069KAPEPEOh28B8/SpRJCwyUH3lrnjE4UMRj2PX8a7DwxJb6hixuXEdzn5G7N7Go/EOhPaTFpVO0Dt0B70AcpGcnDdqewDkle3ard1ZywAM67lbkMvSqSqyNknJHYUANV2VsqSuO4Peuo1q1Txj4c+2Q4bXtNjxKoHNxCO/uV/lXNSp0ZeFbr/hVnR9TuNJ1KG8snKyxHOexHcGgDC8L/APIzaR/1+Q/+hiv0b8cf8k08Qf8AYIuP/RLV8M6nolvJr+jeItEjI025vYRPEP8Al2mLjK/7p6j8q+5vHH/JM/EH/YIuP/RLUAfJngKZY/B9irZzh+3+0a8eu1Mmo3AHeRj+teoeD5/L8MWK7c/K38zXPaD4UOo6y7vPHJa/6x2TPBJzs+tAGFpWmXF46pawO59lz+daF/pFzYBTLAyOw6EAgflXpjaemmww2+kOLeSWQA5+bI79a63TdL+2QbRbmWPox25GaAPErTw9qF55RiVI4GHMhOFB969S+Fnwvh1u3k1vxGTb6BaFuUJBl2nk8c4rrdO0JtL0u8jn08nSpifNZ4/uD1zUnh/xTpun+B9e8Lz3m5lV1tGjbltw6Z9qAOJu7HRrzxJd6nplgsGkxYigiBz5mP4iT61s2x3K58radvAHQVU0m3SO0hsWKuqjJPTn2qxNqsMT/ZEjJOcscZx7ZoAzfF3he0v7ITW8O25ZSCYztBPuOlea6BaY1qPT7yye485vKWPdgq2eoNey3lzIuntNjgJlVxiuN0f7O3ijR725IhYXaxs5OOGOM/hQAat8Pbe3tIIYJZBqZlJmAPyQp2Ge5xUsPhezsLUgxi7kHP70ZJPt6V9O2XhLRJIZUkssks3LyFmYZ6muS8cfDq3tdLnv9GaYywje0LvkFe+KAPnLVfCw1G4YW1lDaBBhgx+8fUYrgfEfh650eYebGQh6EHIP0r1efVjb+IXsnAUSRh1Zug61U8YCO501ork7TtypxxnPWgDmPhe4juwW6eRJ/wChCmfFmVZL6w254jb+dO8EgW19IowwWOQcdD81O8a2LateWwieNZFUBYyTufLdvpQBw9pAZGXCliT8qgZzXR2ugXuwST2sywnqcYrudF8KWOnWsUknz3Srktuxg+1b2jRzCESX0wnd+V+UAKO340AeTwadLd6gYLCB3H8KkZP507UNIutOubZL4BTKN3lr1HtX0FoXhe/ur+C90q0mjnQ8TKmB9Dng/jXO/G7Q5NJj0i/1SwMN4ZyrSrja4HPbjnrigDzPQ9Hn1G7a3ikdI9xMig8ACvRbe3gtbaO3soMKnDyFQWOPSs/4dWw23E/G6Q5Nd6bKC3sxM0YEjkkgcigDEjsobq1minUYcAKcYNeWeMfD0mjTiQMZo3YnD817HJIyR74kGCMEgdjXIeNf9JMcLx5h8snPofWgCj4Z8IWV9p1jrF6gbTnHzRW7HzGfsAD0x3og8F24llmmZhGzkpEcHaueNx7mvafhbpOhrpOinS7K3uLCe3IubqRi+J84aNQeAc13F78ONAuy7eTLC7DH7uQ4FAHyrq+gW7W0scOnQh+FWUYAye/rXKa14Ju4LdpohHIFGT5eeK9j+KWgz+DZZUZjPb7fNhk7kA9CPWuWttUF9YmeHIiZDz1IPpigDx3SUZNSCsMEK/8A6CaK6PWLWGLWhNbyIySBiVXqp2HNFAHnz/fb602nP99vrTaACuz8PWq6Hpg1WfA1G5UizU/8s06GQ+56D86yfCOkx6lqDSXZ22FqvnXDeozwv1J4/OtLVbt7++eeTaQ3CIvRVHAA9MCgCpIzM++VizE5JPU0kOTKFx82eKafl4ByT2q5p1vJK+FGXf5QDz+tAC2NlJdzbFRmfO0Ac5+ldXFp9r4ftA90qzanIP3cPXZ7mtKCCPw7ZIBGr38gwqd2Y9vpVDUdLuoXjEr+Zql6fnY/8sx6CgBvhvRn1W9llncmCM5mlB4J/ur/AFrlvH18t3dyC3+W2ifyo1HTA9K7vxVeJ4d8PRaTZEiV1+cjgn1NeWawhFjAx3EGRuexIAoAxqKKKACr2j24uL1d7bY0G9m9KbpmnXWp3Hk2kTOerHso9Se1dHo2nG3MkagTNklnUZHFAHQeHtYvbSOUW7BVYbFJPAPTpWxo21dXiUSG4ZcOzdcE9Sa5a5xxGDtRRkgevf8AGt3QNPuvtS/ZLyO2t1XM0g+8Qeqk+lAH0Tokv2uxRbXaGAySRw2SMV0Nvo0plQTrLIHOME4xjtXjfg74kW/h3UxGgRoEAX5xuJx7npXskfjfR9UtDe2TvJcgfON+VH4UAdFJazWFrHbWkWxHILqBgfnWdqLHeABhhx/u+9UdJ8Qx6zrNjbxyAWyf6xC3LN6n2Fd5e2lpLFumA4IBcAZb0GaAOLj1CSLj5uBkVopeG6iRZVBLHIB6KP8AE1PfaTMNQeO2iJt2T75GSGP1qvcWgsopBctsmK7mCenT5T60ARXFqpJaLDFePmPf2qPyWKZQY2npn7x9ak+02b2Za386QA7Sx5GfrSQTpsVQqk4z1/SgCFoTEwjUgFecg459TVTXbVbnSLqBySJImwAOv1zW/Bp80zFmRpDnKg9Pxqt4vit9J8M313cy5kWM4BPAJ7UAfD11bC11OX94UdJTtYHuDXpPh2/g8S6SYLsKt3ENpXvJ6GvO9UuJL263lUUsx27epBPWn6Hfz6ReJeqrb0OD23c80AbuoWM2kXEoEfn2x+/ERyB7VWuNEtdRtxcaU6qTktF3Fd9fwxa7pEV3auvnBd4I/i9RXJR6XLIwl0tjFdfxxDoSKAOFubSSCQxSrsXPG4cg1SZGjYqeMjjFejz2sevWskcieVqEWcoeprg7qGW1ne2uFJkHHTO2gDZ8Baq2m+ILGCYLNZ3NxEk0LDKt864OPUHBzX3P47x/wrbxFtGB/ZNxgf8AbFq+AtCAXxDpe48i8h7/APTRa+/PHP8AyTTxB/2CLj/0S1AHxX4cndPD9kq4xsP8zXTeD45PsAO4tH1+ZdpB/qK4jSpXTRrIKxA2H+ZruvCFysnhVHjOGRWDY7EE0AT6reQRZ/eoLiJ12gnnmvpH4RWS2/gy2lwC9wzSsfXnAr5M8P6tZ6lLPBqUkRuGOEdl+Yj0r6R+D/ia3g0630O7kw6ZEEhPDj+79aAPTdSmt4bUi8wYZGERVuQ244x+tfHXh2ztV1bVEQ7VFzIsbDsueVH4Yr6k8W39udU0ewdv3zziQIe5A4/Wvl6yixr2tWsrFDHMZFKAcE0AdXEdkqPFGu1T3HUUrFZrlndMOT/CMVnQG/IjWEOQzY8x1wv0rRnhIQuVBI4Yq1AEupXHmxKiArHjBBFcL4oKx+HHYohlaZGiwOVGfve1bwkN/a3I0xmn8pts5UEiMZxyazW8PSXOlXvlvFuRN21n+bCtnr9KAPp3wPMt7YWN+J1aWeyiR4+4ZeCaj8VT66JrxrXyINLggZnkk6vxzivLFuEh8MeH9Vh1y0soUic/POFY88cdSPaqvxE+LJufDyWtvJ/orjbLNtKtcf7o7L796APLtXjeTUpdUvIP9DhBEbZwSPX86v8A7jVtMjbIaOSFuSclay7jzvFumkxXP2aBT80RTJbHvTpILjQ9DigtwxXDB5XAAQHrQBhaSzRapcHJLBHHIwfvDtWtYTs2txk7ifL2gKmc5bue1c1pVyZpJplJyVfn/gVbvhW5UeI0SY5LwkKT25oA7O88pVxOcI/GTUvwmXdrFmb50mtzeEqJOQEB4zXJa9rht/EYsr1k/s84zuX9fzrr/Ad1pOk65b3ikXOnu2ZYwcjHqBQB9aRhQo8vbt7Y6V45+00YJvD2i2VxkiW9L4HcKp79utepabqGmvpK31ncxtZONwcNwPb2+leH/H7UzqmlaffRqRb2d8yN7gbef1oA4zTbSOxtY47ZcFgGJByTXQWuqSrarbyoT6t7VyVwp010dLgmBgGX39q1AZ5VxcQyRNjIY8Eg+1AGlNcKHzkgduetc/fOJri3MibkZijDPAFTyQyGPLOx2EncR+maGM1jewTylPJ2glRg8Z6HPrQB0/wNF9bWVzbJG0yafrHnvAg58tgVLAexINe2+ONdl0LRHmsoWnvZPlhQIWyffFeMeAIZ79vGE2kXC20quJFdm2BOQRk9uAa3ovigNA06W1vb+21XUIlJAgbzApx/Ew4AFAHnfj/U/EGqwi21kifUW3ZTG0Qoe2K4zQ0i061Onu2y8ZGZ0Y4BHrTpvFUmueJ7qeSd5L6+clpnGET0AHpUB0G7tNfe6lujfSBTzGny8jpk8UAZviWzSzuIhFnZIpfAHAOwjr/SiqOuXs82pRx3PyS7WzGOigKcZ96KAPOH++31pByeKV/vt9a3/A9il3rYmnANvZoblwRwdvQficUAbt3CNF0K00pdv2mTE93jruP3VP0H65rELHsRkdiKs39693ezTyYLSMWPFQEjdwOMce9ADANzAHgfSu48E6cmWvpMLHGflz/E1cXAgedU9SOK9Cv0OneFkVOJNuR7FuM0Aafh2JdV1m61OYbooj5UBPt1IrXjgFxr7SyAN9nixn0J6im6FbfYtFtIFABWPP8AwI85/wAaNRkjsNDu7sfL5wzk9STxQB5b4vvv7Q164YZaJWKp6YFJqtppUngeGW5u/s1+krNDD94yg9eOw96raJYPrOvw22f9Y53Hngd67Z/hMt9qc1xcas32NcbY0j+cD+7noKAPKbbQ7+6tEuLWBpY34GOvXHSrlh4R1m9kVY7QpuOMyHAH1r1q8hsLCOyt7aVEt4gV25+Ye59a0Pspt5oxGWIdtuenH0oAwNO8NfY4IPDdk4MrKJ9RuY+rZ/gB9AK008ORNDONHgmtY0PkHz1x5rDksPauh0uzFlIZIXCvK+XY5JYDtmt7EaJ5xO0bTuU0AeE+KLCbTZNh4dzkntisaG6mjjKROQWP8J613PxCmh1BwtkyZQlnJP3RXO6JBLFKwW1E7FcbSMnmgCKzgM8cjpHJNdYyM/xL3z71Xt728sLhJNPuZYp92AFbAP1HetIQX1rNvgheNyDuHYDvWh4T8F3XjG9lNpcx2wg+d3C5CnPT60AekeD9T1C1e0bVxFa3UgBQrICG98dj7V6D/wAJddQIEdpGVCXjIGQTnOTXzV4u0TVfCusxW+pyNJGoykoY7XHtXpHgfxZCunx/bCt5CBmSAsVlB9vp1oA990Dx0pikfVMrxlfkwc/SsTXvEyXEaOJlM2W3A9h2FZeknwf4kATSdfNpctybe6+V19s1U8VeFRp93FFZ3kcw2bm2PnB7cUAW9F1lrWafayneCjL2wavNrDLHCVkTBbgf3vciuWstPmh3StuRozghu9W0aztbhblmLLjLQtyVOcYFAHrWmeIYotNaW9ZV2j5cfxcd68F+MvjL7ai6XBu8y7Jd0U8pH3J9DS+L/iFZwbLGzkjNwxwFjPH/AAI9q8p8QeJIPs91Z2kKTXFwcz3jn5z9D6UALoNr9ou7lT5bQxuFSQjO0ev/ANapNF8PznVLmPUtRkuopQcxlMAehB7EelQeDb+OwtrySSN2gwoKoMscnGcfjXTfbUtdVNohV7l18wqfvIvv2FAFPw/cXHhjXv7Jvgfslwd0Mh+7u9q6G4t/sGuw3ATENz8pAHRuxp+qW0GvaGuCfMRcxyH7ysO9QaPcLrOhPbXJK3cHySHPO4dCKAK3i7S2hnGqWPyTLjzFX+KuQ8T2Q1Cwj1SBeRxLt7V6hbkT2mSCVxsZsdT04rkLSOODUNR0SWL74LxOehU/4GgDzTRBt8Q6YCcYvIOOv/LRa+/PHP8AyTTxB/2CLj/0S1fBUFtJaeMLGGTduS+hBz/10WvvXxz/AMk08Qf9gi4/9EtQB8FWzhdOswTj93/WtTwDraaXJLbXjPHDMxbLLkfWuf8ANVLKzBz/AKr+tO1zxC+qDT1aEQraQrCNp+8AoG4+/FAHrU+jWd3bg2gjgEgz5kKgMR9aZY6DLpo8yxv51lU5/etuVvqO1ebaL4kvtLkUxSF4cAeW/II9q9O8P+JbHV0KBhFcDrG/f6UAdRZ/ELX9Li3vslmjGEadN6/QOecfjXna3N8Nbu7u0gllnuYybtAASoHO5P17V20hDIVbYR056ViarYSOA+mFra4Uk7ox1yORQBz134+1CPS9Ps4VRTbgh93VjmqWq+OtQv7Yw7EgQ/fKdTWFrGn3FpOn2hdpc4PHQ5q3pOitf21+LYq95EFEaZznJ5P5UAdl4Q1e003SbxZ5fKN1t2MW28cZJGOc/wBK5fVtUnu9akjhvSttnYHQ/KAeCao65DtS2TLi4UeW0WT8pB/rW9omiCNIjcLtfIZm7dKALFp4fmhu1ju5vtVnbH9yinh8989hW/a6Sks7XOoqk05+VFxlY17BR/WkN1Baod0igAclj1rD1HxvZ2+Vt0aeQdwcL+dAHS3lxa6bA0kzpHEoz0A/SvMfFfiJ9VmYRBlto87FHU/WoNY12+1hnDkJb9dnQD6msy01aOynwsfmoUZHPQnIxx9KALOitjTyxOPkb/0KoZrhodQglQybVHzMnUc0umlV0tiM7drY/wC+qltNeOmWd/bRwh/tkewuTgpww4/76oA9GsG07xBbxTOIJ7hEAbzF5H4VG/hZWuTMl7PFJjC+VhVX2Ax0ry7Tr6aAB4JHjkHBKnFegeGfGfmtHbaiuWJx5y/1FAHU6VrHi7w7ayQW9wl9ZtyUK53fVTwag8a/Eq68RaBHouo2EdnIj71aJCCzehBPQ1rxSRSjcrhlI4wazNVs7e/OyZI2BGA56rQBz/8Awkd7ompW8ms2/m3AJaSGWMAKDgqVrRm+IlpM7SPBMXP5Gud8RaNeMHeeaW5EaARyN82FH8JNc9ZQwNcW0VwCpaQLIT2GetAHUap42kufkt4vLi788muau9SubycyTSsw6KpOcD0rpNa0iC00OR54IoLlXITY+7zFzwfyrK8M6TNdyeYQBGG3KG/nQBo6Sy2enSXk15cTXUjFTaRseuOC/titHRtInvsT3KLawk5aKPjf9at2FmbHzGJDAkknbgk/U0lz4jtLKHEkoDf881OSaANYabZ26ny4Y48dwtc54p8TR2UBs7Bg1weGbso/xrJ1TxtcXMTQ2UXl7uNxOTXJ3M5jkMtyfMmbnaTkk+9ABbStLqy7ySdjkk9/lNFSRXy3+o2rlCkkdsYm54barc/rRQByr/fb612Ph9RY+Ebm4wPNvZxED3CIMn9T+lcc/wB9vrXdajF9l0TR7MAArB5rAf3n5/PpQBkHBbByOeh/mKjOF4XnrwakYkAcnHbPOaj6g7sk9MZoA0vDkIuNXt0KAgv369etd74idLnUdO0+AnElwvH+ytch4KAXW7VTnGS20812Jts+KtPuS6yByxI9MUAdnMm2CTy1RiBtXJ/CuS+J135Fvp1mGwzvvIA7DpXXXeyO2aRtwUeh9+n0rgPGEgvfHOlwBQVTb8pPv3oATRLQeGH+1fZvt2oygAgSbVgVvfuccms7U/iXfhby1tGSS3XlRGmwLg4znqRT/FF5c2d35MTtNdXNxIZEjlA3fNjGCMdAOK53wtps/wDauoWF1ZYuJITuWTkKhOT0oA19Isprq7guREjaguJFJOFIPGSPy6V6HJfXUuikORLcx8SnG3Ld8ZrI8OwTw3ZubsoIoQoV8YGM8VR8WeLEeWa3sYI44jkswOSxPegDR0/xxZwRGOaJsoNoPUZ/xrF1/wAaX80Oy3VYFdchSuXfPrWd4Y0Ya1qO53AtYEMspLdcelUJ5ILjVHBbbEpKKQcYA+tAF/w5oM+sThpHbyzy23v7E13lhpF1FdSBIhAiruV84LH0961Ph8In0z7QgRU5jjXAGQOpx/WulubYzsp37nGcDqB9KAOP8MaT9p8T26eJDG0JDEFzhWfoFx612Wvtp3gqQX2mWkaLOQk9tCMFx13gdiPX3qmLSUSLl45FUEH5clSKtfZVkCtcLHluMn7wHpQByms2d/8AFNhLpsUVla2SkYk+ZpHOOp7CuPm8PC31i3tBFJaTjqqncSR3+leuWenLpU8k+nzNafajiSJDwx9QOx6dKlstKtopmm2NLMxHzSHLbie/tQB5zr3hGe3sYrjY5vODFIGKkn6DtXMweKPFdhceWj/bGTo0yZb8DXuPi4NDYMba2a4aIjcqfePqcenWuZtLexh1V4fPt7rESyF4uiA9hQBwdx8RNciWNbixCyjGWJJArH1PxLr+sjBdoIm5Plgrx9fSvYb7R7O5aPbErBQPlGAWNV7jTre1iQTsuVxkZAA47DvigDxnRvDeoarqAt4YZVZmG5zngHqc16RB8KNP+xhDdTrcAcycY/Kup0LU9MkuPs8cka3e75d2AMAdq66wMDRmS43BgMfL0FAHgL6Vc+EdeWK72PHIQUI4Dgdq1dT8P2GpapDq1pf+TcMo+Vn2ggHJB9q6b4xWVtceHPtH3Z0O5DnnP1rxA3k7IBvkKDgAHp+NAHrWoavY2ds9vZ3CySbdpf3/AA6CuW8H6rHbeJ7iHJaKYgN6FveuDErjIQt16A9fxq3ocxhvxIpJZTnGaAPdoMxzyxBQFJ3DHRc1xni8PbeNNJnRiPOXy2Y85Ga7KykWZ7eX7weENg9P/r1yHxBmSHXdEkLAIkmWbrgZFAHO+JrUR+OtPcAjzLq3f6/vFr7T8c/8k08Qf9gi4/8ARLV8heLEZtf8PSlVAa7jXOOo81SK+vfHP/JNPEP/AGCLj/0S1AH55XU2yC0XH/LL+tKTBm3JeA9d20Hjgdagvv8AVWn/AFyH86fDZxuVBkkHAJxGTgY60AWpL63UiKSJJEA4ki+Vh+fWprYo25rS5Ut1Ct8jg1jXKxpLthZmUDqwwc1LDLaiNVmtmZh1dJCCfwPFAHVQ+JNZtAFeV2QcfOuf1rZ07xqu9ReQtjoWRs/pXDQvbEZhmvohnHQP/LFWI5VBB+3M/tNbZ/qaAPTjqegaoi/aZEYZwyvlWI+tWPDujeDpb6VZbrULdmOUaKUMuPQ45rzKJ4ypJmsODnLRyA/oKu22qXFpk2t/pcL5+8kD7vpylAHXarb+HdP1qaW1kuJoEAK+c25mbufp9axtV8WvKTHp8GzP8bjcfwArFudVaR3kea0Zz8zMlqW/nisy4uw+Qbq6Yf3Y4BGP50ATXk11dSb7yfaO5lb+lUZLi2hOI9059SNq/wCNRs1vnItp5D1zLJ/hio2u+MRQQxj1C5P5nmgBlxcyzn94fl7KOAKgp0kjyNl2LH3ptAGzavs0Vmxn5W/9CqrbvHJ5hlMK4HHmZyeD0qePjQ2/3W/9CrPgiWQEu5UAjkDNAF+2uIre2DgQO+3BRgTnmlWe0mbMZa1kJ6H5l/PqKqz20MMOTK/mkZClCO9QQPGkmZYhKuPuliv8qAOls9Q1OxH+jXTNH22NuU/hWna+MLqM/wCkRK5zzyVz+Fcgj2TMAqXUTHj5HBH+NWEaP+G/uV9ngyP50Aej2Xi3T5wI7gNFkchlyPzqjqcOiXd1BKtziIyr5gHGFzzg/SuPjdcj/SbJs/34WX+Qq4k/lMAlzpHB6MkrfzSgD1zx5ovw+i8M202kX93/AGkcMqSMzBlzyDnocc1xZ8UWum2YisbbcQMAsevua5+41q5lTZdX+m3CKcqPJc7fYfKKy7m9DE5uhGRxiC0A/XNAGjqOuanqRO9zGh7L8o/M1iyPBED503mP/dj5/M1DJJbvzI15MfchR/WomnijICWiA9cyMW/TpQAS3rMCkC+UnfHJP1NVDycnrU0lxI4IyFU/wqoAqGgC9o3/AB/r/uP/AOgmijRv+P8AX/cf/wBBNFAGZp9q17qcFsvWWUJ+ZrsvEk6zag5iyyKAi/QcD+VYvg6AnU7m7IO21iZ8jsx+UfzqWVlkcs+RJnv3oAiyQ3BOfTNBOMDBB7HrxS8HtkduaQfd4PPt/jQB0fgmEnxBbFf7p3NjlRiu1ndYde0lDsO7djjpnvXJeCZUj1JNzEnY2cjnpXR6tNANQ0u7iV18ojDHsM46UAdrqCK1hIiqvOB8ufWvN/E85svH2nzzg4UJnPpXrNpAl0FjYhVk6E4ABNeN/FmKSDxIkMsYV4VKnnrg0AJ4y0uS5vpJ7GKUJtV5JIiCWYn+HuCTW14W066sNQt5rq4a6uriPYbZRmSeRvugn0ArA/4SAi1iTDbgq7yDgnHQ/Wva/wBnHw99vW68TakpZwxhtWYZ2KPvHB656UAdDovwqiubOL/hIbhkAUMLOE4UezN3P0rZm+E/g4w7F0WPgk79zZB+ua7kgoo5AAOeR/Kud1zxhpOkymOZjI4GHVE3FR6fjQB5x4l+DFnbW7T+F7iW0uGz+5kYskvoAa8ButB1G08RjSbm0kjvVk2GLHb1PtX2FoHifT9YSW4h80KucqwyUHvivJ/iRpEOqeKW1uPUvszKixIqMA7Y7tnrQBq+HtJttF0u2tohuCrhyTnr1rQlWIAylsLnhc42rXIP4kvdKjB1SD7bBjAnj4cL7jpVCX4h2d3qVpb2gdLcygzST4AODwvtQB6Jb2sk+dzJE2NwUfMxU+v1pbqwvraMGIJK2DkEYxWpBHbvcrdIU3SKCH6huPX+lGpXUdlZvJI6IQvQP060AYvw5uLy5ubjUroxu4ZoIY2GPLGDk/X3rc1jTEuLfFuzxzxp8jjlj3/KvP8AS/iBp2i6oIpZneO4JZyiBRG348nrVjxH8TtKksJ49LeW4mlBRBjAQd2NAGB4C1bU77xXqNpNqPmOYmU7wPlwSvy+hwa4bUILzw1rbPYS/aI/McL8wJcA9SB0APSu403RNDn0gyi7ZZ5csZvMw2Tyc+gridCt4Evb5oXSWOOUosjnk+49qANeXxpLFCkdyjomTk9CM+9Y934nt5CDGJXA+8XPX1/CtWeyju1aJkD+Z0IHQdq0fA/grTdVsna9gbzUcq/bABxQBwtzeveXEZ0mOdLgnLKiliD6+tdlpd58QbaFJFtL6SPbndJalsivYPBcPhXwaz26xQwNIQTMRlgOw55r0/S9Qs9QtQ1leRyoOCYsdPc0AfE/ivVtY1SQLqvmnZ/yzZCn6GqAEJ0WM29qy3Qm2SOSSpB6YHY19ueIvCWja/ZvDqlhBKjZAdkAZfcEc184eKPhtc+FPFNpnMuj3E26J8Y5XkKfQ9vegDxTxVcT6bdDTmjCyxorSs45JYA4+gBFbNvpEllBp87bit9Cs6ZG3APrXV+JnsNVvXvdSsoQyrt/eAZAU8Amr+v7dQ8IG7dWWTT9mwquAV9B6DFAHT6F/qLTLbsRFcda5P4hqLnWtPt8MeMbF9yO9dL4QcTWUbj5SyjGeTj2Fcx4rllfxTDNEA4iiPHoc0AP8T48/QGGRGuoQqCRjjetfW3jn/kmniD/ALBFx/6JavkTxA7Sf8I6Zcf8hCLAPX769q+u/HP/ACTXxB/2CLj/ANEtQB+dd9/q7X/rkKtRSyRRl0LIRGBkSEZ6Ct3SPCfivXNHtrrTfDtxfWKqyRzxw5BAPPOexrn7+4fzTDd29qksRKsp4Kn0PNAAbdZonkwPN+6dz87s8mofsEmSN8eAM5zSi6QYxFacYHUdvxpjTxsxYxWuScn5v/r0AK9vLBbxzCVMP0VW+YfUVB5kn99vzqXzY/8Anla/99f/AF6Xzo/+eVr/AN9f/XoAdZRS3UrIJ1jwpYtI+Bx/WrGoafdWMKyyXEbgkcRybjzVTzY/+eVr/wB9f/XpPNi/55W3/fX/ANegCPzZP77fnR5sn/PRvzqTzY/+edt/33/9ejzY/wDnnbf99/8A16AIzI5GC7EfWmVOZI/+edv/AN9//XpPMj/uQf8AfY/xoAhoqbzI/wC5B/33/wDXo8yP+5B/33/9egC+n/ID/A/+hVTtCdsm0E9OhxWr4fttV1iWSw0PTzfSGJt0MCeYwXOSevFS6vpGt+H2WHVtHexacFlW4j2lh0yM0AZ8ztcy+XMzMM7V3SZCn/8AVUM1mxeQx7FReQN2fyNCB1DAW0XIwcn/AOvSsXZQpt4cZz/nmgBEsJTOIxJEG278lsD8/WqxkkBI3tx71PsP/PvD+f8A9ejYf+feL8//AK9AFfzZB/G/51qw6VeTJvjuYSBgn99yMjNUvLb/AJ94/wA//r0hjP8Az7x/n/8AXoAid5UYqZGyDj71N82T/no/51P5bf8APun5/wD16PLb/n3X8/8A69AEHmyf89H/ADppJY5JJPqas+W3/Puv5/8A16PLb/n3X8//AK9AFWirXlt/z7p+f/16Nh/54J+f/wBegCTRv+P9f9x//QTRS23mxyhooEDYIznoMc96KANLQwLTwtdylcyXdwEXn+FRz+p/SqbBR3wT1DHP5Vp30fk6HpEG1VPlGVs9csSc/lWYAF4AY+57UAIQOMjA5xxSlN2QDyOxOKcwLnCjntgjFAU8dCo4+XtQB0/gJAdWXcAAq8A103iZGWHcsRDxyB3O3GF7c+lYPgEhr5xIDwuRt/lXazxrNFKhI+zzKFfPQj29KAG2WviS3s5lCYGNwJyOK5D4ql59VS8f5ldOSp71JJaHStQgtPMDwuxdACThfQ1P8VYh9msJQoxjHXpgUAcPY28l/c2sEBxNKwjQZ5JzX3J4N0keHvDVjpcbKRbRBWbHVjyT+dfJfwQihu/iHpInPELlx8gJzjjj+tfZcQGCEEigjJZgAfqf8KACa4EKPMWwidWZeenevEfF8/2rULhIFCKHyWx94/XtXsGqXTzGK3TP2cyKkk/Tgnn8K2tfn0Lw9o1xf3ttarBEhbaI1LOcdAO5NAHzVpl3cwTypazmCNv3bR4xuHqc1n6o2++3bVZ0HyAnOK66yml8Y390bbS7ayTy90QX7ygnOGJ6mrUPw31W/kY2yLJGAOSQOfr2xQBxIv8AzIvs8yxuB6EAcf8A168+8W2UcBhMIOHYliOle8z/AAo1SNGaSFQijLMXyFA75rhLvQre71ALcyLNaQNlVB4dh0Y+3060Acf4S1zXnl+w2xu5Ytn7tVfa34Ej19K9w8KfBzXdSFpqPifVpEZlDC3YlmjHv71d+D+g21/r8+qXCRmDTQqxjb/H2PHpz+let6xqDq/kw48oj53Dc59KAOCk+DXhYq0uq3F1eSABRISBsHYcD3rFuvgTYxz/AGzw3qjRzgnalxGGXGOnvXrVpp48lWuIt7Sct7egx/WnOLiK4V0j4zjgjj8e9AHyx8QfAet6dfG2vbiJrho91vHBHtWVQefx9q4nTbW50G7KarEYluBgnGQCDxmvsX4laJD4i8KzIXWGSL99HIeqsBkDPYHpXg+kWn/CSNBaQ2olNwwjUEcbu5yecf4UAc1Cqgw+W+7ceo9K7OzuRbC0jtFxbnImYEk7j60fFTw3beCL/wAK29nEJYpU8uZ243yb8lj6/eAA9AK73/hDpprY3Fvthu9oIDDjp3FAHjGq293fa7ezSySPHu2orH7oFb3g6a40nUo7iCaVVU5eJnO3Hrj/ABrp9Hnt9D1u4i8TaLMYnIJKNnyz6gcZH8qs+JGtvE+oW+l+D7W3strb57q4yW2+iqDj8TQB6jY6p9stYmdlV5U4J+7/AJ9qg1/SodRsTb3BEgIyrEZ2nsRVfw/p62OlRWlxIXmT5Wlb5c/h2q/cB1WPfNJwcfK2f07fjQB8xa3b6euoXkN9dxrPFMyvGzcAA1yvj7XrYeHxpumy+ablhvZf7o7+/NSfF9on+I3iJYZsIHDnI74GeK88Zzczrgvk4C9OB2oA9p8Kym10ixkU/Ika59+O9ZmnSpqOs3zogZlYKM/wqc55qXWZV0zwvawHcJnVVOOMcZNReEDHBpqhS3mvIXYMuC49aAKvjKTdq3hdYlmWNZrZCHChQyuoO3Byc9TkD8a+uvHP/JNPEH/YIuP/AES1fGXiC7W78U6MkRYrFdwgj0PmjNfZvjn/AJJp4h/7BFx/6JagDz79nC8hg+DmlJITuzMen+2a+KvF+P8AhKNTwQQZ2PAx3r60+BN+IPhZpcZQtjzec/7Rr5J8VnPiPUCARmYnk5oAyaKKKACiiigAooooAKnngMMUDswzKm8D0GSOfyqOJGkkREGWYhQPc1a1Z1e/kWM5jixEn0Ubc/jjP41Lb5kkbwgvZSqS8kvzv9yt8ylRRRVGAUUUUAe6/sfypD8Sbt5DhfsMn8xXQ/tnTx3GqaC0bA7YWHI5+81cf+yzOLfx5eOQT/oTjH4itv8AavuRdX2jMFYbYiOvuaAPn6iiigAooooAKKKKACn7G8vzNp2A7S2OM+lMq/efurCzgHVg07fVjgfooP41LlZpG1OmpxlJ9F+qX/B+RQoooqjEKKKKAJIP9fH/ALw/nRRB/r4/94fzooA6u7ujdW9i7sA6wKnHOMcfyqvuQ4G/afXH86qafLvgwxPyMV6/lVxE43YAboCaAEXAcFWU+hxQ4diMNlPf+lP27F+Ugds9M00bR8vb0PXNAHQeEbsW9+nnMFRuC3UgV36B459tsPMgblie2O9eRQO6MWAYAdPf8a6LSPFF1aIInBmi9zg4oA66XRJNVvoHnnVWGQioMDHp+feo/FltLqXhSSBmDXdm2cJzkd8fhUeheJBeXzI4jhiKgBmbv/8AXrUmW9g1qK5toI57SVNr7Bkle/5UAeZeDdXl8PeI7LUATiNwSMY475r7Y8L+II/EGjQ3NvJGUYfOvHGfQd6+NPG+hf2VqBltzmyuG3xEDOOMkVr/AA98faj4ZmWESNLCCCUbHAHbkUAfY6WqXhHnsShG7bzUEui2szKs0SllY4I+bbn6968007446S0ERvLWdH4BORUuq/G/RYYme2huLqRuBH8q4+rUAdN4pstP8OWEupwslsFUt5p55Ht3Ned+Gv2hI9Ht5bfVdLa7lLEo1uwXI7ZzXnHj74g6p4vkkW5RreyU/wCpgPyj0yT1NcE8WZYwFQhyODwetAH1GvjfxH8RtDv5NJtFs7KADfDC5aWRDnn3AxyB69649iLaKONnIbAxtH3sdvrXWfA+ZNI12ztMhEuYWix2zjcPx+XH4103xi0zSIo457aMpq07MAsSgo2OpbsDyORzzzQA34H3SedqkAXBmVZxk/e7dK9N+w+Y6ySN84POAMEelfOfwEu9Qg8dwaffMmRHKVOSWZeSV49OvNe9+NPFFn4W0wXN2S0khKwxj+MigDcZdoGBwvYVFeWy3USgqN4+6x/h968Ivfi1r08pltPs1tCeAmwMfc810fg/4sve31vZa1aoGmYRpNBzliccjtQB2vjC4i0zwdqrkgCOPaXYZ3scdq8c+FWsjRPEKQLYi8MiJCH3bWiZ26L27j/Hrn1L4yult4CvLiXeYYXSR9uOOcDr2yRXgvgG4l0u4/tKRmuvNLTIxAU79p2sR6BsfgKAOo+Pet2nie0099K8xJdPlcu8qqAwyuCpBP8AdPp1r0vw1q0Or6LZ3lvKH3xAksdwzjnjtXi9zbC6idJdpDDhQvP4VU8AeOF8K61JpV4xFuJM/O27r7UAe7a3pi6p5SXEMbYzndn5sj2qlo/h5NKuhcEQk427wCNo9zWlpmvaffwLcJMu05wo561fkvYN0jNMpTOdrN29aAHMkWd8e/1+Xv75qp4h1q20LQ7q/vXxbwqZCvTcwHABPc1Wv9f0+wt5JXnRVVcj5txxXzN8ZPiW/iiU6ZYtJHpcZy4x98igDzHXdSl1LVNQ1CZtr307yfQZz1/Kr3gjTH1LXrRNqlVPmOW5+Uc1jQo9zcBUTeBwAOw9K9Z8F6L/AGVpL3DB0vLoYX5eVWgCTUYDqeoXIAAt4YzCp3DBY9Tj2rQhjhDKWHli1iCHt0FZl09poVtO8Eisxbc6uSdx6/nXJa54slvLOS1twY1lOWPcj0oAykuTd+NrOeNsq9/CRgdB5i193+Of+SaeIP8AsEXH/olq+BtEGdd0nBwftkHb/potffPjn/kmniH/ALBFx/6JagD5/wDg7eSQ/DnTkUKQPM6/7xr5k8SADXr7bnBlJ5NfQHwwnkTwLYKrkDD8f8CNeA6rEr6pds2cmVu/vQBlUVb8hPf86fFZiVsIGNAFGitf+zolGH37u/ahdPibs/50AZFFbS6bAQclv++qX+zIMEjzPzoAr6TBLGxvjG4hgRpFfbxuHCjP+8RWbXoGmyDTfDgWI/vJGYJz09/wrmX0pAN3zEHuGzXPRnKcpNrZ2XyPYzLD0sNRoQpzu5R5muzkl19Ft/mYlFa50sMD5Yc4GfWq8lkU6q34Gug8coUVb8hPf86PIT3/ADoA9N/ZymaDxheOoBP2Vhz9a1f2k5jcXelM4wyxkDHTqayvgpEttrbzQlg8lvJuyfRhU/xyleTUtM3tn90386APIKK0Dz1owPQUAZ9Fa0VszjcQAv0q0luqjCKCfXGaAOforovKBIDAD8KkVEU5ZQR9KAOet4WuLiKGP70jBB9ScVNqcyzX8zRn90DsT/dUYX9AK7fw9b2+y4llSMhCCGI+7welY08Eckz+UiqhJ2qeuK54VOerKNvh/U9fEYN4fAUqzkv3rbt1926X5v8AA5ait2WzGflXafTFV3tpEJBTp7V0HkGVRWgVx1GPwowPQUAU4P8AXx/7w/nRWzowBv1yB91+3+yaKAKmlOFuJVLqueee/Nau5Qx2jJPQ9c1gW7iO8RnJVQ3JHXFdCVMeVHQdjwTQBGQxPzDp2PpT4F5bqGPvS7c8MoyO+c0DGRzx1PbAoAJoiDhWK+x6fpTGBAXPU8fL6fSpVkJcDIAHHBORUVxHl8BsAenb8aAGiYRyZGVUep5JrufC/ism3+yXtwI5NhEMwP3TngGuEGN3XOBxT4weVUYbGc9DigD1m5uLW70dYtYgULJwJl+ZQfUelcPqvh+eykPkkSKQCjDkEexqnpWtXFgnku3mwtnMTjKmuw0DWEvUeKKBPsoyzoTnafUDrQBwkdxJGWWQkgH7r9zn3rsNI8IajqVsJDtt1k+6ZGx+AFaenRaANT+0OfnQ5XeMoGB9K7SHVtPJEYuLclR0UdqAONl+H+osh23kRVuQjHC8etYd74M1fT5/M8gTBCG3IcjPvXodz4iskY+TulkXO5Yoj8u3ryfSk0/x3Bpl/BqcmjXGpWaIcQzYCMT/ABdDkj3oAn0rV7eIW63M5tb4LuVGOGGO4OefwrrtDW71SxuLK2066vhM3mI8aYEco6NuPygHo3PTnqBWdZ/FcX+o50/wXoz2qLmNnj+cN6ZxxV6T476tHfyW8Oi6fHFFwV8xiQceo4oA9G+Gnw9j8M3M+rX7LJq1wu0qpykKnqAe5OBk+1dT4p8Oaf4n0w2WqRsY87lZG2sh9Qa8u8D/ABtGs+JrTRtV05LZrp/LjlicnDH7uQfU8dfSvaCDvB7AUAfNvxI8F3nhi6tfs1rNf2E7iKOSFfmUns3pXffDv4X/ANl3dvqmuOr3EeHitgMiNvVj3I9K6zx4xMenxecYw827GDyV56gV1EYKoASWPcnvQBBqVjbalYXFlfRLNbToY5EYZDA14rq3wv1fRwx0Mx6jaJnZGzBJVHp6HHTivWfGOt/8I74cvdTEQmkgTckRONx9K8Nk/aFv2vNkejW6Q5AJLMxX3oAoX1jrab4pNIvraYLt3PGSE/Hoa4q/+H6XmoSSXl/cJdyMPMUx9D+Fd14h+N3iNLmFNLjsvKkXO7yt2f14qLV/idr+r+HZ9PuLLTjfXSFBKiENGpHUc9fegDE0bQLfR41Avbpz2/e/n0q/PayXm911C7jyBgs+c1xqavf6JbH+0bWRUByWLZBrd0bxDa30A8yRIZD/AMs5Rt9OlAGd4o0K9exlcahPMEB+XPH0NeQXBkd9uWJU4x6V9BXLxSW8rGWN8jqXBH5V5ZDpdlZ6zJcXLG7wxZIojkZ96AL/AIO8Lx2trFf6qB5jncsAzkjsPqa2/EOvQafbyjzd90wwkQb5Ux1yfQVzGu+Ir7adkclqTkLxggen/wBeuPlmMpLOSSe+M5oAuarqtzqMhad8oDgBOg/Cs7G45PbsRSKckjHJ74NPVSpDDBJH5CgDR0DKa3phOfmvIcZ7fvFr728c/wDJNfEH/YIuP/RLV8C6OR/wkGkjt9sg5z38xa++vHP/ACTTxB/2CLj/ANEtQB8n+AJAvg6xBbHyvxn/AGjXjN//AMf9z/11b+deqeDpkTwvYhuu1v5muLsPCt/qerTI0flRnMu9jxtJ46etAHOwQmVvb2rYsEaCaJggJzlQRwa9A0Lw5JpVwyCC0uFCZ3sCDn0FdK/hqzvyGuYzJPtwAhPy/QUAeRanbTG9eWe3aEyneFIOMH0pNUtvJeMW8m9HQMcDG36171N4c1HxBpzwTaK2pzww+TBPEixtDjpuJwDWNa/CuZPDd5fahqFpvtnSOW3hbeVYkcE9M/jQBw/gzw6+p7Xnj8u3TnzMDLn8egrq/wDhHLfzGjGoyqAD8iICB9eK2Lm1t0ihjtf3UUQ27Rxx61XspkhknlZd0Y49jQBymu+EQdK8y2bzQrcBhhx+XBzXKTaW9v5dmLZhdSuMFuOPTFewC4FxEV27dyHb6Z7V6PYp4U8W6Dp/2q1sJNZRVjkRiYpHZR1QjqeM0WsNyctWeDav4St9IsZIr6cjXJVU20NuuVx33ehrOg8FJFb+ZqzSxk8l4yCB9fSvdLnQNDS9t0vbi6s5pHG8XbiRxn7oGOc/0rqNU+GSSacZNKvGaTbkRzKMN7Z7UCPkjX/CT292Fs455oWTcr7a5a/0+eylKTIykdiMV9AaiWs9SS1uk8tyWTB4ww/hrnvFenRavbmJUBnVSUYdQR2+lAHL/Cxtl6DnH7iTn/gQpnxdcPfWGG3fu27+9HgRfs966yjaVjkBHvvpvxAs59Qu7VrSJpFRNrEdiWwKAOCAJOB1q9bWh4ZhknoK62x8FXkCLK6ws+QNjE813sGipNCbeWGCCEKAzRDlvYHGRQB5dDbtcWJSG3c+W26STOQv1pkVmHlMSzouCcOcgGvZdI0KfSxPDpluZrC62rPA8e7zAOgVjyM09/hPd+IvEQm+yf2DpjbVKXBAYt32qM0AeLR2bxTI9yhdCflTu/09q7LRvDFzcWDXQSO0Zj8iyRArt/HmvYvH3gvQPC8OkwW2176KNg8rHJ7YJH8q4QXUruI5DJIwcHnptHtQBhS+FL8WkgYWtwpGWWH5CwH0rn9Q8I32maYt7fafeRxzDMWV/XPpXpP9qKLzKx7VPDe/vXrvhDxHok3g8af4o8o+QrFfNTO9Mkjb744pKKV7dTSdWdRRUnflVl5Lf82z5o8MeCn1KzTVdTuks9KVwJHP3seoqm/hpr7WLlrRpbjTkkKpOq4LL64PWvdvEXhLStUt9PvvCl/I2jXZL/ZGU7C+cYx2OexrZ0f4f6eWe0XU9lymAyxx7kUntnvTMz5x1LwfC1jLNYSSzyR9YyoBH4VyV3otxDGXaGVF9WUgV9H+LtCuvD804by5gMlZIxxJjqPY1zLPbT6d5m1JI5EJw446dDQB4dpCldQAYYOx/wD0E0V0ms6T/Z2rxyRqRBKjsnt8pyKKAPPn++31rr7IRanp0U1tn7VCgjli+nRh9R+tcg/32+tSWtzLaTrNA5SRehFAHRqrfNuBDZwRupwHyHovPccmp7PU7PVolhnVba8xgMOFb/69LJZSRPtfII985NAFM7VLYUMT05pd5BPXZ3HpUkkTDG8c9+1NaIj768Z6H+dAEe0kM64AA55phBLZbOP6dvrUwbLEjoMgD1pwUSPuRT+HegBgUgDAxnnpxip7C7mtZ/NhbBX5mIOOKixtAzjHUZqNm7MMtjPXgUAbzagbzcY22vjdjOMmuq8MRxLZQLIrPIzkEhcfMf6Ed686t7jy5EbGcHJ7Zr1TwiFvdPtpYTvKIY2CnIwOn5ZoAvG2hS1kDu/ClMrxubPQevJqSz0qWERWplYWij5kXuccgevU1Znt9pVlXzGaQMN3RMHg/lWhCgBLEjaW4Oec+3pQBDDpcayMbYrCu37qjH0z6VW07ToLazdIlXaWLNI/JdieeevNbTS70JyM7ghA9e5xTkhUIrDhVPBY/Kp/rQBy8+nz6Nri6vpMUcstvIlwARksQQen9K9o0T45aLNbSPrVrcWF0FG2EDfvOOcHt+NebxzLNJIrSbVibCj+975/GsjXbRpLbNtHC7McDJ3d+cen8qAPpnwP4msvG3h6PUoLYxpvKtDNhijA/wCHNcx41+Lmm+F9Zk09rGe78r5XkiYAK/8AdxW98LvDtn4d8K26WU3nm6AnklByCxA4HsOleU/HjwlbWGt2etxzbY72ba8LH/loBnjHOD6etAGP418ea14405rKxhS0sWYM8jgg7euBnrXC2OgK800hklI6KzAYYjrXTSXLR2UoBXcsfI7A4p2llfskKI2NqgkkcEmgDE0vTY7S7jhfa0Z3sPlGASP1xV1rQxyyylvkVgVKnH0rU1MAqjJt+Q5wRg++KrSzq8L7U5boqjqfQ0AY2ros97Ct7GVhByuScN7e3NR6okUqxmQMEBCogVSQfb1OK07iSWRys4Gw4AJ7VVu/KRl+RvLXkBR/H2xQBx/iiIWluk9uSkLuEbnGWOe3rVnw1Lb22ltc3OzrgZIJH0q14stx/Z08kg+VQrKvZSe/1NebSXkjIUDjZnOOn5igDe8V6qNSu22MNq8Agda50/KB05HAIpueAcYPX/IpykbC+SoH5UASIoCrzz1+tJjcfm5PX/8AVSRs38Rx9MHmlT5gPQZxQBf0En+3dKUgf8fcOM/9dFr738c/8k18Qf8AYIuP/RLV8UeD/Dss0trq11mDT4LuEmSReCfMXAHuTX2x46wfhr4hx0/si4x/35agD4s8Mz+X4dsl25+Vv5mum8Nw+RpsbW4jwTukOev/ANeuI0i4ePRbJVxjYf5mu48M3Vq3h+3YOPn+Rhn+LpQBWtPEEd54hW1tQWj5DH1Yent719UeAPDthpOlR4jjkv2VWmlK5OSM4HtXynpOjPpXiC7u5wqJISI0A5ANfSfgzxf/AGtp1r9kCvPAgSVN+A4Axke/HSgDU8UT6jp17dTwwCTTvs4ZljGGJB+bnv8AL/KvFPHOqXkesW+iaSqjQ1WO+Z8AGZm53MfyAFfQd/dXF5oMxs4VS8kjZUSY4CNjGT7DNeB+OLNLLxLZ2Iuo1hewjgWXHyyFRnr270AZN3H5xZUxsPINZt9PstEiUDB6gVWs703czxRPIqQMQzJyGNQX7TJlPJZhnO/1oAu292yRqoHAGSQadZv9p8W2FtGxgDXERjZeCjAgn8xmsiFZZHTzMxxZzz1NTaRdQ3XiCxNsytcG4LfKTk7RwR6c8YoA9r03wnL4o8WDV5rhfLsLyVZoZByZA/HHpt6V7ECuPlPHQViRXcVrBNLfLFaMQpZyQnmHaOp7muD8WfEI6bMYtCeJoRHl5GXIVvY9xQBx/wC0T4ZvItSttV0mKRzM4ZlQZw3Q8fka8q1CDUNLgkEjk3KJliwPJzz171654JtPEXjbxTZ63PcyzadazfNIz4iODyFXuaoftELp8evQfZMPczRFZUTs+eP060AeJ6HIsepTOAuPLf7pJH3h610GnrHcamJ3UFo0wqk85z1A71yunSsLq5b5d2HHAwPvVv8Aha4R9YkExUMsW5c/WgDU1fX4rDMM6tHc7NyfLkE5r1/4M+HbfW2a+1BPNtrdV2ow4dyM5PtXNH4ZW2t+EZvFF5LKrW6F4o0wTIAeck9q9C+Eni/w/B4agsnmNtcgkyCZcbjn1oA7jxk9xYeG7ifS7WGSSFdwj8vIx7CvLPEOvS/2Hrur2LyRaxbRKY3zkeUxA3D3AOM169b6xFcXRgMUwVgdr7cow+vpXEeOvD6wWGtXcIhigksDbQWqDBILbnY/pxQB4TYaxeax9rGoyNNPIQ6SyNkviq6zGK4eToxBHvUAltNO0+1knnAIdoQi8tu+lF+Jo5FKRuU2gYI5B9aACGZlm80jPNaqaoWhiWfkF/L9sEdK5yNbiV8JGwP06Ut5eR2trLCS0rLzIcY2MTx9TQB7N4W8P358G2EFi8ksl5PdyIw6RNtAUH8j+deh/C/w7d6Nptxc6ugXUbpgXGc7VHAHtWL8G7u8j8OW8flF7ZpiNx/hG0En86ueMfHdraxSDQtRWa9jkCNGq7kx3znv9KANzxDo1r4q025tAgiIYslwpBBb+dfMuv8AgbxV4dN2dSUCwgYhHjbIkHY+30NeiXfxT17zIdK0e3tPt0hG0IuW56sQeAPU16d4zWKbwdcw6msLu9tvuCvygkL1U9jnpQB8Y67cvPcrHNsLRblU8g42Ht0xRUfiFTDqKqpBSTeRkc8IRRQB5o/32+tNpz/fb602gBeladlq80MYilJdB0yeRWXRQB1Ftqsc22OQbnzkEVo20DSMP3e/d6964cEg5Bwa6Tw94kNiphuYEnRuA5OGWgDcuNHkYb4ItwXOUFZZOfRGHYDtXTWutiW4R4IQgyAAOeKn1bTbbUoHuLAiK7Ay0YOAx+tAHKCSNnTzUDbP4T/EfWkvrgXMu9YwiDgjimzwSQOUkXbIv3i3bHpTAA5PJB67vT2oAbIEWMHGW65HP41veD9c/sm9Ebufsshwwx096wSCGzjCjABPGTRPEVcq/wAq9OvJoA95RoLpI5I5uMhyoOQfbFSNO8drclyAANxKjAA9jXlPhfxI2m/uJM7CMBgOa6aHxCl0zWsUrWqDAZnb7wzzjPbFAHeWURijjX7w+9z1yef85pklx5Zc7trDoWHtXE2fi23sLv7LcTm4RmJLx/cXPTPrXSw3lrdyTJBPukQDcQOASP8ACgCqlyIdUlt2wfMUTJjgkDg4FQX2oqts8Ns5iyhwVUH9DWB44luLbVba8gB2woAP8Kry31vqLwy27mNpVHmQqCc//W60AfQnwZ8Q2Xhvw0lnqVzOY5f3qE5cJkcjjpnrXn3xg8R3Os+IraaW7kFnvP2WHA2oBj9T61xTeIJo3FvpqFIIlA3DofYe1VrnWrq6gEd/5TSK26PegIb2yeR9aANFtUK6ZdmKR92CzfL3PHPvWl4Wv0uNOt2UhWA2Mv0riNY1WaW12G0NvxnAP3j9a0vChddPZlyp3ZAB6+9AHobATTSw7vlPBzyCPrVfcTcNCFP7tgN2PasNfEtla28zXUjCWPB4GQT6Y9ar2Hi2wuJGRmCb+SwGCh+lAG2zO0qqxZo054657fhTY+ZSGjLKfm3Zxt+tQJdxRISr7sHqDwoPesTxH4ritUljtTuuGyC+cAe2KAMX4haojsLK3dCAcyfUdq4bbuXc44z/AA/yq1d77iVpJTuJ5JIyagKlSMsenRelADDliE5wOeaRySQq5K44PqakPyp8igN03GoXJ+bduGfToKAHCRFHzkhuvy1r+F4bW81JWvXCWKHMkh9PSuauGYttxn09anj3yR+WikKeMDufWgDtfEfjt/EnibQNK0yH7F4esLyIW9up5kbeMyOe5Pb0r7f8cf8AJM/EH/YIuP8A0S1fnR4eTy/FelpnO29iH/j4r9F/HH/JM/EH/YIuP/RLUAfBtm7LplmAxA8s/wAzWj8Pr3F8kRYHEpDRlsbgeQR7g1hK4FjZgnH7r+tSa1qOmSf2aNKg8h44VS4bbgtJtGTn0zn9aAPWPGdudQ0czbZjqEP+qaNMF8nuR6VleC9X8RaFeRXJspyyNuDLIFb8R3rmfDvjC7sHjhuW8+2zja3UD2NenW0kc8azANtYZAIoA6mT4pprkTw6jYyxtHkuYpvKkA78HjFc18XfEGgeIPDdhf8Ah6WaO9sQI3gf7ygd/fqc1VuLezvwUntlZB3KYINZVzZ3ql3+0K1rtaMQ+Uudh7bqAOI0nxE2jxXH2QLK0hzlutVpPiHqxUgQ2wbPXaeKtanok8OGEIWTHzID8rj1H+FQzwWM1pYIYHZpAASBj5s4YE0ARad441V7pkuPKlSRSu0KFxn0Nbnw11v+x/EcF80Mcwh3BElfapY9Oawl0+yFlIsNoyXTOFidmxnJ5yPpXV6H4bjMcf2iIPFHyuHGCe5P9KAOu1P4kTa5rEsGuubcwBhtI37W9Ao/nWPqGnXGrrKs2oObQn5RCuNw9/8ACp/7OggkLlYkhHJULyT7mln1Sys4g8sqwr2zxmgDpvCPiDV/C2hDRtP1D/QUyULoNyZ5ODXmPj7xR9puHt7abzNpLPPnJJ7jNJ4m8Vw3MD2unZkdxgyDsK423ns4phHfkHcjhuCQhxxnHvQBNo8rNaPISdzK5J/4FTHufK1W2MjlUYbSwPTPeo9NwumN8wICtz6/NVi0vNLgs79dQh825kjxbMRkI2G5P6UAfVnwr8W6VN4LTRNfYRxmMxBzysiHryPrXjviV20PxtqdloL3GoaKjD7O5AbB9NxHIFeaaJr99YeXJazshAwVz8v5V6f4c11NdtA0kYSePhwCMH3oA7zwH8QNW0+z+yTWp2sfuTuOD/snrj2rpLT4j+HdRa8g15mtpZY2gDCTciZ6gZ6V5vOY3UxPGGX0ZeDWVdaTCmlXECu0SSPvYRgfgBnOKAOT8d2sFhr19Db3wubdW8xHiIYEnnI7VyreJ9YtrvMN5JsHRX5Brutc02YwwzuRJb+UI2QJgjHQj39a56ysLeK8eG/iD28kZ8kkDBb+hoAy5vGuuF+bhEwc4RAKmbVZLy7+0TKrNNhmA4GRjmnX2hKQJ5LZ7SBgSGfHIz0+tWNF0KW9kVQoRXPBY/dQf1NAHrtl8Vby08J2mmWcXkWzKUEqDh/XLf0rMkguvszzwXlv5zYwqgkYPOR24qrY2EFkNnlIiKcqNvA/OpzcLaglndy3HPSgCvodhd6TrH9prexzSsCskc8e5JFPVSM9OK6r4ifEe/1DRAl08ESLgpbQg4Y+/fFcXf8AijTrZCHmDMB91DmvPtb1Nr64kupiyQ9EXPP0FAFea/lvdXUyuWO1yR2HynpRUKSW02o2sloQD9m2yLgg7wrZP8qKAOUf77fWm05/vt9abQAUUUUAFOjUvIqr94nAptKCQcjg0AdvoodrRocq0ykABuM++a3LUXMGC0WzH3TnvXDaZqwQqtwduBgOo/U111tfTm3EsbrLEOrKcj/61AFy+ii1CHFypSbnDjiubu7WS3mxt+Xsw6H3rd/tQSQojL/tct1pTLG6mNwrhe3fPtQBzQbkY2nHJBPQ1KGjywcEMf5+tatxpe9Qbc4z1AArOls7iEbTFgDqcZOaAIhCfl2MroOmOBUgjLthuVPYnkevNRx56Nldo9OOanRmVCNwBPAH+frQAxonIJgZGOOmMHFaOi6peadIAA+E+UMD8w/xHtVIuyDOQQOmcHmm+a8YYlVXBxk9aAOr1PVbfU4VF69xLKOduAoYn1qpLevKifJFBGoC8DGQP51y/wBqk3As44P8PU+1T2cMuoXohV3weNx7DuaANY3524iDc5LbO496mjv0Ylbs7VAAG8cium0bRbXTbB7rUZkggVQDJIQAKi8ReHYL63N3pkqShsMjocqQaAMYXKCPZDMHiZcGNjyB6Cq91fQW8Wy1tJEUgfKZiVz+Fc/dpJb3BSVWVl4weKYt420DzG6cbuaAJ7+7urySOSdMBc7VQfL9frVZIZFJKqy4PHY/WpXumOPlJHTgVGWGWZo2YDsc0Aaa6nem3KyXTeWwwyrVKWUnn5cHuwzURlLZ2jaewNRkbmO5cn1oAFOZCSSVHdelM2jLjcSCO3FOHJ2xjGOxNKMjgDnk89qAGeWxxjPWpksw5xk/ielLGTglQoPcGlWYodoX6e1AFyDTYWwzYYgfLxyataxYQ6NpQvLjbE8g/cxdTIfp2A9auaa0Gm2Tavq6HyIf9VEBgyv2FcH4g1q817UpL2/fdI3CqOFReygdhQAvhklvE+kk9TeRH/x8V+jXjj/kmfiD/sEXH/olq/OTwv8A8jNpH/X5D/6GK/Rvxx/yTPxB/wBgi4/9EtQB+etxKqW1mG6+V/U002ag25MbqJc9WHPAqG+P7q0/65D+ZpI7OWQrskj+bgZcDtmgDSnktF2RTI9vKF4cHcp+orR0zWNS01VNtOLi3HYNuX/EVy1zC0MmxnVzjOVbIqe1W22Am6lgl7/uyR+YNAHo1r45hZMXcDo3+yc1eh8X6ZNIqSPIgPXeDivNk8zb8moWcvosmc/qP61KkF0fmaG0l91nRf60Aeq6ldabf6eTHcREqCVKsMisXw1aabNqGJNUkgZlLERR7uffP864lElVv+PLn/ZuF/xrU07UrzTXaa00mJZ8YV3nBA/DNAG9rTaTa64Ra3Vxc2+BveZCGz3x7VZm8Y6faQ+XaRvIAMBQMD865XVL66v5Wmk061jlbBLfa1x+W6saQzD71xYQ/wDAsn9AaAOhvvFOo3vmJbr5UZ79ePrXPXFxECWup3ml/uo2fzNVZPKYHzr539kQkGoS1qv3I5ZD6u2B+lADpb6RgViURKf7vU/jVWnSMHbIRVHoKZQBs2rBNGYnptb/ANCqrDEt1vIR2CAkkEADg9anj/5Abf7rf+hVnQxPJkIwHblsUAaVkIre0aSWBpEZecPgg57VPYXZt5RJpt0Vf+6x2sf6GsuS0lS38xnTbjIG/k846VDAIi+J2dU9VGf0oA9DsvGc8Q2ajbk4/iXir6+M7RiMiRV75WvO4wobEGpIB/01Vl/xqdY7p/uPZTD2dRn88UAes2uvaddxlftUO0jBVjiub8Qy2QHlxTLt64HzfiK47yrgH57KMn/ZuFP/ALNViAzof+QX5g68z/4GgDvNb03w/b+HLWeLVbya62BkSSEhSe49B/8AWrM0jxLY2CZmWSSXHGF6VlXmvald2S2c2mW32ZD+7XzgpX8d3NYcq3WSxjs4R/tTK39TQB1154z84OlvbOWPQsen5Vzep6pdXYH264EaDog6n8Ky5S+B5moQgd1iycfoKrMLRST5k0p9QAufzoAmkvkUn7PGfZpDn9KpSyPK+6Rizepp7yRkERwqo9SSTUNAF7Rv+P8AX/cf/wBBNFGjf8f6/wC4/wD6CaKAMN/vt9abTn++31ptABRRRQAUUUUAFWrG+ubKQtayshPBA6H6iqtKDjpQB1dtrEF2ALqEwSngvH90j6fWr0ML7TLHKGjPG4GuSgv5EwHAcAY56itrT9Zs1H71Wj5zgCgDdsrmVHG7IHB69B/jW/p9yhcCZU+YYwR071g2uoaY6KGvE3kjqcEe1a0Op6HAFzfpgAHk9T3oA6eHStOvEUGJW9eNuT7UreA7OYFoJHXLYGT1rn08V6FbkGO+5HGAhxVyL4t6bp4KpZPd4GBsbYM+vNABqXgGSMsUkLYOAT/hXNah4UurZRvYsB0x7d60tX+Mktzt+x6SkWP+ekpP9K5TVfiFrWoE5+zxD0SPp+dAGppPh0XbhpWCqG+YDA7+tbk+u+HfDEJVAt5eg/6mI8f8CbtXllzqt9cx7JbqQx/3QcD8hVGgDd8UeJ9Q8RXG67cJbqSY7ePhE/xPuad4X8U6h4em/wBGfzLZvvwOcq309D71gUUAey21xo/i6z3WxEd4MF4WwHH09fqK5zV/Dd1aS/6NGZomJC+tcBFLJDIskTsjqchlOCK7XSPiFeQQrb6rAl7EOPMztkH49DQBmPHIkgjYMsnpT4g5Yg5CouTmu1g8R+E9RXErtayMP+W0eMfiM1YXSvD94rC11S02uOQJlBOPrzQBwiMJCdxbAAIJ60ffJBByfWu8j8Iaa0O7+0rdSRk4mU8fnSPofhm0ANxrNqAOxmUkfgKAOCLHIXA/xqe2iaUkIhZj0wM11UupeBbBSDLLeSBif3cZIP0JwKz7n4i2VopXQtEiQ5yslwckfgP8aAH6d4U1O+KtFbbIh/ExwB+dT3p8PeHOb65F9fL0gtyGAPox6CuM1vxhrmsgrd30iwnjyovkT8h1/GsCgDY8TeILnXrsSTKkMCcRQR/dQf1PvWNRRQBp+F/+Rm0j/r8h/wDQxX6N+OP+SZ+IP+wRcf8Aolq/OTwv/wAjNpH/AF+Q/wDoYr9G/HH/ACTPxB/2CLj/ANEtQB+dd9/q7X/rkKtwTLGpfYjnywDviyO2P171DJNbzW9urQSh402Fl5Dc9adcTwOirFHcRADBxzn9aAInthJG8yZ/3VQ4DZ5FQG3mBwYnBxnpVtZ414AusHkjsTnk9aY8ysxw1yF7DA49utAEQE0MQcxfumOQzpkH86b57Y+5F/37FSM4aNUZrkovRSOB+tM2xek//fIoAkt2uLhzHbwrI2MlUjBOBT7hLy3UNcW3lqTwXix1qOJliJMTXKEjaSoA49OtS3F3JcIEnnvJFGOGOR/OgCv9oYA/JFyMfcFJ9oP9yL/vgUu2L0n/AO+RRth9J/8Avkf40AIZ2IICxjjHCAVDU+2H0n/75H+NG2H0n/75H+NAEFFT7Yf+m/8A3yP8aNsP/Tf/AL5H+NAF5P8AkCH6H/0KqVqRskDD0/hzVqK7gS0a3eGV1KEBuAQSc5qOGW2jWQeVOS3Q8cfrQBJdFbmTYERGXpsjILH0NVJbZ1kcIrsq99uKlSRASSbkt1B9D69ac86lcA3IOeT1yPTrQBXjgn80COJy4+YALngUGZs4KR590FTLNtbcsl0GxjI9PTrURWInpP8A98igBPPI/gjH/ABVsQX7AOLSQg858rjkVV2w+k//AHyP8atR300SlY7m8UHGQD6dO9AFQzMMhkTPTlRQZyTkxxZ/3BSsImYljOSeSdo/xpNsP/Tb/vkf40AHnH+5H/3yKjdi7ZOB24GKk2w/9Nv++R/jRti/6bf98j/GgCGiptsX/Tb/AL5H+NG2L0m/75H+NAFjRv8Aj/X/AHH/APQTRSWcsdvOJAspOCuCAByMf1ooAxH++31ptOf77fWm0AFFFFABRRRQAUUUUAFFFKoLMAoJJ4AHegBKKUggkEYI7GkoAKKKKACilpKACiiigAooooAKKKKACiiigAopcnGO1JQAUUUUAFFFFABRRS0AaXhf/kZtI/6/If8A0MV+jfjj/kmniD/sEXH/AKJavzl8L/8AIzaR/wBfcP8A6GK/Rrxx/wAk08Qf9gi4/wDRLUAebfs5adpc/wAINMku7OxlmZpstLCjMfnPcjNfJ+uI48RXsaxyBPtEnCvgdTjHpX078AtUstO+EtjLfF/LjWZmCoXJHmZ4A5PHpXikl94K1DxPA+q2kenwhiLpbeG4YNuhUuxJLEMJTLtKgjhcjB3UAcHIgjt/NcXGB12yDA5qn9rg2uCbjcSdh3jpXo91Z+B9M0eyfU7ZmmmtJZIY0lkEz/JDtMxBZVct5+wqNv3d2MHHKaXe6fZ6B4hjTULRJbhRHDaSQyusw28sH8vJZT91WKgN83OBQBh293CpTz1ncD7218ZouLuIqfIWZSRxufODVCigC5Zrd3k3k27O8hBbG7HA61ZltLyyVZr0N5JOPlfnPassEg5BIPsaUsxGCzEe5oAutdxeapVZvLBOQX5IpWvIPLIVZ/M7EvxWfRQB0NhavqUTvY28zCMANmUcHHvUv9jXzXEey1m2bcspkGTzjI/MVzSsy/dZh9DU0BeSZV80j3ZjigDoodMmlV5Es7oxIzK/71eCMZ/nVZ9NvViMxt5vJ3MA28HOMcVQl3PNJGpiThckOcfhU1tIkqkeXDHg4w8hFAHsP7MthDL8Q/s+rW0Muyzn3JPGrgEMPXIrV/aysrOz1nRP7NtIIVNs+4WyLGCdxxkAc1hfs5SpB44ZpGXb9knGVOR94Vo/tPzwzatpDKVYLbPwVPXcaAPF4Yi6puSYEr2cZJFVpZoopgjC4yrfMC46UNAjqrPN5RI4XaetU5kEbAbstjn2NAFk3Mfm5XzvLx0Lc5qX7ZbeWBsuN+OT5nBrNooAnkuHLkozKvoTV+LTNUkRXVGwwBGWHIIzWTTvMcDh3H/AjQBeNzEi7XWXzV4PzcZ//XRFdQBV8xZicc4bqaz89aKANW1linn8lI5mkkYCMBxWjPo19GkoNpOrgZB3qQv1/OuZB2nIOCO9OMz4P71/++jQB0h0q5jaGCa0uPtEgOCJFwSo5ps2lXnnJFHaTiXkshkHTBP9KygWSzVmaNyzDHzncKdG4jm+cRuZDkPvOFoAvW1ncw3CtNG4jAZGLEEFtpNFFrtM8bKYeVb7jkn7p7UUAcpIjBzlSM8jI7etIInPRG6Z6dq9PufiHo/9q/bP7Jnu22yxiO6YGOGOWQFo0A6KirtXoCGOVxnLdW+JUD2F3baTHqNv9osXtSxkVQCXQqAo4ACKw+XGdx4HNAHmXlvz8jcDd07etNwcZwcdM167qHxWsdQvmuJtOniCEbI4QgWaJXlIgk/2GEi7uoygwPTnYfGGmReCNH0pLG6+3aderd4aQGGU7ssT3BIwMYwOeueADhQrEgBSSewFKY3AyUYduRXod34401nkksoL60mgltp7SWPYGLI07OHx0B+0EDGfuDPtpt8U7Seyuba906W4SXUJNQzJtZmPmb442J/hACg4544IFAHk54pK1vFOpW+r65c6ha232VbnbI8I+6shUb9v+zuzjPOOuTWTQAUo4pKKANvT/E2o2dutuxt7u2UYWK8gSdVHou4EqPYEVeXxFo06Eaj4TsGfbjzLO4lt2z643Mv/AI7XLUUAdMv/AAiFwEyNcsGP3uYrlR/6AalOg+HZ1Y2ni2FWHRLuxljz+K7hXKUUAdOfCLOoNrrugXGRnAvhGfykC1Y/4V14kaPzLe0trlOube9gk/QPXIUUAdZL8OfGMShm8N6oVIyCkBYH8s1nP4T8RI2H0HVgR2NnJ/hWjrHjK4u/Cvh7RLMS20elpIWlWVgZHdiTgA4Axt7ZznNY8PiDWYTmHV9RjP8AsXLj+tADZNB1eP8A1mlX6f71u4/pUDabfL96zuR9Ym/wrTj8Y+JY/ueINVH/AG9yf41IPG3icAD/AISDVMDp/pL/AONAGN9huz/y6z/9+zUsekalKcR6feOf9mFj/StM+NfE5GP7f1P/AMCW/wAaQ+NPE5Of+Eg1X8Lpx/WgCunhjXnGU0TVGHqLSQ/0pl74e1exheW+027tURdx8+MxnGcZwcHFSTeKfEEwxLrmqOPRruQ/1rMurq4u5PMup5Z3xjdI5Y4+poAhooooAKKKKACiiigDvvBnjmz0HR4LK60v7U0dy0pfK/dIBwMjrvVD/wABB6gVb8HeO7bRpNSSZdRljv8AaGhjChE4Ul1QFdsgKYDg5IOcqRz5tXbTeJ9O/t2y1G0fU7XZHbiURLGrK8cAiJRupBwDg4yCc84NAGr4h8WWfibxJ4ZFnphsjDeh2LKFxukTEagEgIu3tjJZjjJJP3H44/5Jn4g/7BFx/wCiWr4n8YeO7Txt4p8PS2tvdQSJqImdJtuyLeYl8uPH8IKE8/3q+2PHH/JM/EH/AGCLj/0S1AHg3wU1NbD4a2j4jDxxzsjSHChtxI52Pj67W+leWaq/hB7a4uRe3F5qDG9kBwYomcK/ljahwAT5RXaACd4Y4wB23wsuni8B6eqgY/edf9414VqF/cx6herHMyq0rggfWgDvrq28ASaxbtHdtIJri5lunnkMUZQM2wELhufkKhdmRuyeAK5CCfTLWz8QxL9kf7TYRm1cgyMkvnxMQhIBQ7BJkHJwMbj1OBJI8rbpGLN0yaZQAUU5VLHAFSpBk8n8qAIKKurbpjOMinfZwThVycdKAKFFXHt49mRuD55GKia3cdOfagCCilZSvUEUlABUsEzQkkBWz1DDNRUUAevfAS48vxKJXGc2s3A/3hWh8fpzc6tphilaEiBgRjO7k1g/BaUw6wrAAn7NKOf94VL8cb2U6ppjIdh8pun1oA87ljkWXm5OIxkPjGM9qrvErRmQ3EZfGSvfNJPeXE+fNlZt3X3qvQAUUU9ImfpwKAGUVbS1Bxuani2Tnj9aAOg0O90GLQVutQC/2vpwmFtB5YKXO4ExlxjDbXYk56qAOcAVf8WDw5f2tgdHu7CKGxMlq8bOY57hVSNUlJEeDuKljkZySPeuPNqmcfMDUUlsyEhTnFAHf6BqnhOPQNAiQQ22swi6+0TXlsroXYwEOzfNldqyooK8EnocMdXSvEXhO2ithDDpSO/nIjyxbvs9v5iHO0xkibCvgMXBLcFVOyvJCpBwQRSUAenW2o+FY4o/3mmzabD9iingnixcTgbHllBEYJILOgUEdCSW+UGSz13QLTUGubmTRLvZJatJH9lws9yvl+ZIMJ/qjiTpgDJ+Q7gV8tooA6nV76G98X3UlrJDLCygl4ECx7/JAcJgDKBtwBIyQATkkmisTRv+P9f9x/8A0E0UAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan images of the abdomen (left) and pelvis (right) demonstrating a locally advanced bladder tumor (red arrows, right panels) and obstructing both ureters (white arrows, left panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Machele Donat, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_42_15011=[""].join("\n");
var outline_f14_42_15011=null;
var title_f14_42_15012="Vaginal tubal sterilization B";
var content_f14_42_15012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vaginal tubal sterilization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_42_15012=[""].join("\n");
var outline_f14_42_15012=null;
var title_f14_42_15013="Degarelix: Drug information";
var content_f14_42_15013=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Degarelix: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/47/24308?source=see_link\">",
"    see \"Degarelix: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8018442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Firmagon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9746641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Firmagon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6850409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Gonadotropin-Releasing Hormone Antagonist;",
"     </li>",
"     <li>",
"      Gonadotropin Releasing Hormone Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6850463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Prostate cancer, advanced:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loading dose: 240 mg administered as two 120 mg (3 mL) injections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maintenance dose: 80 mg administered as one 4 mL injection every 28 days (beginning 28 days after initial loading dose)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6850464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6850465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-80 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6850466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate hepatic impairment: No dosage adjustment necessary; monitor serum testosterone levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe hepatic impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6850472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as acetate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Firmagon&reg;: 80 mg, 120 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6850407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6850467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer (deep) SubQ in the abdominal area by pinching skin and elevating SubQ tissue; insert needle deeply at a 45 degree angle. Avoid pressure exposed areas (eg, waistband, belt, or near ribs). Rotate injection site. Inject loading dose as two 3 mL injections (40 mg/mL) in different sites; maintenance dose should be administered as a single 4 mL injection (20 mg/mL); begin maintenance dose 28 days after initial loading dose. Not for I.V. use; do not inject into a vein or into muscle.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6850410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of advanced prostate cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6850405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Degarelix may be confused with cetrorelix, ganirelix",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6850420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hot flashes (26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injections site reactions (35%, grade 3: &le;2%; pain 28%, erythema 17%, swelling 6%, induration 4%, nodule 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Chills (5%), dizziness (1% to 5%), fever (1% to 5%), headache (1% to 5%), insomnia (1% to 5%), fatigue (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Hyperhydrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia (3%), gynecomastia, testicular atrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Weight gain (9%), constipation (5%), nausea (1% to 5%), diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (5%), erectile dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (10%; grade 3: &lt;1%), AST increased (5%; grade 3: &lt;1%), GGT increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (6%), arthralgia (5%), weakness (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Antidegarelix antibody formation (10%), night sweats (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Bone metastases worsening, cerebral stroke, depression, injection site pruritus, injection site soreness, lymphoma (malignant), mental status changes, MI, osteoarthritis, QT interval prolongation, squamous cell cancer, unstable angina",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6850415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to degarelix or any component of the formulation; pregnancy (or potential to become pregnant)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6850416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased bone mineral density: Androgen deprivation therapy is associated with decreased bone mineral density.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Hypersensitivity reactions (including anaphylaxis, urticaria, and angioedema) have been reported. Discontinue for serious hypersensitivity reaction (immediately if dose not fully injected); manage hypersensitivity as clinically indicated. Do not rechallenge after serious hypersensitivity reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation: Long-term androgen deprivation therapy may prolong the QT interval. Use with caution in patients with a known history of QT prolongation or other risk factors for QT prolongation (eg, concomitant use of medications known to prolong QT interval, heart failure, and/or electrolyte abnormalities).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Androgen-deprivation therapy may increase the risk for cardiovascular disease (Levine, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Androgen deprivation therapy may cause obesity and insulin resistance; the risk for diabetes is increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Degarelix exposure is decreased in patients with hepatic impairment, dosage adjustment is not recommended in patients with mild-to-moderate hepatic impairment, although testosterone levels should be monitored. Has not been studied in patients with severe hepatic impairment; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Data for use in patients with moderate-to-severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute) is limited; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6862046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6850411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6850412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Use is contraindicated in women who are or may become pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6850414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16342191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if degarelix is excreted in breast milk. Not indicated for use in women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6850455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Supplementation with 500 mg calcium and 400 units of vitamin D is recommended (due to increased risk for osteoporosis with androgen deprivation therapy).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Firmagon Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (1): $504.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (1): $757.11",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6850470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prostate-specific antigen (PSA) periodically, serum testosterone levels (if PSA increases; in patients with hepatic impairment: monitor testosterone levels monthly until achieve castration levels, then consider monitoring every other month), liver function tests (at baseline), serum electrolytes (calcium, magnesium, potassium, sodium); bone mineral density",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Screen for diabetes and cardiovascular risk prior to initiating treatment.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Firmagon (AT, AU, BE, CH, CZ, DE, DK, EE, FR, GB, IE, IL, NL, NO, PE, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6850459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gonadotropin-releasing hormone (GnRH) antagonist which reversibly binds to GnRH receptors in the anterior pituitary gland, blocking the receptor and decreasing secretion of luteinizing hormone (LH) and follicle stimulation hormone (FSH), resulting in rapid androgen deprivation by decreasing testosterone production, thereby decreasing testosterone levels. Testosterone levels do not exhibit an initial surge, or flare, as is typical with GnRH agonists.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6850446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Rapid; ~96% of patients had testosterone levels &le;50 ng/dL within 3 days (Klotz, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : &gt;1000 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatobiliary, via peptide hydrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Biphasic release: Rapid release initially, then slow release from depot formed after subcutaneous injection administration (Tornoe, 2007). Bioavailability is decreased in patients with mild-to-moderate hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Loading dose: SubQ: ~53 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Loading dose: SubQ: Within 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (~70% to 80%, primarily as peptide fragments); urine (~20% to 30%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Crawford ED, Tombal B, Miller K, et al, &ldquo;A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 2011, 186(3):889-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/42/15013/abstract-text/21788033/pubmed\" id=\"21788033\" target=\"_blank\">",
"        21788033",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Damber JE, Tammela TL, Iversen P, et al, &ldquo;The Effect of Baseline Testosterone on the Efficacy of Degarelix and Leuprolide: Further Insights From a 12-Month, Comparative, Phase III Study in Prostate Cancer Patients,&rdquo;",
"      <i>",
"       Urology",
"      </i>",
"      , 2012, 80(1):174-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/42/15013/abstract-text/22748873/pubmed\" id=\"22748873\" target=\"_blank\">",
"        22748873",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gittelman M, Pommerville PJ, Persson BE, et al, &ldquo;A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 2008, 180(5):1986-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/42/15013/abstract-text/18801505/pubmed\" id=\"18801505\" target=\"_blank\">",
"        18801505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klotz L, Boccon-Gibod L, Shore ND, et al, &ldquo;The Efficacy and Safety of Degarelix: A 12-month, Comparative, Randomized, Open-Label, Parallel-Group Phase III Study in Patients With Prostate Cancer,&rdquo;",
"      <i>",
"       BJU Int",
"      </i>",
"      , 2008, 102(11):1531-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/42/15013/abstract-text/19035858/pubmed\" id=\"19035858\" target=\"_blank\">",
"        19035858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, D&rsquo;Amico AV, Berger P, et al, &ldquo;Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 121:831-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/42/15013/abstract-text/20124128/pubmed\" id=\"20124128\" target=\"_blank\">",
"        20124128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith MR, Klotz L, Persson BE, et al, &ldquo;Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 2010, 184(6):2313-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/42/15013/abstract-text/20952020/pubmed\" id=\"20952020\" target=\"_blank\">",
"        20952020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tornoe CW, Agerso H, Senderovitz T, et al, &ldquo;Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modelling of the Hypothalamic-Pituitary-Gonadal Axis Following Treatment With GnRH Analogues,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2007, 63(6):648-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/42/15013/abstract-text/17096678/pubmed\" id=\"17096678\" target=\"_blank\">",
"        17096678",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9073 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_42_15013=[""].join("\n");
var outline_f14_42_15013=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018442\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9746641\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850409\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850463\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850464\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850465\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850466\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850472\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850407\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850467\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850410\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850405\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850420\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850415\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850416\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299130\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6862046\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850411\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850412\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850414\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342191\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850455\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321895\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850470\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961945\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850459\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850446\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9073\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9073|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/47/24308?source=related_link\">",
"      Degarelix: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_42_15014="Rosiglitazone and metformin: Patient drug information";
var content_f14_42_15014=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rosiglitazone and metformin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/39/27255?source=see_link\">",
"     see \"Rosiglitazone and metformin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avandamet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avandamet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700337",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause or make heart failure worse. It may raise the chance of chest pain or heart attack. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A small number of people may have more acid in their blood. Metformin may cause this. It may happen in people whose liver or kidneys do not work the right way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3602102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may only get this drug through the AVANDIA-Rosiglitazone Medicines Access Program.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702484",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to metformin, rosiglitazone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem, drink too much alcohol, fluid loss, kidney disease, liver disease, very weak heart, or type 1 diabetes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having an x-ray with dye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop this drug for 2 days after you have an x-ray with dye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you are having surgery, if you have had a heart attack, bad infection, or stroke, or if you are 80 years of age or older and have not had your kidney function tested.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697269",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a chance of pregnancy in women of childbearing age who have not been ovulating.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698129",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Heart failure may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Too much acid in the blood (lactic acidosis) may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain or loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699084",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight or in the way you see color.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11036 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-23D1513A50-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_42_15014=[""].join("\n");
var outline_f14_42_15014=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219452\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219453\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028182\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028184\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028183\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028188\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028189\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028191\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028186\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028187\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028192\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028193\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/39/27255?source=related_link\">",
"      Rosiglitazone and metformin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_42_15015="Surrogate pregnancy";
var content_f14_42_15015=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surrogate pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/42/15015/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15015/contributors\">",
"     Raymond M Anchan, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15015/contributors\">",
"     Elizabeth S Ginsburg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/42/15015/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15015/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/42/15015/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15015/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/42/15015/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical science allows motherhood to be divided into three categories: the genetic, the gestational, and the social mother. These \"mothers\" may be represented by as many as three different individuals.",
"   </p>",
"   <p>",
"    A &ldquo;gestational&rdquo; surrogate is a woman who agrees to carry a pregnancy for another woman (intended mother). The intended mother provides the egg and the intended father provides the sperm; rarely, egg donors or sperm donors are involved. In vitro fertilization (IVF) is used to create an embryo, which is transferred into the uterus of the gestational surrogate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/1\">",
"     1",
"    </a>",
"    ]. The gestational surrogate has no genetic connection to the embryo.",
"   </p>",
"   <p>",
"    By comparison, a &ldquo;traditional&rdquo; surrogate typically has a genetic connection to the embryo. The surrogate's own egg is fertilized by intrauterine insemination (IUI) of sperm from the intended father (or a sperm donor) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/2\">",
"     2",
"    </a>",
"    ]. Therefore, the surrogate has a genetic, as well as a gestational, connection to the embryo.",
"   </p>",
"   <p>",
"    The role of surrogates is usually limited to carrying the pregnancy and delivery of the infant; it does not extend to the raising of the child (social mother). However, gestational and traditional surrogates may be family members, and thus may maintain familial contact with the child [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review issues related to gestational surrogate pregnancy. Many of these issues also apply to traditional surrogacy.",
"   </p>",
"   <p>",
"    In 2009, gestational surrogates were used in 1 percent of assisted reproductive technology (ART) cycles using fresh nondonor embryos in the United States (883 cycles) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of a gestational surrogate may be indicated in the following situations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women without a functional uterus",
"     </li>",
"     <li>",
"      Women with medical conditions potentially associated with pregnancy-related maternal mortality or serious maternal morbidity",
"     </li>",
"     <li>",
"      Women with medical conditions that pose significant risk to the fetus",
"     </li>",
"     <li>",
"      Biologic inability to conceive or bear a child (eg, single male, male couple, recurrent pregnancy loss or in vitro fertilization [IVF] failure)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nonfunctioning uterus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absence of a functional uterus may result from congenital or acquired abnormalities (eg, Mayer-Rokitansky-Kuster-Hauser syndrome, hysterectomy for benign or malignant disease, Asherman syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. However, some of these women may also have ovarian abnormalities or decreased ovarian reserve, which may limit their ability to provide an egg. In these situations, an egg donor or surrogate can be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29014?source=see_link\">",
"     \"Surgical management of congenital uterine anomalies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26101?source=see_link\">",
"     \"Intrauterine adhesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12602?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of hysterectomy\", section on 'Earlier menopause'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Uterine transplantation may be a future alternative approach. However, this technique is only in the early phases of investigation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link&amp;anchor=H14#H14\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\", section on 'Future directions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Maternal medical disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal physiological changes that accompany pregnancy can aggravate concurrent medical conditions, resulting in significant maternal and fetal morbidity, or mortality. For example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with poor cardiac or renal function may experience irreversible deterioration during pregnancy. Pregnancy in women with Eisenmenger syndrome is associated with maternal mortality of 30 to 50 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/21/35159?source=see_link\">",
"       \"Pregnancy in women with congenital heart disease: Specific lesions\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=see_link\">",
"       \"Pregnancy in women with underlying renal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women with medical conditions, such as cancer or organ transplants, may need treatment with drugs that cross the placenta or other interventions, such as radiation therapy, that can adversely affect the fetus. Cancers that express estrogen receptors may be stimulated during ovulation induction or pregnancy; thus, it may be desirable to avoid these processes in affected women. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=see_link\">",
"       \"Overview of fertility and pregnancy in cancer survivors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=see_link\">",
"       \"Long-term management of adult liver transplant recipients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20487?source=see_link\">",
"       \"Pregnancy after cardiac transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15258?source=see_link\">",
"       \"Overview of care of the adult kidney transplant recipient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women with hypertension are at risk of developing superimposed preeclampsia, which may necessitate premature delivery of the fetus for maternal indications. Consequently, the fetus is at risk of developing long-term severe sequelae of prematurity. Severe preeclampsia is also associated with increased maternal morbidity, and rarely mortality. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"       \"Preeclampsia: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See additional individual topic reviews on specific medical disorders that may complicate pregnancy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Biologic inability to conceive or bear a child",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with recurrent pregnancy losses (RPL) or IVF implantation failures may consider use of a gestational surrogate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Women who decide to pursue this route should undergo a thorough evaluation as to the etiology of the RPL or failed IVF. If RPL or recurrent IVF failure is a result of aneuploidy, then one might consider a donor egg IVF cycle with or without a donor sperm prior to embarking on a gestational surrogate approach to pregnancy.",
"   </p>",
"   <p>",
"    Poor pregnancy outcome is another potential indication for using a gestational surrogate. As an example, one report described a 29-year-old woman with three consecutive pregnancies complicated by early onset severe preeclampsia causing fetal demise at 22 and 24 weeks of gestation, a neonatal death at 25 weeks of gestation, and life-threatening maternal hemolysis, elevated liver enzymes, and low platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/13\">",
"     13",
"    </a>",
"    ]. An IVF procedure was performed using the woman's eggs and her husband's sperm, and two embryos were transferred into the uterus of a friend who offered to be a gestational surrogate. The pregnancy progressed without complications to delivery of a healthy 3.2-kg infant at 39 weeks of gestation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1491496531\">",
"    <span class=\"h1\">",
"     FINDING A GESTATIONAL SURROGATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gestational surrogates are recruited through advertisements by the couple's attorney, by independent recruiters, by the IVF program, or by the couple themselves using personal contacts and the media. This can take several months, or more. In the US, at least one state requires that the gestational surrogate be related to one of the intended parents.",
"   </p>",
"   <p>",
"    In one study in which gestational surrogates were evaluated by psychodiagnostic interview and by the Minnesota Multiphasic Personality Interview-2, gestational surrogates were motivated by a wish to help an infertile couple, enjoyed being pregnant, showed narcissistic needs, and expressed a wish for secondary financial gain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/14\">",
"     14",
"    </a>",
"    ]. The majority considered becoming a traditional surrogate, but felt they could not surrender a child that was genetically theirs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SELECTION OF A GESTATIONAL SURROGATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no universal guidelines regarding criteria for choosing a gestational surrogate, but several factors need to be considered in selection of the surrogate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/11\">",
"     11",
"    </a>",
"    ]. Obviously, review of the potential gestational surrogate's obstetrical and general medical history is important to select women at low risk of pregnancy complications. A successful obstetrical history is predictive of favorable gestational outcomes for the intended parents. As an example, a history of preterm birth is the strongest risk factor for recurrent preterm birth, although most women who have had a preterm birth will have subsequent pregnancies of a normal duration. We use gestational surrogates that have a history of at least one uncomplicated pregnancy (eg, no preeclampsia, gestational diabetes, preterm birth) and no chronic medical conditions, with the exception of adequately treated hypothyroidism.",
"   </p>",
"   <p>",
"    Some programs restrict selection of gestational surrogates to women who have only had vaginal births; others allow women with one prior cesarean delivery to become a gestational surrogate.",
"   </p>",
"   <p>",
"    A young maternal age is desirable since advancing age may have deleterious effects on the uterus, which render it a less favorable environment for pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/15\">",
"     15",
"    </a>",
"    ]. As an example, older women are more likely to have uterine leiomyoma or endometrial scarring from previous surgical procedures. They may also have reduced uterine artery blood flow or endometrial receptivity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]; however, these factors appear to play no more than a minor role compared to ovarian aging [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=see_link\">",
"     \"Effect of advanced age on fertility and pregnancy in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Societal and cultural beliefs or legal regulations may preclude use of gestational surrogates who are of a different race than the intended parents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The emotional well-being of the gestational surrogate is important since she must be emotionally prepared to give the newborn child to the intended parents upon delivery. The range of emotions associated with the delivery and transfer of the infant to",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    intended parents is unpredictable. Both biological and nonbiological factors play a role in defining the relationship between a parent and a child [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. A thorough review of the potential gestational surrogate's religious, moral, and ethical views with regard to this process increases the likelihood that transfer of the newborn to the intended parents will proceed smoothly [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of familial members for gestational surrogacy raises unique relationship considerations. Given the inherent long-term relationship between a family member and the intended parent, the association continues well beyond the delivery of the child. This raises social and psychological concerns that need to be properly discussed prior to embarking on use of a family-member for surrogacy. Relationships need to be addressed on at least three levels: (i) the potential surrogate and the rest of the family; (ii) the surrogate and the intended parent; (iii) the surrogate and the child. Given varying family dynamics, one might anticipate and evaluate for undue familial pressure on the potential surrogate to consent to surrogacy. During pregnancy, specific guidelines must be predetermined for the interaction and regulation of the intended parent with the surrogate. As a family member, these interactions may be significantly different since lifestyle patterns of the surrogate are much more familiar to the intended parent, who might attempt to regulate activity beyond the level of traditional intended parent-surrogate agreements. Finally, following delivery, will the relationship between the child and their biological relative be altered in any manner due to the unique involvement as a surrogate? The Society of Assisted Reproductive Technology guidelines suggest psychological screening for all women involved in third party reproduction and more so with specific focus on these areas for familial surrogates.",
"   </p>",
"   <p>",
"    Laboratory screening is also performed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/5\">",
"     5",
"    </a>",
"    ]. The gestational surrogate is tested for HIV-1, HIV-2, hepatitis B, hepatitis C, syphilis, gonorrhea, chlamydia, varicella and rubella titers, and CMV to minimize the chance of transmitting disease to the fetus. Blood type and Rh factor are also performed. Cervical cytology and urine drug screen should be normal. Under the guidelines of the American Society of Reproductive Medicine, the potential surrogate should have a physician evaluation, evaluation of the uterine cavity, and be in excellent physical health. She should not use tobacco, alcohol, or illegal drugs.",
"   </p>",
"   <p>",
"    The gestational surrogate&rsquo;s partner, if there is one, must also consent to infectious disease (gonorrhea, chlamydia, HTLV-1 and HTLV-2, CMV) and psychological screening [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CONTRACTUAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An expert team of healthcare providers, counselors, and attorneys should be involved in drafting the agreement between the gestational surrogate and the intended parents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/22-32\">",
"     22-32",
"    </a>",
"    ]. Both the gestational surrogate and the intended parents should be represented by an attorney, even if the gestational surrogate is a family member. While it is impossible to anticipate every possible scenario, it is prudent to have extensive discussion and clear statements of intent prior to embarking on this route.",
"   </p>",
"   <p>",
"    The expectations of both parties during the gestational process and immediately following delivery should be determined before any assisted reproductive technology is applied. Individual state law governs to what extent, if any, the intended parent may influence actions and behaviors of the gestational surrogate that might impact the pregnancy. As an example, the intended parents may not want the gestational surrogate to smoke during the course of the pregnancy. They may facilitate this intervention by paying for treatment for smoking cessation. However, the intended parents may not be able to require the gestational surrogate to engage in a smoking cessation program.",
"   </p>",
"   <p>",
"    Another important issue is how the parties will resolve issues relating to prenatal diagnosis. Who has the authority to make decisions about terminating the pregnancy if a fetal abnormality is diagnosed? What are the legal rights of a gestational surrogate if she wants to continue the pregnancy when the intended parents choose to terminate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/29\">",
"     29",
"    </a>",
"    ]?",
"   </p>",
"   <p>",
"    When is the gestational surrogate's obligation to the intended parents fulfilled? Following delivery, the intended parents may want the gestational surrogate to provide breast milk or breastfeed the newborn. These postpartum issues should be addressed contractually.",
"   </p>",
"   <p>",
"    Financial remuneration also needs to be determined. What is the appropriate compensation for the gestational surrogate and what expected and unexpected expenses will be covered by the intended parents? Expenses may involve medical, housing, transportation, legal, or health insurance bills. Generally, relatives are not financially compensated by those for whom they carry a pregnancy. For gestational surrogates that are not relatives or friends, the amount of remuneration varies depending on the chosen surrogate, legal fees, geographic region, and agencies involved. When the gestational surrogate has been recruited by the couple's attorney, by independent recruiters, or by IVF programs themselves, these entities have vested financial interests in pairing a gestational surrogate with the intended parent.",
"   </p>",
"   <p>",
"    Finally, what role, if any, will the gestational surrogate assume in the event of the untimely demise of an intended parent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/30\">",
"     30",
"    </a>",
"    ]? This is more than a theoretical issue for gestational surrogates for women with serious medical disorders.",
"   </p>",
"   <p>",
"    We recommend that couples considering use of a gestational surrogate consult with an attorney with expertise in third party reproduction. The laws of the state in which the gestational surrogate delivers determine whether the contracting couple or the gestational surrogate will be the legal parent at the time of delivery. In some states, prebirth adoption is possible, while in others, legal documents created prior to birth can result in the intended parents' names being legally placed on the birth certificate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/33\">",
"     33",
"    </a>",
"    ]. It is vital that these policies be clear to the intended parents and gestational surrogate prior to embarking on pregnancy.",
"   </p>",
"   <p>",
"    The Committee on Ethics of the American College of Obstetricians and Gynecologists has published a Committee Opinion on Surrogate Motherhood that reviews these issues [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PROTECTION OF GESTATIONAL SURROGATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines should be in place to protect the health and ensure the safety of the gestational surrogate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. As an example, HIV infected couples have requested use of a gestational surrogate. Although there are no definitive data that gametes can transmit HIV to the embryo and, in turn, to the gestational surrogate, the theoretical risk of transmitting infection to the gestational surrogate has been ascertained as an unacceptable infectious health risk, and such requests have been denied [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration regulations require the performance of a broad panel of infectious disease screening tests for both intended parents prior to transfer of embryos into a gestational surrogate, and any abnormal test results must be fully disclosed to the gestational surrogate prior to embryo transfer. These screening tests are the same as those performed on the gestational surrogate. These tests are performed before initiation of each fertility treatment cycle. The gestational surrogate may refuse the embryo transfer if parental tests for infection reveal positive results.",
"   </p>",
"   <p>",
"    There is no clear evidence that women with poor obstetrical histories transfer these obstetrical risks to their gestational surrogate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The few cases of obstetrical complications in gestational surrogates reported in the literature do not appear to be above the baseline rate for the general obstetrical population [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/38\">",
"     38",
"    </a>",
"    ]. However, there is a paucity of studies examining this issue and further investigation is necessary.",
"   </p>",
"   <p>",
"    In some cases, obstetrical complications may have been related to preexisting conditions in the gestational surrogate. Thus, it is important to thoroughly review the prior medical and obstetrical history of gestational surrogate candidates, as with any woman seeking preconception counseling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/25/16794?source=see_link\">",
"     \"Preconception evaluation and counseling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1570951720\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications are used to synchronize the menstrual cycles of both the gestational surrogate and the intended mother. The intended mother uses fertility medication to stimulate the development of eggs (unless an egg donor is used). The gestational surrogate takes medication to prepare her uterus for pregnancy. At the appropriate time, the eggs are removed from the intended mother (or independent egg donor) and fertilized in vitro with her partner&rsquo;s sperm (or with donor sperm). The cultured embryos are then transferred into the uterus of the gestational surrogate. Cryopreserved embryos can also be used.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The live birth rate of gestational surrogates is as high or higher than that in age matched controls undergoing routine IVF [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/1,2,7,11,12,15,40-46\">",
"     1,2,7,11,12,15,40-46",
"    </a>",
"    ]. A possible explanation of the higher success rates is that the gestational surrogate may be younger than the intended mother and thus may provide a more favorable uterine environment. Another reason is that infertile couples appear to have a higher rate of adverse pregnancy outcomes compared to normal fertile couples. Thus, pregnancies in gestational surrogates may be more comparable to those in the general obstetrical population than those in the infertility population undergoing IVF.",
"   </p>",
"   <p>",
"    A retrospective analysis of data from the Society for Assisted Reproductive Technologies (SART) compared obstetric outcome for gestational surrogate pregnancies, pregnancies in couples undergoing IVF with their own gametes, and pregnancies conceived using donor eggs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/47\">",
"     47",
"    </a>",
"    ]. Infants of gestational surrogate pregnancies had higher mean birthweight than infants from the other two groups (3309 versus 3236 to 3265 grams), but slightly lower mean gestational age at birth (37.2 weeks versus 37.4 weeks in donor egg pregnancies and 37.7 weeks in IVF pregnancies). The higher birthweight in gestational surrogate pregnancies may reflect the proven uterine environment and absence of infertility-related disorders in these women. The slightly lower gestational age at birth in gestational surrogates and donor egg pregnancies is unexplained.",
"   </p>",
"   <p>",
"    Surrogate pregnancy does not appear to negatively impact parenting or child development when compared to natural conception families [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15015/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A gestational surrogate is a woman who agrees to carry a pregnancy for another woman (intended mother). The intended mother provides the egg and the intended father provides the sperm; rarely, egg donors or sperm donors are involved. In vitro fertilization (IVF) is used to create an embryo, which is transferred into the uterus of the gestational surrogate. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for use of gestational surrogate include: absence of a functional uterus, medical conditions potentially associated with pregnancy-related mortality or serious morbidity, and poor obstetrical history. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical and emotional health of potential gestational surrogates should be evaluated. We suggest an expert team of healthcare providers, counselors, and attorneys be involved in drafting an agreement between the gestational surrogate and the intended parents for the protection of both parties (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Selection of a gestational surrogate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Contractual issues'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Protection of gestational surrogates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The live birth rate of gestational surrogates is as high or higher than that in age matched controls undergoing routine IVF. Surrogate pregnancy does not appear to negatively impact parenting or child development. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/1\">",
"      Utian WH, Sheean L, Goldfarb JM, Kiwi R. Successful pregnancy after in vitro fertilization and embryo transfer from an infertile woman to a surrogate. N Engl J Med 1985; 313:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/2\">",
"      Utian WH, Goldfarb JM, Kiwi R, et al. Preliminary experience with in vitro fertilization-surrogate gestational pregnancy. Fertil Steril 1989; 52:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/3\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Using family members as gamete donors or surrogates. Fertil Steril 2012; 98:797.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2009 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports. Atlanta: U.S. Department of Health and Human Services; 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/5\">",
"      Practice Committee of the American Society for Reproductive Medicine, Practice Committee for the Society for Assisted Reproductive Technology. Recommendations for practices utilizing gestational carriers: an ASRM Practice Committee guideline. Fertil Steril 2012; 97:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/6\">",
"      Steigrad S, Hacker NF, Kolb B. In vitro fertilization surrogate pregnancy in a patient who underwent radical hysterectomy followed by ovarian transposition, lower abdominal wall radiotherapy, and chemotherapy. Fertil Steril 2005; 83:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/7\">",
"      Meniru GI, Craft I. Assisted conception options for patients with good-prognosis cervical cancer. Lancet 1997; 349:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/8\">",
"      Siddle N, Sarrel P, Whitehead M. The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil Steril 1987; 47:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/9\">",
"      Esfandiari N, Claessens EA, O'Brien A, et al. Gestational carrier is an optimal method for pregnancy in patients with vaginal agenesis (Rokitansky syndrome). Int J Fertil Womens Med 2004; 49:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/10\">",
"      Beski S, Gorgy A, Venkat G, et al. Gestational surrogacy: a feasible option for patients with Rokitansky syndrome. Hum Reprod 2000; 15:2326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/11\">",
"      Brinsden PR. Gestational surrogacy. Hum Reprod Update 2003; 9:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/12\">",
"      Stafford-Bell MA, Copeland CM. Surrogacy in Australia: implantation rates have implications for embryo quality and uterine receptivity. Reprod Fertil Dev 2001; 13:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/13\">",
"      Farley DM, Grainger DA, Tjaden BL, et al. Use of a gestational carrier for a patient with recurrent adverse pregnancy outcomes from early onset severe pre-eclampsia. Fertil Steril 2007; 87:189.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/14\">",
"      Braverman AM, Corson SL. Characteristics of participants in a gestational carrier program. J Assist Reprod Genet 1992; 9:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/15\">",
"      Marrs RP, Ringler GE, Stein AL, et al. The use of surrogate gestational carriers for assisted reproductive technologies. Am J Obstet Gynecol 1993; 168:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/16\">",
"      Pirhonen J, Bergersen TK, Abdlenoor M, et al. Effect of maternal age on uterine flow impedance. J Clin Ultrasound 2005; 33:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/17\">",
"      Ubaldi F, Rienzi L, Baroni E, et al. Implantation in patients over 40 and raising FSH levels--a review. Placenta 2003; 24 Suppl B:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/18\">",
"      Pellicer A, Sim&oacute;n C, Remoh&iacute; J. Effects of aging on the female reproductive system. Hum Reprod 1995; 10 Suppl 2:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/19\">",
"      Cano F, Sim&oacute;n C, Remoh&iacute; J, Pellicer A. Effect of aging on the female reproductive system: evidence for a role of uterine senescence in the decline in female fecundity. Fertil Steril 1995; 64:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/20\">",
"      Abdalla HI, Wren ME, Thomas A, Korea L. Age of the uterus does not affect pregnancy or implantation rates; a study of egg donation in women of different ages sharing oocytes from the same donor. Hum Reprod 1997; 12:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/21\">",
"      Navot D, Drews MR, Bergh PA, et al. Age-related decline in female fertility is not due to diminished capacity of the uterus to sustain embryo implantation. Fertil Steril 1994; 61:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/22\">",
"      Cherry AL. Nurturing in the service of white culture: racial subordination, gestational surrogacy, and the ideology of motherhood. Tex J Women Law 2001; 10:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/23\">",
"      Pretorius, D. Surrogate motherhood: A worldwide view of the issues. New Eng J Med 1994; 331:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/24\">",
"      Golombok S, MacCallum F, Murray C, et al. Surrogacy families: parental functioning, parent-child relationships and children's psychological development at age 2. J Child Psychol Psychiatry 2006; 47:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/25\">",
"      Van Zyl L. Intentional parenthood: responsibilities in surrogate motherhood. Health Care Anal 2002; 10:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/26\">",
"      Fuscaldo G. Genetic ties: are they morally binding? Bioethics 2006; 20:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/27\">",
"      Bravennan AM, Corson SL. A comparison of oocyte donors' and gestational carriers/surrogates' attitudes towards third party reproduction. J Assist Reprod Genet 2002; 19:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/28\">",
"      Gunn, W. Bioethics and Law: Standard of Care: The Law of American Bioethics. JAMA 1994; 271:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/29\">",
"      Yamamoto K, Moore SA. A trust analysis of a gestational carrier's right to abortion. Fordham Law Rev 2001; 70:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/30\">",
"      Rosen A. Third-party reproduction and adoption in cancer patients. J Natl Cancer Inst Monogr 2005; :91.",
"     </a>",
"    </li>",
"    <li>",
"     Brinsden, PR. Surrogacy. In Brinsden, PR (Ed). A textbook of in vitro fertilization and assisted reproduction. Parthenon, Carnforth and New York 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/32\">",
"      MacCallum F, Lycett E, Murray C, et al. Surrogacy: the experience of commissioning couples. Hum Reprod 2003; 18:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/33\">",
"      Massachusetts. Supreme Judicial Court. Culliton v. Beth Israel Deaconess Medical Center. Wests North East Rep 2001; 756:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/34\">",
"      Committee on Ethics. ACOG committee opinion number 397, February 2008: surrogate motherhood. Obstet Gynecol 2008; 111:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/35\">",
"      Guichon J. The body, emotions and intentions: challenges of preconception arrangements for health care providers. CMAJ 2007; 176:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/36\">",
"      Reilly DR. Surrogate pregnancy: a guide for Canadian prenatal health care providers. CMAJ 2007; 176:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/37\">",
"      Adams KE. Gestational surrogacy for a human immunodeficiency virus seropositive sperm donor: what are the ethics? J Am Med Womens Assoc 2003; 58:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/38\">",
"      Duffy DA, Nulsen JC, Maier DB, et al. Obstetrical complications in gestational carrier pregnancies. Fertil Steril 2005; 83:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/39\">",
"      Parkinson J, Tran C, Tan T, et al. Perinatal outcome after in-vitro fertilization-surrogacy. Hum Reprod 1999; 14:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/40\">",
"      Brinsden PR, Appleton TC, Murray E, et al. Treatment by in vitro fertilisation with surrogacy: experience of one British centre. BMJ 2000; 320:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/41\">",
"      Meniru GI, Craft IL. Experience with gestational surrogacy as a treatment for sterility resulting from hysterectomy. Hum Reprod 1997; 12:51.",
"     </a>",
"    </li>",
"    <li>",
"     Batzofin, J, Nelson, J, Wilcox, J, et al. Gestational surrogacy: is it time to include it as part of ART? Fertil Steril ASRM Annual Meeting Programme Supplement 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/43\">",
"      Goldfarb JM, Austin C, Peskin B, et al. Fifteen years experience with an in-vitro fertilization surrogate gestational pregnancy programme. Hum Reprod 2000; 15:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/44\">",
"      Raziel A, Schachter M, Strassburger D, et al. Eight years' experience with an IVF surrogate gestational pregnancy programme. Reprod Biomed Online 2005; 11:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/45\">",
"      Corson SL, Kelly M, Braverman AM, English ME. Gestational carrier pregnancy. Fertil Steril 1998; 69:670.",
"     </a>",
"    </li>",
"    <li>",
"     Anchan, RM, Ginsburg, ES. Gestational carriers: A viable alternative in assisted reproductive medicine. American Society for Reproductive Medicine 62nd Annual Meeting Abstract P-133. New Orleans, Louisiana.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15015/abstract/47\">",
"      Gibbons WE, Cedars M, Ness RB, Society for Assisted Reproductive Technologies Writing Group. Toward understanding obstetrical outcome in advanced assisted reproduction: varying sperm, oocyte, and uterine source and diagnosis. Fertil Steril 2011; 95:1645.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7431 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_42_15015=[""].join("\n");
var outline_f14_42_15015=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nonfunctioning uterus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Maternal medical disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Biologic inability to conceive or bear a child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1491496531\">",
"      FINDING A GESTATIONAL SURROGATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SELECTION OF A GESTATIONAL SURROGATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CONTRACTUAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PROTECTION OF GESTATIONAL SURROGATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1570951720\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=related_link\">",
"      Clinical manifestations and diagnosis of congenital anomalies of the uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=related_link\">",
"      Effect of advanced age on fertility and pregnancy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26101?source=related_link\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=related_link\">",
"      Long-term management of adult liver transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15258?source=related_link\">",
"      Overview of care of the adult kidney transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=related_link\">",
"      Overview of fertility and pregnancy in cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12602?source=related_link\">",
"      Overview of hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/25/16794?source=related_link\">",
"      Preconception evaluation and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20487?source=related_link\">",
"      Pregnancy after cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/21/35159?source=related_link\">",
"      Pregnancy in women with congenital heart disease: Specific lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=related_link\">",
"      Pregnancy in women with underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29014?source=related_link\">",
"      Surgical management of congenital uterine anomalies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_42_15016="Amniotic fluid embolism syndrome";
var content_f14_42_15016=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Amniotic fluid embolism syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/42/15016/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15016/contributors\">",
"     Marie R Baldisseri, MD, FCCM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/42/15016/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15016/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15016/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/42/15016/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15016/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/42/15016/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amniotic fluid embolism syndrome (also called anaphylactoid syndrome of pregnancy) is a catastrophic condition that occurs during pregnancy or shortly after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although first reported in 1926, it was not widely recognized until 1941 when an autopsy series of eight women who had died from sudden shock during labor reported squamous cells and mucin of fetal origin in the maternal pulmonary vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Fetal squamous cells have also been described in the vascular beds of the maternal kidneys, liver, spleen, pancreas, and brain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amniotic fluid embolism syndrome is reviewed here. The management of critically ill obstetric patients is discussed separately, including those with venous thromboembolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34681?source=see_link\">",
"     \"Critical illness during pregnancy and the peripartum period\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amniotic fluid embolism syndrome is rare. Most studies indicate that the incidence rate is between 1 and 12 cases per 100,000 deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/6-11\">",
"     6-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors have been associated with amniotic fluid embolism syndrome. They include precipitous or tumultuous labor, advanced maternal age, cesarean and instrumental delivery, placenta previa and abruption, grand multiparity (&ge;5 live births or stillbirths), cervical lacerations, fetal distress, eclampsia, and medical induction of labor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/6,11,12\">",
"     6,11,12",
"    </a>",
"    ]. Our understanding of the pathogenesis suggests that these factors probably are associated with amniotic fluid embolism syndrome, but not the direct cause. The syndrome is best considered unpredictable and unpreventable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amniotic fluid probably enters the maternal circulation through the endocervical veins, the placental insertion site, or a site of uterine trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/13\">",
"     13",
"    </a>",
"    ]. Once it reaches the maternal circulation, it can precipitate cardiogenic shock, respiratory failure, and, most likely, an inflammatory and anaphylactoid response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cardiogenic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal studies indicate that amniotic fluid can cause occlusion and vasospasm of the maternal pulmonary vasculature, resulting in rapid development of pulmonary hypertension, acute cor pulmonale, and systemic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. However, invasive hemodynamic measurements from women with amniotic fluid embolism syndrome (AFES) seem to contradict these animal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The combination of an elevated pulmonary arterial pressure, elevated pulmonary capillary wedge pressure, decreased cardiac output, and decreased cardiac index suggest that the principal hemodynamic alteration in humans is left ventricular failure, rather than pulmonary hypertension and right ventricular failure.",
"   </p>",
"   <p>",
"    A biphasic pattern of cardiogenic shock in AFES has been proposed in an effort to reconcile the animal and human observations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/2,14,18\">",
"     2,14,18",
"    </a>",
"    ]. According to the hypothesis, initial acute pulmonary hypertension and right ventricular failure (usually lasting 15 to 30 minutes) is followed by left ventricular dysfunction. Supporting this biphasic hypothesis, studies that used transesophageal echocardiography to noninvasively measure hemodynamic parameters early during AFES reported diffuse vasospasm of the pulmonary vasculature, elevated pulmonary arterial pressure, and right ventricular failure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of left ventricular failure during the later phase is unclear. Animal data suggest that it may be due to hypoxic injury to the left ventricle, release of maternal inflammatory mediators, or a direct depressant effect of amniotic fluid on the myocardium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxemia is the most common manifestation of respiratory failure among patients with AFES. Hypoventilation can also occur.",
"   </p>",
"   <p>",
"    Severe",
"    <span class=\"nowrap\">",
"     ventilation/perfusion",
"    </span>",
"    <span class=\"nowrap\">",
"     (V/Q)",
"    </span>",
"    mismatching appears to be the primary cause of hypoxemia. Factors that contribute to the",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    mismatching include acute pulmonary hypertension during the first phase of cardiogenic shock and cardiogenic pulmonary edema during the second phase [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/2\">",
"     2",
"    </a>",
"    ]. Other contributors may include bronchospasm (approximately 15 percent of patients) and noncardiogenic pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/7,21\">",
"     7,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noncardiogenic pulmonary edema occurs in up to 70 percent of patients who survive the first several hours [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/21\">",
"     21",
"    </a>",
"    ]. It generally develops as left ventricular dysfunction improves. Evidence for damage to the endothelial-alveolar membrane and a capillary leak syndrome includes the high protein concentration in edema fluid and the presence of amniotic fluid debris in the sputum and alveolar spaces. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=see_link\">",
"     \"Noncardiogenic pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the noncardiogenic edema that occurs in AFES appears to result from widespread damage to the alveolar-capillary membrane, it usually does not produce a clinical pattern typical of acute respiratory distress syndrome (ARDS). Patients who survive the first hours of AFES generally recover rapidly, whereas the course of ARDS tends to be protracted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It seems unlikely that obstruction of the pulmonary vasculature is the lone cause of AFES, since there can be a lag of many hours between the entry of amniotic fluid into the maternal circulation and the onset of the symptoms and signs of AFES. It has been proposed that the lag may reflect the evolution of an immunologic response or inflammatory reaction to the amniotic fluid. This is supported by reports of decreased complement and increased inflammatory markers in some patients with AFES, including elevated serum tryptase levels and pulmonary mast cell activity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/22-27\">",
"     22-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to this hypothesis, fetal antigens enter the maternal circulation via the amniotic fluid. The severity of the clinical manifestations may be related to the degree of immunologic stimulation or the balance of leukotrienes and other arachidonic acid metabolites in the amniotic fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of the symptoms and signs of AFES most commonly occurs during labor and delivery, or immediately postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/2\">",
"     2",
"    </a>",
"    ]. Rarely, it has been reported as late as 48 hours after cesarean delivery or postpartum, as well as following a first or second trimester abortion, amniocentesis, or",
"    <span class=\"nowrap\">",
"     abdominal/uterine",
"    </span>",
"    trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/7,30-34\">",
"     7,30-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major clinical findings are the abrupt and fulminant onset of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypotension due to cardiogenic shock",
"     </li>",
"     <li>",
"      Hypoxemia and respiratory failure",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation",
"     </li>",
"     <li>",
"      Coma or seizures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    According to a review of 272 cases, most patients present with rapid cardiorespiratory collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/9\">",
"     9",
"    </a>",
"    ]. Nonspecific symptoms (eg, chills, nausea, vomiting, agitation) may precede the onset of dyspnea and hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. Tonic-clonic seizure activity may also occur.",
"   </p>",
"   <p>",
"    There appears to be a less severe presentation of AFES (ie, partial amniotic fluid embolism syndrome) in which only some of the major symptoms and signs occur [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/14,35,36\">",
"     14,35,36",
"    </a>",
"    ]. Such patients generally present with the sudden onset of milder dyspnea and hypotension. The clinical course tends to be abbreviated and the prognosis is much better, compared to women who have the full syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotension due to cardiogenic shock is a prominent feature of AFES. Approximately 85 percent of patients with AFES die from cardiogenic shock or its complications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/9\">",
"     9",
"    </a>",
"    ]. The clinical manifestations of cardiogenic shock are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac dysrhythmias may complicate the management of cardiogenic shock. These include pulseless electrical activity, bradycardia, ventricular fibrillation, and asystole [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/7\">",
"     7",
"    </a>",
"    ]. The management of these dysrhythmias is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hypoxemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Profound hypoxemia is the most common manifestation of respiratory failure and a common early finding in AFES. It is most commonly detected by pulse oximetry, but clinical findings may include confusion, agitation, somnolence, dyspnea, tachycardia, tachypnea, cyanosis, and acidemia. There may be evidence of cardiogenic or noncardiogenic pulmonary edema, including crackles and radiographic air space disease. Wheezing is occasionally detected.",
"   </p>",
"   <p>",
"    Hypoxemia causes about 50 percent of the deaths that occur within the first hour. Permanent, severe neurologic impairment or maternal brain death can result from profound or prolonged hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=see_link\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 80 percent of patients with AFES develop disseminated intravascular coagulation (DIC) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/1,2,7\">",
"     1,2,7",
"    </a>",
"    ]. It can begin as quickly as 10 to 30 minutes after the onset of cardiopulmonary symptoms and signs, or may be delayed by as many as four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/2,37-40\">",
"     2,37-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prolonged bleeding from sites of invasive interventions and bruising are the most common manifestations of DIC. However, in some cases, major hemorrhage may be the clinical manifestation. This can delay the diagnosis of AFES since an exhaustive search for structural causes of hemorrhage is likely [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous causes of hypotension, hypoxemia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemorrhage in women who are pregnant or postpartum. They can be divided into obstetrical, anesthetic, and nonobstetrical causes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/2\">",
"     2",
"    </a>",
"    ]. Obstetrical causes include placental abruption, uterine rupture, uterine atony, eclampsia, and peripartum cardiomyopathy. Anesthetic causes include high spinal anesthesia and local anesthetic toxicity. Nonobstetrical causes include pulmonary embolism, air embolism, anaphylaxis, septic shock, massive aspiration, transfusion reaction, and myocardial infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;AFES is essentially a clinical diagnosis that is based upon the constellation of clinical findings, rather than isolated symptoms and signs. Clinicians should suspect AFES whenever shock",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory compromise develops during labor or immediately postpartum. Other causes of sudden intrapartum or postpartum cardiorespiratory failure must be excluded. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Amniotic fluid debris (squamous cells, trophoblastic cells, mucin, and lanugo) can sometimes be identified in blood samples drawn from the distal port of a pulmonary artery catheter. However, finding amniotic fluid debris should not be considered diagnostic of AFES since such debris is common in the maternal circulation of women without AFES [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serological assays and immunohistochemical staining that use a monoclonal antibody (TKH-2) to detect a common fetal antigen in the mother's blood appear to have a high sensitivity for AFES [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. However, these methods have not been fully validated and cannot be recommended for routine clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific treatment for AFES. The goal of therapy is to correct hypoxemia and hypotension so that ischemic consequences (eg, hypoxic brain injury, acute kidney injury) are prevented in the mother and adequate oxygen delivery to the fetus is ensured in women who have not delivered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Initial assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous monitoring of the maternal oxyhemoglobin saturation, heart rate and rhythm, and respiratory rate should be immediately initiated in all patients with suspected AFES. The blood pressure should be measured noninvasively at frequent intervals, with the goal of eventually establishing continuous blood pressure monitoring. Continuous monitoring of the fetal heart rate is desirable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the initial assessment, plans should be made for both an arterial and a central venous catheter to be inserted. It is important that the initiation of the therapies described below not be delayed by catheter insertion, which can be time consuming.",
"   </p>",
"   <p>",
"    The arterial catheter can be used to continuously monitor blood pressure. It also provides access to arterial blood for frequent measurement of arterial blood gases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26424?source=see_link\">",
"     \"Arterial catheterization techniques for invasive monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The central venous catheter can be used to infuse intravenous fluids, infuse medications (including vasopressors and inotropic medications), infuse blood products, and draw venous blood. In addition, it can be used for limited hemodynamic monitoring by measuring the central venous pressure and the central venous oxyhemoglobin saturation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link\">",
"     \"Overview of central venous access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemodynamic monitoring via a pulmonary arterial catheter should not be performed routinely. However, it may be helpful in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/17,45,46\">",
"     17,45,46",
"    </a>",
"    ], particularly those who have shock, pulmonary edema, and an uncertain intravascular volume status. In such patients, invasive hemodynamic monitoring ensures that the amount of intravenous fluid administered is enough to correct intravascular hypovolemia and optimize cardiac output, but not so much that it exacerbates the pulmonary edema. In a series of five patients with AFES who were managed with invasive hemodynamic monitoring, all five survived [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Oxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen should be provided to all patients. A reasonable goal is a maternal arterial oxygen tension (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) above 65 mmHg. This often requires high flow rates of supplemental oxygen by facemask or invasive mechanical ventilation. Invasive mechanical ventilation provides the clinician with additional options to improve oxygenation. These include increasing the fraction of inspired oxygen, increasing the positive end-expiratory pressure, and prolonging or inversing the inspiratory to expiratory ratio. Noninvasive positive pressure ventilation should be avoided during pregnancy because of the high risk of aspiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link&amp;anchor=H19#H19\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'Refractory hypoxemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors that impair oxygen delivery to the fetus (eg, anemia, diminished cardiac output) should be corrected in all women who have not delivered. This may require red blood cell transfusions and inotropic agents. In women who have delivered, these factors should be corrected if there is evidence of persistent hypoperfusion despite optimization of the PaO",
"    <sub>",
"     2",
"    </sub>",
"    . Common signs of hypoperfusion include cool, vasoconstricted skin due to redirection of blood flow to core organs (although warm, flushed skin may be present in the early phases of sepsis), obtundation or restlessness, oliguria or anuria, and lactic acidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31430?source=see_link&amp;anchor=H4#H4\">",
"     \"Oxygen delivery and consumption\", section on 'Oxygen delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rationale for maintaining a maternal PaO",
"    <sub>",
"     2",
"    </sub>",
"    greater than 65 mmHg is best explained using women who have not delivered as an example. However, it is similar for women who have delivered, except the primary concern is end organ oxygen delivery rather than fetal oxygen delivery. Fetal oxygen delivery is directly related to umbilical vein oxygen tension, umbilical vein oxyhemoglobin saturation, fetal hemoglobin concentration, and maternal cardiac output. In healthy pregnant women, increased fetal hemoglobin concentration and maternal cardiac output compensate for low umbilical vein oxygen tension, thereby maintaining sufficient fetal oxygen delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31430?source=see_link&amp;anchor=H4#H4\">",
"     \"Oxygen delivery and consumption\", section on 'Oxygen delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The compensatory increase in fetal hemoglobin concentration and maternal cardiac output may be inadequate to maintain fetal oxygen delivery in pregnant women who have an even lower umbilical vein oxygen tension due to systemic hypoxemia. The degree of maternal hypoxemia at which the compensatory mechanisms become inadequate is uncertain. In a study that exposed healthy pregnant women to low fractions of inspired oxygen, a maternal PaO",
"    <sub>",
"     2",
"    </sub>",
"    below 47 mmHg was associated with a decline in the umbilical vein oxygen tension [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/47\">",
"     47",
"    </a>",
"    ]. This PaO",
"    <sub>",
"     2",
"    </sub>",
"    lies on the steep portion of the hemoglobin dissociation curve, where small changes in PaO",
"    <sub>",
"     2",
"    </sub>",
"    may cause large changes in oxyhemoglobin saturation and oxygen delivery. Given this observation, it seems prudent to maintain the maternal oxygen tension at a level that lies on the flat portion of the hemoglobin dissociation curve (ie, &gt;65 mmHg), assuming there are no complicating abnormalities in maternal cardiac output, hemoglobin, or pH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hemodynamic support",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to hypotensive patients with AFES is the same regardless of whether they have delivered. Patients who are hypotensive should have their intravascular volume status immediately assessed by history and physical examination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are intravascularly normovolemic or hypervolemic, a vasopressor is the preferred initial therapy.",
"     </li>",
"     <li>",
"      For patients whose intravascular volume status is uncertain, there are two reasonable approaches to initial therapy. First, empiric therapy can be initiated using a vasopressor. This is based on the observation that hypotension in AFES is almost always due to cardiogenic shock and coexisting intravascular hypovolemia is rare. Second, therapy can be guided by hemodynamic measurements from a pulmonary arterial catheter. With this approach, the intravenous fluids are titrated to optimize cardiac output and cardiac filling pressures. Vasopressors are then added to achieve the desired blood pressure once the volume status is optimized.",
"     </li>",
"     <li>",
"      For the rare patients who have obvious intravascular hypovolemia, a trial of intravenous fluids is reasonable initial therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Vasoactive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;When vasopressor therapy is selected, norepinephrine and dopamine are the initial drugs of choice. Adding the inotrope,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    , may be beneficial since it increases the low cardiac output and decreases the high afterload that are characteristic of cardiogenic shock. However, dobutamine should not be used until after the vasopressors have improved the blood pressure. When used alone, dobutamine tends to reduce blood pressure by causing a drop in the systemic vascular resistance that is out of proportion to the increase in cardiac output. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vasopressors are used to treat hypotension in AFES even though they may diminish uteroplacental perfusion pressure. The rationale is that untreated shock also diminishes uteroplacental perfusion pressure and has numerous additional potential adverse consequences. These include decreasing the fetal oxygen delivery, increasing the mother's risk of ischemic complications (eg, acute kidney injury, hypoxic brain injury), and increasing the mother's risk of death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Intravenous fluids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever a trial of intravenous fluids is selected, a cautious approach is warranted since pulmonary edema is common in AFES. The fluids should be administered as small boluses and recurrent assessment is required. Once the intravascular volume has been replenished, the intravenous fluids should be discontinued. New or worsening pulmonary edema should prompt immediate discontinuation of intravenous fluids. Patients whose pulmonary edema worsens during a trial of intravenous fluids should be regarded as having an uncertain intravascular volume and be managed as described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Blood products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood product transfusion may be required for some patients with coagulopathy or bleeding due to disseminated intravascular coagulation (DIC). The management of DIC and the potential complications of massive blood product transfusion are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Delivery of the fetus",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, AFES most commonly occurs during labor and delivery or postpartum. When AFES presents intrapartum, the need for immediate delivery must be determined. The decision is made on a case-by-case basis, but factors that favor urgent delivery include a nonreassuring fetal heart rate tracing, rapid and progressive deterioration of the mother's condition, or the opinion that delivery of the fetus may facilitate maternal resuscitative efforts. Operative vaginal delivery is reasonable if the cervix is fully dilated and the fetal head has descended to a station of at least",
"    <span class=\"nowrap\">",
"     +2/5.",
"    </span>",
"    Otherwise, an emergency cesarean delivery is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=see_link\">",
"     \"Operative vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Major maternal morbidity or death is a significant risk when a cesarean is performed in the presence of coagulopathy. Some clinicians recommend that operative intervention not begin until the coagulopathy is corrected. However, this is not always possible, especially if a delay could lead to fetal death, further blood loss, and worsening of the coagulopathy. If a cesarean has to be performed urgently, blood, fresh frozen plasma, platelets, and cryoprecipitate should be available in the operating room and should be administered if there is any evidence of impaired coagulation (eg, persistent bleeding without clotting from incision or needle sites).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Novel interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have described novel interventions that have been used in patients with AFES:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhaled nitric oxide and a right ventricular assist device have been used in patients with pulmonary hypertension and right ventricular failure [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/4/38982?source=see_link\">",
"       \"Inhaled nitric oxide in adults with pulmonary hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiopulmonary bypass, intraaortic balloon pump counterpulsation, and extracorporeal membrane oxygenation (ECMO) have been used in patients with severe left ventricular failure and hypoxemia [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/20,50\">",
"       20,50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37863?source=see_link\">",
"       \"Extracorporeal membrane oxygenation (ECMO) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"       Recombinant human factor VIIa",
"      </a>",
"      has been used in patients with severe coagulopathy and bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=see_link\">",
"       \"Therapeutic uses of recombinant coagulation factor VIIa\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maternal mortality rate due to AFES has been reported to be anywhere from 10 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/1,6,7,51-53\">",
"     1,6,7,51-53",
"    </a>",
"    ], although more recent data from large unselected populations suggest that overall mortality rates may be closer to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/6,10,11\">",
"     6,10,11",
"    </a>",
"    ]. Even those who survive generally have a poor outcome, with as many as 85 percent suffering significant neurologic injury due to cerebral hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. It is one of the leading causes of maternal mortality and is reported to cause 10 percent of all maternal deaths in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neonatal outcomes are also poor. The mortality rate is estimated to be between 20 and 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Only 50 percent of survivors are neurologically intact. Overall neonatal outcomes have improved with prompt delivery if the fetus is in utero and the mother sustains an amniotic fluid embolism-induced cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15016/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amniotic fluid embolism syndrome (AFES) is a catastrophic condition that occurs during pregnancy or shortly after delivery. It is characterized by the abrupt and fulminant onset of hypotension due to cardiogenic shock, hypoxemia, respiratory failure, and disseminated intravascular coagulation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AFES is unpredictable, unpreventable, and rare (occurring once in every 8000 to 80,000 deliveries). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AFES is a clinical diagnosis that is based upon the constellation of clinical findings. Clinicians should suspect AFES whenever shock or respiratory compromise develops during labor and delivery, or immediately postpartum. Other causes of sudden intrapartum or postpartum cardiorespiratory failure must be excluded. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific treatment for AFES. The goal of therapy is to expeditiously correct hypoxemia and hypotension, so that ischemic consequences (eg, hypoxic brain injury, acute kidney injury, and myocardial injury) in the mother are prevented and adequate oxygen delivery to the fetus is ensured. This may require mechanical ventilation, vasopressors, inotropes, intravenous fluids, and blood products. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal mortality due to AFES remains high, although less than in previous years. This most likely reflects early recognition of the syndrome and appropriate aggressive therapy. However, even those who survive generally have a poor outcome, most often neurologic injury due to cerebral hypoxia. Neonatal outcomes are also poor, although they improve with early delivery. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/1\">",
"      Gilmore DA, Wakim J, Secrest J, Rawson R. Anaphylactoid syndrome of pregnancy: a review of the literature with latest management and outcome data. AANA J 2003; 71:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/2\">",
"      Gist RS, Stafford IP, Leibowitz AB, Beilin Y. Amniotic fluid embolism. Anesth Analg 2009; 108:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/3\">",
"      Meyer, JR. Embolia pulmonar amnio caseosa. Brasil Medico 1926; 2:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/4\">",
"      Steiner PE, Lushbaugh CC. Landmark article, Oct. 1941: Maternal pulmonary embolism by amniotic fluid as a cause of obstetric shock and unexpected deaths in obstetrics. By Paul E. Steiner and C. C. Lushbaugh. JAMA 1986; 255:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/5\">",
"      Liban E, Raz S. A clinicopathologic study of fourteen cases of amniotic fluid embolism. Am J Clin Pathol 1969; 51:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/6\">",
"      Abenhaim HA, Azoulay L, Kramer MS, Leduc L. Incidence and risk factors of amniotic fluid embolisms: a population-based study on 3 million births in the United States. Am J Obstet Gynecol 2008; 199:49.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/7\">",
"      Clark SL, Hankins GD, Dudley DA, et al. Amniotic fluid embolism: analysis of the national registry. Am J Obstet Gynecol 1995; 172:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/8\">",
"      Tuffnell DJ. United kingdom amniotic fluid embolism register. BJOG 2005; 112:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/9\">",
"      Morgan M. Amniotic fluid embolism. Anaesthesia 1979; 34:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/10\">",
"      Kramer MS, Rouleau J, Baskett TF, et al. Amniotic-fluid embolism and medical induction of labour: a retrospective, population-based cohort study. Lancet 2006; 368:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/11\">",
"      Knight M, Tuffnell D, Brocklehurst P, et al. Incidence and risk factors for amniotic-fluid embolism. Obstet Gynecol 2010; 115:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/12\">",
"      Turner LA, Kramer MS, Liu S, Maternal Mortality and Morbidity Study Group of the Canadian Perinatal Surveillance System. Cause-specific mortality during and after pregnancy and the definition of maternal death. Chronic Dis Can 2002; 23:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/13\">",
"      Courtney LD. Amniotic fluid embolism. Obstet Gynecol Surv 1974; 29:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/14\">",
"      Clark SL. New concepts of amniotic fluid embolism: a review. Obstet Gynecol Surv 1990; 45:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/15\">",
"      ATTWOOD HD, DOWNING ES. EXPERIMENTAL AMNIOTIC FLUID AND MECONIUM EMBOLISM. Surg Gynecol Obstet 1965; 120:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/16\">",
"      Reis RL, Pierce WS, Behrendt DM. Hemodynamic effects of amniotic fluid embolism. Surg Gynecol Obstet 1969; 129:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/17\">",
"      Clark SL, Cotton DB, Gonik B, et al. Central hemodynamic alterations in amniotic fluid embolism. Am J Obstet Gynecol 1988; 158:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/18\">",
"      Clark SL, Montz FJ, Phelan JP. Hemodynamic alterations associated with amniotic fluid embolism: a reappraisal. Am J Obstet Gynecol 1985; 151:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/19\">",
"      Shechtman M, Ziser A, Markovits R, Rozenberg B. Amniotic fluid embolism: early findings of transesophageal echocardiography. Anesth Analg 1999; 89:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/20\">",
"      Stanten RD, Iverson LI, Daugharty TM, et al. Amniotic fluid embolism causing catastrophic pulmonary vasoconstriction: diagnosis by transesophageal echocardiogram and treatment by cardiopulmonary bypass. Obstet Gynecol 2003; 102:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/21\">",
"      Price TM, Baker VV, Cefalo RC. Amniotic fluid embolism. Three case reports with a review of the literature. Obstet Gynecol Surv 1985; 40:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/22\">",
"      Nishio H, Matsui K, Miyazaki T, et al. A fatal case of amniotic fluid embolism with elevation of serum mast cell tryptase. Forensic Sci Int 2002; 126:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/23\">",
"      Farrar SC, Gherman RB. Serum tryptase analysis in a woman with amniotic fluid embolism. A case report. J Reprod Med 2001; 46:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/24\">",
"      Benson MD, Kobayashi H, Silver RK, et al. Immunologic studies in presumed amniotic fluid embolism. Obstet Gynecol 2001; 97:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/25\">",
"      Fineschi V, Gambassi R, Gherardi M, Turillazzi E. The diagnosis of amniotic fluid embolism: an immunohistochemical study for the quantification of pulmonary mast cell tryptase. Int J Legal Med 1998; 111:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/26\">",
"      Benson MD. A hypothesis regarding complement activation and amniotic fluid embolism. Med Hypotheses 2007; 68:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/27\">",
"      Benson MD. Current concepts of immunology and diagnosis in amniotic fluid embolism. Clin Dev Immunol 2012; 2012:946576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/28\">",
"      Azegami M, Mori N. Amniotic fluid embolism and leukotrienes. Am J Obstet Gynecol 1986; 155:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/29\">",
"      Benson MD. Nonfatal amniotic fluid embolism. Three possible cases and a new clinical definition. Arch Fam Med 1993; 2:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/30\">",
"      Lawson HW, Atrash HK, Franks AL. Fatal pulmonary embolism during legal induced abortion in the United States from 1972 to 1985. Am J Obstet Gynecol 1990; 162:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/31\">",
"      Hasaart TH, Essed GG. Amniotic fluid embolism after transabdominal amniocentesis. Eur J Obstet Gynecol Reprod Biol 1983; 16:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/32\">",
"      Mainprize TC, Maltby JR. Amniotic fluid embolism: a report of four probable cases. Can Anaesth Soc J 1986; 33:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/33\">",
"      Ellingsen CL, Eggeb&oslash; TM, Lexow K. Amniotic fluid embolism after blunt abdominal trauma. Resuscitation 2007; 75:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/34\">",
"      Rainio J, Penttil&auml; A. Amniotic fluid embolism as cause of death in a car accident--a case report. Forensic Sci Int 2003; 137:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/35\">",
"      Masson RG, Ruggieri J, Siddiqui MM. Amniotic fluid embolism: definitive diagnosis in a survivor. Am Rev Respir Dis 1979; 120:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/36\">",
"      Wasser WG, Tessler S, Kamath CP, Sackin AJ. Nonfatal amniotic fluid embolism: a case report of post-partum respiratory distress with histopathologic studies. Mt Sinai J Med 1979; 46:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/37\">",
"      Peterson EP, Taylor HB. Amniotic fluid embolism. An analysis of 40 cases. Obstet Gynecol 1970; 35:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/38\">",
"      Beller FK. Disseminated intravascular coagulation and consumption coagulopathy in obstetrics. Obstet Gynecol Annu 1974; 3:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/39\">",
"      Bastien JL, Graves JR, Bailey S. Atypical presentation of amniotic fluid embolism. Anesth Analg 1998; 87:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/40\">",
"      Malhotra P, Agarwal R, Awasthi A, et al. Delayed presentation of amniotic fluid embolism: lessons from a case diagnosed at autopsy. Respirology 2007; 12:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/41\">",
"      Davies S. Amniotic fluid embolism and isolated disseminated intravascular coagulation. Can J Anaesth 1999; 46:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/42\">",
"      Lee W, Ginsburg KA, Cotton DB, Kaufman RH. Squamous and trophoblastic cells in the maternal pulmonary circulation identified by invasive hemodynamic monitoring during the peripartum period. Am J Obstet Gynecol 1986; 155:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/43\">",
"      Oi H, Kobayashi H, Hirashima Y, et al. Serological and immunohistochemical diagnosis of amniotic fluid embolism. Semin Thromb Hemost 1998; 24:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/44\">",
"      Kobayashi H, Ooi H, Hayakawa H, et al. Histological diagnosis of amniotic fluid embolism by monoclonal antibody TKH-2 that recognizes NeuAc alpha 2-6GalNAc epitope. Hum Pathol 1997; 28:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/45\">",
"      Clark SL. Amniotic fluid embolism. Crit Care Clin 1991; 7:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/46\">",
"      Vanmaele L, Noppen M, Vincken W, et al. Transient left heart failure in amniotic fluid embolism. Intensive Care Med 1990; 16:269.",
"     </a>",
"    </li>",
"    <li>",
"     Wulf KH, Kunzel W, Lehman V. Clinical aspects of placental gas exchange. In: Respiratory gas exchange and blood flow in the placenta, Longo LD, Bartels H (Eds), United States Public Health Service, Bethesda, MD 1972. p.505.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/48\">",
"      McDonnell NJ, Chan BO, Frengley RW. Rapid reversal of critical haemodynamic compromise with nitric oxide in a parturient with amniotic fluid embolism. Int J Obstet Anesth 2007; 16:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/49\">",
"      Nagarsheth NP, Pinney S, Bassily-Marcus A, et al. Successful placement of a right ventricular assist device for treatment of a presumed amniotic fluid embolism. Anesth Analg 2008; 107:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/50\">",
"      Hsieh YY, Chang CC, Li PC, et al. Successful application of extracorporeal membrane oxygenation and intra-aortic balloon counterpulsation as lifesaving therapy for a patient with amniotic fluid embolism. Am J Obstet Gynecol 2000; 183:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/51\">",
"      Gilbert WM, Danielsen B. Amniotic fluid embolism: decreased mortality in a population-based study. Obstet Gynecol 1999; 93:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/52\">",
"      Clark SL. Amniotic fluid embolism. Clin Perinatol 1986; 13:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/53\">",
"      Suidan JS. Amniotic fluid embolism. Middle East J Anesthesiol 1989; 10:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/54\">",
"      Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol 2010; 116:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15016/abstract/55\">",
"      Clark SL. Amniotic fluid embolism. Clin Obstet Gynecol 2010; 53:322.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1591 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_42_15016=[""].join("\n");
var outline_f14_42_15016=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cardiogenic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Initial assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Oxygenation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hemodynamic support",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Vasoactive agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Intravenous fluids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Blood products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Delivery of the fetus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Novel interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26424?source=related_link\">",
"      Arterial catheterization techniques for invasive monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=related_link\">",
"      Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34681?source=related_link\">",
"      Critical illness during pregnancy and the peripartum period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37863?source=related_link\">",
"      Extracorporeal membrane oxygenation (ECMO) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=related_link\">",
"      Hypoxic-ischemic brain injury: Evaluation and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/4/38982?source=related_link\">",
"      Inhaled nitric oxide in adults with pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=related_link\">",
"      Operative vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=related_link\">",
"      Overview of central venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31430?source=related_link\">",
"      Oxygen delivery and consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_42_15017="Calciphylaxis";
var content_f14_42_15017=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Calciphylaxis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/42/15017/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15017/contributors\">",
"     Peter W Santos, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15017/contributors\">",
"     J Edward Hartle, II, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15017/contributors\">",
"     L Darryl Quarles, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/42/15017/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15017/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/42/15017/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15017/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/42/15017/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calciphylaxis is a rare and serious disorder characterized by systemic medial calcification of the arterioles that leads to ischemia and subcutaneous necrosis. Histologic inspection may reveal small vessel mural calcification with or without endovascular fibrosis, extravascular calcification (amorphous luminal calcium), and thrombotic vaso-occlusion (leading to ischemic skin necrosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calciphylaxis is one of several types of extra-osseous calcification (which also includes intimal, medial, and valvular calcifications) that may occur in patients with end-stage renal disease (ESRD). Traditionally, it has been classified as metastatic calcification indicating passive mineralization of serum calcium and phosphate crystals.",
"   </p>",
"   <p>",
"    Calciphylaxis most commonly occurs in patients with end-stage renal disease (ESRD) who are on hemodialysis or who have recently received a renal transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. However, it does not exclusively occur in ESRD patients. A systemic review revealed 36 cases of nonuremic causes of calciphylaxis, and the most common cause reported is primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to vascular calcification are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20185?source=see_link\">",
"     \"Biology of vascular calcification in renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"calciphylaxis\" is a misnomer, since it implies a systemic anaphylactic reaction that was first observed in an animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/7\">",
"     7",
"    </a>",
"    ]. Calcific uremic arteriolopathy is more descriptive of this process in ESRD patients, however, calciphylaxis is still widely used to describe this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of calciphylaxis is poorly understood and likely represents a severe form of the same process leading to vascular and soft tissue calcification in ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/11\">",
"     11",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Metastatic calcifications, including dystrophic medial deposits in medium-sized arteries, are much more common in ESRD than calciphylaxis. These common types of vascular calcifications, however, do not lead to ischemic changes despite often impressive radiographic findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis of renal osteodystrophy\", section on 'Extraosseous calcification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A reduction in the arteriolar blood flow that is a consequence of intimal fibrosis associated with the calcifications, massive mural calcifications of the dermohypodermic arterioles, and thrombus formation within the venules is the proximate cause of calciphylaxis clinical manifestations. Three-dimensional analysis of a calciphylaxis plaque reveals that medial vessel calcification is the first process in its development [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/12\">",
"     12",
"    </a>",
"    ]. Vascular endothelial injury and dysfunction result in cutaneous arteriolar narrowing and hypercoagulable state producing frank tissue infarction that is clinically observed in established cases of calciphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historically, hyperparathyroidism, active vitamin D administration, hyperphosphatemia, and an elevated plasma calcium x phosphate product (Ca x P), were implicated in the genesis of calciphylaxis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A role for parathyroid hormone (PTH) is supported by the reported clinical improvement following parathyroidectomy and by the ability to experimentally induce ischemic skin necrosis in animals via excess administration of PTH. However, there has been no systematic or prospective evaluation of the effectiveness of parathyroidectomy to treat calciphylaxis due to the sporadic nature of this disorder. Moreover, most patients with severe hyperparathyroidism do not have skin necrosis and many patients with calciphylaxis do not have hyperparathyroidism, indicating the important role of additional factors. The mechanism underlying the beneficial effect of parathyroidectomy may be secondary to the loss of PTH effects on bone that lead to a transient uptake of calcium and phosphate into bone (ie, \"hungry bone syndrome\") and a lower (Ca x P) product.",
"     </li>",
"     <li>",
"      Vitamin D administration (at high doses) can also induce calciphylaxis as well as exacerbate soft-tissue calcifications in experimental models. This association may be of particular relevance, since calcitriol and other vitamin D analogs are administered to treat secondary hyperparathyroidism in subjects with ESRD. Active vitamin D analogs may contribute to calciphylaxis indirectly through their actions to increase serum phosphate or directly through their effect on the vasculature. Whether excessive doses of active vitamin D analogues are associated with an increased incidence of calciphylaxis in ESRD is unclear.",
"     </li>",
"     <li>",
"      Much of the attention on Ca and P levels in contributing to vascular calcification among ESRD patients has been extracted from national dialysis data suggesting associated increased rates of mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/14\">",
"       14",
"      </a>",
"      ]. Hyperphosphatemia has been regarded as a risk factor for calciphylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Inhibitors of vascular calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional studies suggest a possible role for a deficiency in inhibitors of vascular calcifications, such as fetuin-A (2-Heremens-Schmid glycoprotein) and matrix Gla protein (MGP):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetuin-A (eg, 2-Heremens-Schmid glycoprotein) is an abundant serum glycoprotein that binds calcium and phosphate in the circulation, thereby forming \"calciprotein particles\" that help clear the circulation of excess Ca X PO4 [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/15\">",
"       15",
"      </a>",
"      ]. Fetuin limits organ and soft tissue calcification, including vascular calcium deposition, in a murine deficiency model [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/16\">",
"       16",
"      </a>",
"      ]. Tissue calciphylaxis mediated by vitamin D is associated with downregulation of circulating levels of this glycoprotein [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/17\">",
"       17",
"      </a>",
"      ]. In an ex-vivo assay, fetuin A levels from hemodialysis patients were significantly lower and had an impaired capacity to inhibit Ca X PO4 precipitation in an ex-vivo assay [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/18\">",
"       18",
"      </a>",
"      ]. Fetuin A is downregulated in inflammatory states [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Matrix Gla protein, a mineral binding extracellular matrix protein that is synthesized by vascular smooth muscle and chondrocytes, has been characterized in an animal model to actively inhibit calcification of arteries and cartilage [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/20\">",
"       20",
"      </a>",
"      ]. Its activity is dependent upon vitamin K-dependent carboxylation, which is critical in mediating the activity of the protein to inhibit calcification locally [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/21\">",
"       21",
"      </a>",
"      ]. Calciphylaxis can develop in the setting of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      anticoagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20185?source=see_link\">",
"       \"Biology of vascular calcification in renal failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of chronic inflammation on the development of calciphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic inflammatory states appear to be involved in nonuremic and uremic calciphylaxis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a systemic review of the literature, connective tissue disease and Crohn&rsquo;s disease were observed in nonuremic calciphylaxis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/6\">",
"       6",
"      </a>",
"      ]. Additional findings in a retrospective case control study revealed that autoimmune conditions were the most common clinical feature of nondialysis patients presenting with calciphylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In dialysis patients, autoimmune conditions such as SLE may be a contributing factor in the development of calciphylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. Low fetuin A levels correlate with a chronic inflammatory state and cardiovascular calcification in hemodialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, calciphylaxis is a complex human disorder that results from a multitude of predisposing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sensitizing events coupled with pathogenic factors associated with vascular calcification. Further studies on the molecular regulators and inhibitors of skeletal and extraskeletal mineralization would be needed to further our knowledge on the pathogenesis of calciphylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20185?source=see_link\">",
"     \"Biology of vascular calcification in renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calciphylaxis was first described in 1962 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/7\">",
"     7",
"    </a>",
"    ]. Although previously rare, the incidence of this disorder has appeared to be increasing, due in part to the awareness and the recognition of clinical signs and risk factors associated with calciphylaxis. As an example, a cross sectional study of 242 hemodialysis patients in an outpatient unit revealed a prevalence of four percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/27\">",
"     27",
"    </a>",
"    ]. However, further epidemiological studies are required to reveal its true prevalence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple studies have identified major clinical factors and comorbid conditions that may help recognize patients at risk for the development of calciphylaxis in both ESRD and non ESRD patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Females undergoing dialysis have higher risk of developing calciphylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/10,22\">",
"       10,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients with ESRD, obesity (BMI &gt;30) may lead to excess stress on dermal and hypodermal arterioles, resulting in focally dystrophic calcification of arterioles [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/4,28\">",
"       4,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increasing increments in phosphorus levels among those with ESRD is a risk factor [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The administration of different medications is associated with an increased risk of calciphylaxis in patients with ESRD. These include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/22\">",
"       22",
"      </a>",
"      ], calcium based binders and vitamin D analogues [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/5\">",
"       5",
"      </a>",
"      ], and systemic corticosteroids [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/23\">",
"       23",
"      </a>",
"      ]. Calciphylaxis can develop in the setting of warfarin anticoagulation through inhibition of vitamin K-dependent carboxylation of matrix Gla protein, a mineral-binding extracellular matrix protein that actively inhibits calcification of arteries and cartilage in an animal model [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. In a case control study, the use of warfarin was more prevalent in ESRD subjects with calciphylaxis compared to ESRD control subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/10\">",
"       10",
"      </a>",
"      ].",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of autoimmune disorders was the major feature in patients without ESRD in two case series: polymyositis, Sj&ouml;gren's Syndrome, rheumatoid arthritis, sarcoidosis, Crohn&rsquo;s disease [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/6,23\">",
"       6,23",
"      </a>",
"      ]. Systemic lupus erythematosus has been reported in both ESRD and non ESRD patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Calciphylaxis has been observed in patients with primary hyperparathyroidism but without ESRD [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a subset of ESRD patients, a hypercoagulable state, such as protein C and S deficiency and antiphospholipid syndrome, may underlie the development of the disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/29-32\">",
"       29-32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a case control study of calciphylaxis in Japanese ESRD patients, both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy and hypoalbuminemia were significant risk factors for development of calciphylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calciphylaxis is typically characterized by areas of excruciatingly painful ischemic necrosis that usually develop on areas with greatest adiposity including abdomen, buttock, and thigh [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/4\">",
"     4",
"    </a>",
"    ]. There are violaceous, painful, plaque&ndash;like subcutaneous nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/4\">",
"     4",
"    </a>",
"    ]. The initial purpuric plaques and nodules subsequently progress to",
"    <span class=\"nowrap\">",
"     ischemic/necrotic",
"    </span>",
"    ulcers with eschars that often become superinfected.",
"   </p>",
"   <p>",
"    The ischemic changes observed clinically as livedo reticularis are a reflection of medial arteriolar calcification and subintimal fibrosis leading to luminal narrowing, diminished blood flow, hypoxia, and procoagulant state (",
"    <a class=\"graphic graphic_picture graphicRef52454 \" href=\"UTD.htm?36/53/37718\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65250 \" href=\"UTD.htm?5/13/5333\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/33\">",
"     33",
"    </a>",
"    ]. Once vascular thrombosis is advanced, the result is necrotic ulcer with eschar that is clinically evident in the calciphylaxis lesion (",
"    <a class=\"graphic graphic_picture graphicRef52395 \" href=\"UTD.htm?28/7/28784\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ischemic myopathy is a less frequent complication that can occur without skin necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/34\">",
"     34",
"    </a>",
"    ]. Digital ischemia has a somewhat better prognosis than proximal skin necrosis, but these patients are still at appreciable risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory and radiographic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific laboratory findings in patients with calciphylaxis. In some patients, elevated levels of PTH, phosphorous, calcium, and the calcium-phosphorous product are observed; however, these abnormalities are not always present [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Roentgenographic imaging modalities, such as plain radiographs, high resolution CT scans, and mammographic techniques, can distinguish calcium from surrounding non-calcium containing radiolucent tissues. These techniques vary in their ability to resolve such differences. In a case report, for example, radiography using mammography was superior to CT or plain films in revealing diffuse arteriolar calcification in a mesh-like pattern of an involved calciphylaxis lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/35\">",
"     35",
"    </a>",
"    ]. However, a significant limitation of x-ray mammography is that the technique used to obtain the study can be quite painful, as it involves compressing the affected calciphylaxis extremity between two plates.",
"   </p>",
"   <p>",
"    Empiric observations suggest that bone scintigraphy may be useful in assessing soft tissue calcifications that can be associated with calciphylaxis in certain settings [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/36\">",
"     36",
"    </a>",
"    ]. In one study, for example, a bone scan was positive in 97 percent of cases (34 of 36 patients), with most patients having subcutaneous nonulcerating nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/5\">",
"     5",
"    </a>",
"    ]. Further studies are needed to define the role of routine bone scanning in assessing the risk of calciphylaxis and following its progression (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54302 \" href=\"UTD.htm?37/39/38513\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic examination of skin lesions reveals arterial medial arteriolar calcification, subintimal fibrosis, and arterial occlusion in the absence of vasculitic change (",
"    <a class=\"graphic graphic_picture graphicRef72408 \" href=\"UTD.htm?37/7/38000\">",
"     picture 4",
"    </a>",
"    ). The most common pathologic finding in both early and late stage cases is acute and chronic calcifying septal panniculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/37\">",
"     37",
"    </a>",
"    ]. Subcutaneous or dermal vascular thrombosis can also be present [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calciphylaxis should be suspected in patients with skin lesions characterized by painful, nonulcerating subcutaneous nodules or plaques, nonhealing ulcers,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    necrosis, which are most commonly present in the thigh and areas of increased adiposity. There may also be a trend for increasing Ca X P product and PTH levels in ESRD patients over the preceding several months (particularly in the setting of medication noncompliance)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    use.",
"   </p>",
"   <p>",
"    The importance of obtaining a skin biopsy to establish a tissue diagnosis of calciphylaxis is not certain. However, since there are other disorders that may mimic calciphylaxis, knowledge of the tissue histology may be helpful in confirming a strong clinical suspicion.",
"   </p>",
"   <p>",
"    We therefore recommend a skin biopsy, if there are no contraindications, to confirm the diagnosis. This is performed after considering and discussing the risk and benefits of the procedure with the patient.",
"   </p>",
"   <p>",
"    A skin biopsy is frequently avoided in cases when the patient has an active infection (such as bacteremia or sepsis) since a biopsy may invite further infection. Additional possible risks with the procedure include ulceration in the region of the incision among nonulcerating patients and poor healing post-biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients may also refuse a skin biopsy due to the very painful nature of the disease.",
"   </p>",
"   <p>",
"    Findings on histology are discussed in the previous section. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Pathology'",
"    </a>",
"    above.) Overall, the specificity and sensitivity of skin biopsies in the diagnosis of calciphylaxis have not been determined, nor have definitive criteria for making the diagnosis been established.",
"   </p>",
"   <p>",
"    A three-phase technetium 99m methylene diphosphate bone scintigraphy may have a role in the diagnosis of calciphylaxis, although the exact sensitivity and specificity of this technique is unclear. A positive scan suggests the presence of calcifications in subcutaneous nodules or non-ulcerating lesions in viable tissue (which is capable of technetium 99m methylene diphosphate uptake). A baseline positive scan can also reveal the extent of vascular calcification and the presence of metastatic calcification. In one case series, bone scan was used to monitor the progression of calciphylaxis during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    treatment (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54302 \" href=\"UTD.htm?37/39/38513\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although painful, radiography using mammography technique can also be employed as a primary or secondary imaging study to help confirm the diagnosis of calciphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients, initial histologic and radiographic tests are inconclusive. In this setting, a presumptive clinical diagnosis of calciphylaxis should be made and treated accordingly if other causes have been excluded and a strong clinical suspicion of calciphylaxis remains (eg, characteristic painful nonhealing skin lesions in the setting of the clinical and laboratory risk factors previously described). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Epidemiology and risk factors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of calciphylaxis are similar to those of a significant number of other disorders, thereby sometimes confounding the diagnosis. These disorders include cholesterol embolization,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    necrosis, cryoglobulinemia, cellulitis, and vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, atherosclerosis, atheroemboli, and vasculitis must be excluded in the patient with calciphylaxis presenting with peripheral gangrene in the absence of skin lesions. Affected patients typically lack other signs of vasculitis and, in contrast to atherosclerosis, have intact peripheral pulses, bilateral necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/30\">",
"     30",
"    </a>",
"    ], and frequent involvement of the upper extremity. The diagnosis of calciphylaxis can be established by a biopsy of affected areas that is highly suspicious for the disorder. (See appropriate topic reviews for the clinical manifestations of these disorders).",
"   </p>",
"   <p>",
"    Calciphylaxis is also broadly classified into the group of cyanotic-infarctive \"pseudovasculitis\" that results from vaso-occlusion. Other diseases that need to be distinguished from calciphylaxis are vaso-occlusion by emboli, thrombi, or fibrointimal hyperplasia (endarteritis obliterans) that occurs in a variety of conditions such as purpura fulminans, Coumadin necrosis, antiphospholipid antibody syndrome, cardiac myxoma, cholesterol embolization, and radiation arteritis.",
"   </p>",
"   <p>",
"    Calciphylaxis can also be mistaken in its early stages for nephrogenic systemic fibrosis. The lesions of nephrogenic fibrosing dermopathy are typically described as erythematous papules that coalesce into erythematous to brawny plaques, and the skin involved becomes thickened and woody in texture [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/39\">",
"     39",
"    </a>",
"    ]. Histopathological examination of skin and deep punch biopsies are essential to differentiate these two disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREVENTION AND TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high mortality associated with calciphylaxis, more effective ways to treat this disorder are needed.",
"   </p>",
"   <p>",
"    There are no controlled prospective studies that compare different treatment strategies in patients with calciphylaxis. Rather, specific therapeutic regimens have been evaluated only in a limited number of patients.",
"   </p>",
"   <p>",
"    A reasonable plan of intervention should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An aggressive program of wound care and adequate pain control.",
"     </li>",
"     <li>",
"      Avoidance of local tissue trauma, including subcutaneous injections.",
"     </li>",
"     <li>",
"      Correction of underlying abnormalities in plasma calcium and phosphorus concentrations, with lowering of the Ca X P product below 55",
"      <span class=\"nowrap\">",
"       mg2/dL2",
"      </span>",
"      in ESRD patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/40\">",
"       40",
"      </a>",
"      ]. There are no randomized prospective or observational studies that have compared the different available agents in this setting. The administration of non-calcium containing phosphate binders, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      carbonate or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/37/28244?source=see_link\">",
"       lanthanum carbonate",
"      </a>",
"      , rather than calcium-based phosphate binders for the treatment of hyperphosphatemia is rational, given the effect of calcium binders to increase the rate of vascular calcifications and the case reports suggesting benefit with lowering elevated serum phosphorus and calcium levels,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Ca x P product [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/41-43\">",
"       41-43",
"      </a>",
"      ]. Among dialysis patients, serum levels of phosphate should be maintained between 3.5 and 5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.13 to 1.78",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Among dialysis patients, normalize serum PTH levels (intact PTH should be between 150 to 300",
"      <span class=\"nowrap\">",
"       pg/mL)",
"      </span>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"       cinacalcet",
"      </a>",
"      . There are no randomized prospective or observational studies that have compared cinacalcet with vitamin D analogues among dialysis patients with calciphylaxis. If PTH levels are elevated, the use of cinacalcet rather than vitamin D analogues to lower PTH is reasonable, since vitamin D analogues have a tendency to raise the Ca X P product, whereas cinacalcet lowers the product while suppressing PTH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"       \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"       Cinacalcet",
"      </a>",
"      may serve as an alternative to parathyroidectomy since it can provide biochemical control of secondary hyperparathyroidism. Several case reports support this approach [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/44-46\">",
"       44-46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"       \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"       \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Parathyroidectomy should also be considered for ESRD patients with refractory hyperparathyroidism. The role of urgent parathyroidectomy is uncertain even in calciphylaxis associated with frank hyperparathyroidism. Surgical series suffer from selection bias and small numbers of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/47-50\">",
"       47-50",
"      </a>",
"      ]. In one retrospective study of 35 patients, the 23 patients who underwent a parathyroid resection had a longer median overall survival than those treated non-surgically (80 versus 35 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/50\">",
"       50",
"      </a>",
"      ]. However, a retrospective case control study failed to show a survival advantage among calciphylaxis patients who had parathyroidectomy compared to non-surgical-treated calciphylaxis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/23\">",
"       23",
"      </a>",
"      ]. We believe that prompt parathyroidectomy may benefit patients whose plasma calcium and phosphorous concentrations are uncontrollable with dialysis and medication.",
"     </li>",
"     <li>",
"      Increasing the sessions of renal replacement therapy in end-stage renal disease patients with inadequate clearance [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Consideration of lowering the dose of immunosuppression in the renal transplant patient who demonstrates progressive or persistent calciphylactic lesions despite institution of the above noted interventions.",
"     </li>",
"     <li>",
"      Since the activity of matrix Gla protein is dependent on vitamin K carboxylation, discontinuation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy should be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of surgical debridement is controversial because removal of necrotic tissue exposes vital subcutaneous tissue to bacteria and increases the risk of sepsis. A retrospective analysis of patients who had undergone debridement led to a 62 percent overall survival rate at one year compared to 27.4 percent survival rate in patients who had no debridement [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/23\">",
"     23",
"    </a>",
"    ]. However, patients may require more pain control and aggressive wound care after debridement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sodium thiosulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been growing interest in the initiation of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    (STS) as an adjunctive off-label treatment in patients with debilitating calciphylactic necrotic lesions in ESRD patients including children and young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/38,51-54\">",
"     38,51-54",
"    </a>",
"    ]. It has been used in a patient with calciphylaxis and normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose of STS is empiric. The most commonly reported dose is 25 grams (two 12.5 gram vials diluted in 100 ml of normal saline) infused over 30 to 60 minutes during the last hour of each hemodialysis session [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intraperitoneal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    was successfully administered to an ESRD patient on peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/56\">",
"     56",
"    </a>",
"    ]. However, there was another case report describing the development of chemical peritonitis after intraperitoneal sodium thiosulfate administration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/57\">",
"     57",
"    </a>",
"    ]. Oral sodium thiosulfate has been utilized as a secondary prevention of calciphylaxis following successful resolution of calciphylaxis with intravenous sodium thiosulfate. The reported tolerated dose was 2.6 grams three times a week after each hemodialysis session since higher frequent dosing of 2.6 grams per day lead to the development of diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacokinetic simulations have been proposed to calculate dose requirement for each different hemodialysis regimens since assays for STS blood levels are unavailable and the rigorous studies on pharmacokinetic extracorporeal clearance of STS are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/59\">",
"     59",
"    </a>",
"    ]. The reported length of treatment varies. Dramatic reduction in pain has been reported within two weeks of starting STS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/51\">",
"     51",
"    </a>",
"    ], and almost complete resolution of calciphylaxis lesions within six months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The consensus on most of the case reports and series is that STS treatment is utilized until there is almost complete resolution of the lesions and patients have reported less pain.",
"   </p>",
"   <p>",
"    While all reported patients have thus far tolerated therapy, an associated increased anion gap metabolic acidosis has been reported, probably due to sulfate retention [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The use of high bicarbonate dialysate may resolve",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    induced metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The probable mechanism of action is dissolution of insoluble calcium salts embedded in tissue into soluble calcium thiosulfate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/60\">",
"     60",
"    </a>",
"    ]. Furthermore, it may have ability to restore endothelial function and promote vasodilation through its antioxidant properties [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the high morbidity and mortality associated with calciphylaxis, we suggest the administration of STS for ESRD patients who have this condition. The preferred STS dosage is 25 grams given over 30 to 60 minutes three times weekly, generally during the last hour of hemodialysis sessions. This regimen should be continued until there is complete resolution of lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Novel and experimental therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of novel and experimental therapies have been evaluated in calciphylaxis. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an experimental model, administration of bisphosphonate inhibited calciphylactic reaction in rats treated with sub-lethal doses of vitamin D [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/62\">",
"       62",
"      </a>",
"      ]. In a case report, six doses of intravenous pamidronate therapy resolved the calciphylaxis lesions in a chronic renal failure patient [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/63\">",
"       63",
"      </a>",
"      ]. Oral etidronate disodium therapy was also shown to improve skin ulcers in one case report [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/64\">",
"       64",
"      </a>",
"      ]. On both studies, it was speculated that bisphosphates may have anti-inflammatory activity as observed in decreased C reactive protein levels after the administration [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/63,64\">",
"       63,64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of five patients, hyperbaric oxygen therapy, which consisted of 25 to 35 90-minute sessions at 2.5 atmospheres, resulted in complete healing of extensive necrotic ulcers in two individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/65\">",
"       65",
"      </a>",
"      ]. Lesions did not respond in the remaining patients. In the largest retrospective case series of patients with calciphylaxis treated with hyperbaric oxygen therapy, there was resolution of lesions in eight out of nine patients treated for 90 minutes at 2.5 atmospheres, with a mean of 40.6 sessions [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A single-center study reported the successful use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      in ESRD patients with non-ulcerating plaques [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/5\">",
"       5",
"      </a>",
"      ]. Among 14 patients without ulcers and an increased risk of infection, prednisone resulted in stabilization or improvement in 11. However, a retrospective case control study reported systemic corticosteroids are a risk factor for calciphylaxis in non ESRD patients with an autoimmune disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/23\">",
"       23",
"      </a>",
"      ]. Given the lack of an adequate control group and the marked risks associated with corticosteroids, further study is clearly needed to understand the role, if any, of corticosteroids in this setting.",
"     </li>",
"     <li>",
"      Daily low-dose infusion of tissue plasminogen activator was used successfully as adjuvant treatment in a small number of patients, but many such treatments were complicated by bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leg revascularization was attempted in two patients with calciphylaxis, but the results were poor [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response to therapy is assessed principally by physical examination. The utility of sequential radiography such as bone scans and x-ray using mammography technique needs further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calciphylaxis is a lethal disease that carries a high morbidity and mortality. Because of the sporadic nature of the disease, prospective studies regarding the exact outcomes associated with calciphylaxis do not exist. The response to any therapeutic regimen, however, appears to be poor, and there remains a high mortality associated with calciphylaxis, regardless of efforts to treat the underlying disordered mineral metabolism. Features that negatively impact prognosis include more advanced disease at the time of therapy as well as the presence of proximal ischemic and necrotic lesions in the skin and soft tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection is the primary cause of the high mortality associated with this condition (up to 58 percent in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/1\">",
"     1",
"    </a>",
"    ]. Ulceration carries a mortality of greater than 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/5\">",
"     5",
"    </a>",
"    ]. An estimated one-year survival rate of calciphylaxis was reported to be 45.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CALCIPHYLAXIS REGISTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an effort to collect information regarding the clinical course of calciphylaxis, the authors have started an on-line registry for",
"    <strong>",
"     ESRD",
"    </strong>",
"    patients with calciphylaxis. Using this vehicle, we will collect information to characterize the natural progression of, and treatment practices for, this debilitating disorder. The registry can be found at the following web address:",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www2.kumc.edu/calciphylaxisregistry/\">",
"     www2.kumc.edu/calciphylaxisregistry/",
"    </a>",
"   </p>",
"   <p>",
"    The initial results of the registry were presented at the American Society of Nephrology Renal Week 2007 Poster Session [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15017/abstract/70\">",
"     70",
"    </a>",
"    ]. There were 15",
"    <strong>",
"     ESRD",
"    </strong>",
"    subjects entered with a median age of 60 years. Approximately 80 percent of subjects were on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and 67 percent were on calcitriol analogue at the time of diagnosis. The Ca x P product mean was 54.5",
"    <span class=\"nowrap\">",
"     mg2/dL2",
"    </span>",
"    and intact PTH was 530",
"    <span class=\"nowrap\">",
"     pg/mL.",
"    </span>",
"    The mean survival time was three months with 67 percent of subjects having died from sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calciphylaxis is a disorder characterized by systemic medial calcification of the arteries that most commonly occurs in end-stage renal disease (ESRD) patients who are on dialysis. Although previously rare, the incidence of this disorder has appeared to be increasing, due in part to the awareness and the recognition of clinical signs and risk factors associated with calciphylaxis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of calciphylaxis is poorly understood. Abnormalities in mineral metabolism that predispose to vascular and soft tissue calcification in uremia are clearly involved. Thus, in addition to biological factors, hyperparathyroidism, vitamin D supplementation, hyperphosphatemia, and an elevated or even normal plasma calcium concentration play a role in calciphylaxis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Calciphylaxis is typically characterized by areas of ischemic necrosis in the dermis, subcutaneous fat, and (less often) muscle. These ischemic changes lead to livedo reticularis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      violaceous, painful, plaque&ndash;like subcutaneous nodules, which progress to",
"      <span class=\"nowrap\">",
"       ischemic/necrotic",
"      </span>",
"      ulcers with eschars that often become superinfected. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no specific diagnostic laboratory tests for calciphylaxis, which is usually suggested by the characteristic ischemic skin lesions and their distribution. If there are no contraindications, we recommend that the diagnosis be confirmed by skin biopsy, which shows arterial occlusion and calcification in the absence of vasculitic change. Bone scan and x-ray mammographic techniques are noninvasive diagnostic tools that can aid in the diagnosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of calciphylaxis are similar to those of a significant number of other disorders. These include cholesterol embolization,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      necrosis, cryoglobulinemia, cellulitis, vasculitis, and nephrogenic fibrosing dermopathy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal therapy of calciphylaxis is to prevent its development. Although unproven, rigorous control of phosphate and calcium balance may help avoid the metabolic milieu in which calciphylaxis occurs. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prevention and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with established calciphylaxis, we suggest the following measures:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There should be an aggressive program of wound care and adequate pain control, avoidance of local tissue trauma (including subcutaneous injections), and an increase of dialysis dose among those with inadequate dialysis.",
"     </li>",
"     <li>",
"      Underlying abnormalities in plasma calcium and phosphorus concentrations in ESRD patients should be corrected, with lowering of the Ca X P product below 55",
"      <span class=\"nowrap\">",
"       mg2/dL2.",
"      </span>",
"      Among dialysis patients with hyperphosphatemia (greater than 5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.78",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      we suggest the administration of non-calcium containing phosphate binders, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/37/28244?source=see_link\">",
"       lanthanum carbonate",
"      </a>",
"      , rather than calcium-based phosphate binders (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Among dialysis patients with elevated PTH levels (greater than 300",
"      <span class=\"nowrap\">",
"       pg/mL),",
"      </span>",
"      we suggest the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"       cinacalcet",
"      </a>",
"      rather than vitamin D analogues (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"       \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients with refractory hyperparathyroidism, we suggest prompt parathyroidectomy in those with plasma calcium and phosphate concentrations that are uncontrollable with dialysis and medication (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"       Sodium thiosulfate",
"      </a>",
"      is increasingly used to treat calciphylaxis. The preferred dosage is 25 grams given over 30 to 60 minutes three times weekly, generally during the last hour of hemodialysis sessions. This regimen should be continued until there is complete resolution of lesions. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Sodium thiosulfate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients who are being treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , the risk and benefits of continuing warfarin in setting of calciphylaxis need to be weighed against risk of progressive nonhealing necrotic ulcers. Among patients who have progressive calciphylaxis despite aggressive control of bone mineral abnormalities, wound care, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"       sodium thiosulfate",
"      </a>",
"      , warfarin should be discontinued if at all possible. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prevention and treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The response to any therapeutic regimen is never assured and the prognosis associated with calciphylaxis remains poor. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/1\">",
"      Adrogu&eacute; HJ, Frazier MR, Zeluff B, Suki WN. Systemic calciphylaxis revisited. Am J Nephrol 1981; 1:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/2\">",
"      Kent RB 3rd, Lyerly RT. Systemic calciphylaxis. South Med J 1994; 87:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/3\">",
"      Perloff LJ, Spence RK, Grossman RA, Barker CF. Lethal post-transplantation calcinosis. Transplantation 1979; 27:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/4\">",
"      Janigan DT, Hirsch DJ, Klassen GA, MacDonald AS. Calcified subcutaneous arterioles with infarcts of the subcutis and skin (\"calciphylaxis\") in chronic renal failure. Am J Kidney Dis 2000; 35:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/5\">",
"      Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002; 61:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/6\">",
"      Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 2008; 3:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/7\">",
"      SELYE H, GABBIANI G, STREBEL R. Sensitization to calciphylaxis by endogenous parathyroid hormone. Endocrinology 1962; 71:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/8\">",
"      Floege J. When man turns to stone: extraosseous calcification in uremic patients. Kidney Int 2004; 65:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/9\">",
"      Hafner J, Keusch G, Wahl C, et al. Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol 1995; 33:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/10\">",
"      Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001; 60:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/11\">",
"      Hayashi M, Takamatsu I, Kanno Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 2012; 27:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/12\">",
"      Au S, Crawford RI. Three-dimensional analysis of a calciphylaxis plaque: clues to pathogenesis. J Am Acad Dermatol 2002; 47:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/13\">",
"      Weenig RH. Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol 2008; 58:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/14\">",
"      Block. Hyperphosphatemia has been regarded as a risk factor for calciphylaxis. Clin Neph 2000; 54:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/15\">",
"      Heiss A, DuChesne A, Denecke B, et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 2003; 278:13333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/16\">",
"      Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/17\">",
"      Price PA, Williamson MK, Nguyen TM, Than TN. Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. J Biol Chem 2004; 279:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/18\">",
"      Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/19\">",
"      Lebreton JP, Joisel F, Raoult JP, et al. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979; 64:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/20\">",
"      Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/21\">",
"      Wallin R, Cain D, Sane DC. Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells--a cell system which resembles the system in bone cells. Thromb Haemost 1999; 82:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/22\">",
"      Coates T, Kirkland GS, Dymock RB, et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 1998; 32:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/23\">",
"      Weenig RH, Sewell LD, Davis MD, et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007; 56:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/24\">",
"      Mandelbrot DA, Santos PW, Burt RK, et al. Resolution of SLE-related soft-tissue calcification following haematopoietic stem cell transplantation. Nephrol Dial Transplant 2008; 23:2679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/25\">",
"      Slough S, Servilla KS, Harford AM, et al. Association between calciphylaxis and inflammation in two patients on chronic dialysis. Adv Perit Dial 2006; 22:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/26\">",
"      Cozzolino M, Galassi A, Biondi ML, et al. Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. Am J Nephrol 2006; 26:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/27\">",
"      Angelis M, Wong LL, Myers SA, Wong LM. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 1997; 122:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/28\">",
"      Bleyer AJ, Choi M, Igwemezie B, et al. A case control study of proximal calciphylaxis. Am J Kidney Dis 1998; 32:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/29\">",
"      Wong JJ, Laumann A, Martinez M. Calciphylaxis and antiphospholipid antibody syndrome. J Am Acad Dermatol 2000; 42:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/30\">",
"      Fischer AH, Morris DJ. Pathogenesis of calciphylaxis: study of three cases with literature review. Hum Pathol 1995; 26:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/31\">",
"      Rostaing L, el Feki S, Delisle MB, et al. Calciphylaxis in a chronic hemodialysis patient with protein S deficiency. Am J Nephrol 1995; 15:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/32\">",
"      Mehta RL, Scott G, Sloand JA, Francis CW. Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis. Am J Med 1990; 88:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/33\">",
"      Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial 2002; 15:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/34\">",
"      Edelstein CL, Wickham MK, Kirby PA. Systemic calciphylaxis presenting as a painful, proximal myopathy. Postgrad Med J 1992; 68:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/35\">",
"      Bleibel W, Hazar B, Herman R. A case report comparing various radiological tests in the diagnosis of calcific uremic arteriolopathy. Am J Kidney Dis 2006; 48:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/36\">",
"      Norris B, Vaysman V, Line BR. Bone scintigraphy of calciphylaxis: a syndrome of vascular calcification and skin necrosis. Clin Nucl Med 2005; 30:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/37\">",
"      Essary LR, Wick MR. Cutaneous calciphylaxis. An underrecognized clinicopathologic entity. Am J Clin Pathol 2000; 113:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/38\">",
"      Araya CE, Fennell RS, Neiberger RE, Dharnidharka VR. Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults. Clin J Am Soc Nephrol 2006; 1:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/39\">",
"      Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003; 15:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/40\">",
"      Block GA. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients. Clin Nephrol 2000; 54:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/41\">",
"      Bleyer AJ, White WL, Choi MJ. Calcific small vessel ischemic disease (calciphylaxis) in dialysis patients. Int J Artif Organs 2000; 23:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/42\">",
"      Russell R, Brookshire MA, Zekonis M, Moe SM. Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care. Clin Nephrol 2002; 58:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/43\">",
"      Don BR, Chin AI. A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol 2003; 59:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/44\">",
"      Velasco N, MacGregor MS, Innes A, MacKay IG. Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy? Nephrol Dial Transplant 2006; 21:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/45\">",
"      Robinson MR, Augustine JJ, Korman NJ. Cinacalcet for the treatment of calciphylaxis. Arch Dermatol 2007; 143:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/46\">",
"      Sharma A, Burkitt-Wright E, Rustom R. Cinacalcet as an adjunct in the successful treatment of calciphylaxis. Br J Dermatol 2006; 155:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/47\">",
"      Budisavljevic MN, Cheek D, Ploth DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol 1996; 7:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/48\">",
"      Kang AS, McCarthy JT, Rowland C, et al. Is calciphylaxis best treated surgically or medically? Surgery 2000; 128:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/49\">",
"      Girotto JA, Harmon JW, Ratner LE, et al. Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery 2001; 130:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/50\">",
"      Arch-Ferrer JE, Beenken SW, Rue LW, et al. Therapy for calciphylaxis: an outcome analysis. Surgery 2003; 134:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/51\">",
"      Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004; 43:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/52\">",
"      Brucculeri M, Cheigh J, Bauer G, Serur D. Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. Semin Dial 2005; 18:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/53\">",
"      Guerra G, Shah RC, Ross EA. Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous haemofiltration using low calcium replacement fluid: case report. Nephrol Dial Transplant 2005; 20:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/54\">",
"      Baldwin C, Farah M, Leung M, et al. Multi-intervention management of calciphylaxis: a report of 7 cases. Am J Kidney Dis 2011; 58:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/55\">",
"      Hackett BC, McAleer MA, Sheehan G, et al. Calciphylaxis in a patient with normal renal function: response to treatment with sodium thiosulfate. Clin Exp Dermatol 2009; 34:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/56\">",
"      Mataic D, Bastani B. Intraperitoneal sodium thiosulfate for the treatment of calciphylaxis. Ren Fail 2006; 28:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/57\">",
"      Gupta DR, Sangha H, Khanna R. Chemical peritonitis after intraperitoneal sodium thiosulfate. Perit Dial Int 2012; 32:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/58\">",
"      Musso CG, Enz P, Vidal F, et al. Oral sodium thiosulfate solution as a secondary preventive treatment for calciphylaxis in dialysis patients. Saudi J Kidney Dis Transpl 2008; 19:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/59\">",
"      Singh RP, Derendorf H, Ross EA. Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. Clin J Am Soc Nephrol 2011; 6:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/60\">",
"      Yatzidis H. Successful sodium thiosulphate treatment for recurrent calcium urolithiasis. Clin Nephrol 1985; 23:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/61\">",
"      Hayden MR, Tyagi SC, Kolb L, et al. Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol 2005; 4:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/62\">",
"      Price PA, Omid N, Than TN, Williamson MK. The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 2002; 71:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/63\">",
"      Monney P, Nguyen QV, Perroud H, Descombes E. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant 2004; 19:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/64\">",
"      Shiraishi N, Kitamura K, Miyoshi T, et al. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 2006; 48:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/65\">",
"      Podymow T, Wherrett C, Burns KD. Hyperbaric oxygen in the treatment of calciphylaxis: a case series. Nephrol Dial Transplant 2001; 16:2176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/66\">",
"      Basile C, Montanaro A, Masi M, et al. Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series. J Nephrol 2002; 15:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/67\">",
"      el-Azhary RA, Arthur AK, Davis MD, et al. Retrospective analysis of tissue plasminogen activator as an adjuvant treatment for calciphylaxis. JAMA Dermatol 2013; 149:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/68\">",
"      Friedman SG. Leg revascularization in patients with calciphylaxis. Am Surg 2002; 68:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15017/abstract/69\">",
"      Roe SM, Graham LD, Brock WB, Barker DE. Calciphylaxis: early recognition and management. Am Surg 1994; 60:81.",
"     </a>",
"    </li>",
"    <li>",
"     Santos, PW, Quarles, LD, and Wetmore, JB. Calciphylaxis Registry: Description of Database and Initial Results. SU-PO647. ASN Renal Week 2007.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1944 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-3C09538E6E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_42_15017=[""].join("\n");
var outline_f14_42_15017=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Inhibitors of vascular calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of chronic inflammation on the development of calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory and radiographic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREVENTION AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sodium thiosulfate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Novel and experimental therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CALCIPHYLAXIS REGISTRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1944\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1944|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/39/38513\" title=\"diagnostic image 1\">",
"      Bone scan in calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1944|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/53/37718\" title=\"picture 1\">",
"      Early calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/13/5333\" title=\"picture 2\">",
"      Progressive calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/7/28784\" title=\"picture 3\">",
"      Advanced calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/7/38000\" title=\"picture 4\">",
"      Micrograph showing calcification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20185?source=related_link\">",
"      Biology of vascular calcification in renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=related_link\">",
"      Vascular calcification in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_42_15018="Surgical sterilization of women";
var content_f14_42_15018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical sterilization of women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/42/15018/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15018/contributors\">",
"     Thomas G Stovall, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15018/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/42/15018/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15018/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15018/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/42/15018/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/42/15018/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/42/15018/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical sterilization is a safe, highly effective, permanent, and convenient form of contraception. Numerous methods for achieving permanent sterilization have been described, and subsequently modified to improve success rates, simplify surgical technique and reduce postoperative pain and length of hospital stay. Laparoscopic techniques are preferred for most patients, as they are effective, and are usually performed on an outpatient basis, and result in rapid patient recovery. In 1995, almost 30 percent of contraceptive users in the United States used tubal sterilization [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubal sterilization is an elective and essentially permanent procedure. There are virtually no absolute contraindications, although a patient's gynecologic disease may require sterilization by hysterectomy and bilateral oophorectomy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Known extensive intra-abdominal adhesions increase the potential for intraoperative morbidity during laparoscopy. With the development of transcervical (or hysteroscopic) sterilization, laparotomy is now rarely necessary for sterilization. Alternatively, other forms of contraceptive can be offered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12665?source=see_link\">",
"       \"Hysteroscopic sterilization\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"       \"Overview of contraception\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnancy may pose a significant risk to women with some medical disorders; thus forming a basis for elective sterilization. However, consultation with a maternal-fetal medicine specialist is advisable to determine the current magnitude of risk to mother and offspring, since occasionally women have been told that pregnancy is contraindicated when, in fact, it is not.",
"     </li>",
"     <li>",
"      Women with mental disabilities or their",
"      <span class=\"nowrap\">",
"       families/caregivers",
"      </span>",
"      may request sterilization. Physicians caring for these women must be aware of the federal, state, and local regulations pertaining to their ability to give informed consent. Court approval of the procedure may be required and input from a hospital ethics committee can be useful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;A woman's decision to undergo sterilization must be voluntary and not coerced by her family, partner, or health care providers. Complete, nonbiased information about the procedure and alternatives to surgery helps to reduce post-sterilization regret. Failure of one method of contraception is not an indication for permanent sterilization. The woman's husband is not required to give consent before performing the procedure (in the United States); however, ideally both partners should have an understanding of the procedure as well as the benefits, alternatives, and potential risks. This discussion includes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of the risks and benefits of reversible and permanent methods of contraception, as well as information about male sterilization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link&amp;anchor=H878447#H878447\">",
"       \"Overview of contraception\", section on 'Vasectomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The woman's reasons for choosing sterilization.",
"     </li>",
"     <li>",
"      Screening for risk indicators of regret (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Regret after sterilization'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      An explanation of the details of the procedure, including anesthesia.",
"     </li>",
"     <li>",
"      The permanence of the procedure and information on reversal.",
"     </li>",
"     <li>",
"      The causes and probability of sterilization failure, including the chance of ectopic pregnancy.",
"     </li>",
"     <li>",
"      The need to use condoms for protection against sexually transmitted diseases (eg, HIV) if she has multiple sex partners or a partner with other partners.",
"     </li>",
"     <li>",
"      A reduction in the risk of ovarian cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/1,3\">",
"       1,3",
"      </a>",
"      ] and pelvic inflammatory disease.",
"     </li>",
"     <li>",
"      No consistent differences in menstrual cycle characteristics occur as a result of tubal sterilization (see",
"      <a class=\"local\" href=\"#H34\">",
"       'Postablation tubal sterilization syndrome'",
"      </a>",
"      below)&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/4-8\">",
"       4-8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient should have an opportunity to ask questions and express any concerns that might exist following this discussion. Women whose sterilization will be federally funded must sign a special consent document, be at least 21 years of age, and wait 30 days between signing the consent form and the procedure. Insurance coverage for the procedure and possible reversal should also be addressed, as many patients believe if sterilization is covered, reversal will be too even though this is not usually the case. It is also prudent to have consent for mini-laparotomy when planning interval laparoscopic sterilization, since unexpected intraoperative findings may make mini-laparotomy necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Regret after sterilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;This occurs in approximately 3 to 25 percent of women. However, only about 1 to 2 percent of all women who have undergone sterilization seek reversal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. The most common factor associated with regret is a change in marital status [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Some, but not all, studies also report an association between regret and marital discord at the time of procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, a prospective multicenter series of 7590 women who were followed for up to five years reported young age at the time of sterilization was the strongest predictor of regret, regardless of parity or marital status [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/17\">",
"     17",
"    </a>",
"    ]. The incidence of regret in women aged 20 to 24 years at sterilization compared to those 30 to 34 years was 4.3 versus 2.4 percent. However, other researchers have not confirmed this association [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors not generally related to regret include religious, socioeconomic, and educational background or low parity at the time of sterilization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Timing of sterilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sterilization can be performed postpartum, postabortion, as an interval procedure (unrelated to pregnancy), or in conjunction with another surgical procedure (eg, cholecystectomy). Ideally, postpartum procedures are performed immediately after delivery or within 24 hours, but may be done up to seven days later [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. Further delay increases the risk of infection and difficulty due to uterine involution. About one-half of procedures are performed postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/24\">",
"     24",
"    </a>",
"    ], and follow 10 percent of births [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Luteal phase pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraception should be used for at least one month before sterilization and continued until the next menstrual cycle to decrease the occurrence of luteal phase pregnancies. Performance of the procedure postpartum or during the menstrual or proliferative phase of the cycle reduces the chance of pregnancy at the time of the procedure. If this is not practical, a sensitive urine or serum pregnancy test can be done on the day of the procedure to help detect a luteal phase pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/25\">",
"     25",
"    </a>",
"    ]. Concurrent dilation and curettage at the time of sterilization does not lower the risk of luteal phase pregnancy and increases cost and morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/2,26\">",
"     2,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sterilization method",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interval sterilizations are typically performed by laparoscopy and postpartum sterilizations are done by minilaparotomy. The advantages of the laparoscopic procedure include decreased operative time, less postoperative pain, shorter hospital stay, and more rapid return to normal functional activities [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/27\">",
"     27",
"    </a>",
"    ]. Minilaparotomy requires less technical expertise and, in postpartum women, does not lengthen hospital stay. A Cochrane review comparing laparoscopic sterilization and minilaparotomy concluded major morbidity was rare for both techniques, but culdoscopy was not recommended because of a higher complication rate in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/28\">",
"     28",
"    </a>",
"    ]. The personal preference of the woman",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgeon, as well as clinical circumstances (eg, postpartum versus interval procedure), should guide the choice of technique.",
"   </p>",
"   <p>",
"    Procedures that result in the least amount of damaged tube are most likely to allow reversal, if desired in the future. However, this should not typically be a consideration in choosing a technique as the goal of the procedure is permanent sterilization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=see_link\">",
"     \"Reproductive surgery for female infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MINILAPAROTOMY STERILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minilaparotomy can be used for interval sterilization, but is more commonly employed for postpartum sterilization. The enlarged uterus and thinned subumbilical area facilitate exposure through a minilaparotomy incision, while the laparoscopic approach is much less feasible. General, regional, or local anesthesia all provide adequate anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential advantage of laparotomy is that a tissue specimen is removed (partial salpingectomy) and can provide histologic documentation of complete transection of the fallopian tubes. However, this can also be accomplished at laparoscopy if such documentation is important. Minilaparotomy is also useful if the surgeon is not trained in laparoscopy or suitable equipment is not available, when the patient is morbidly obese, or when severe tubal adhesive disease is present.",
"   </p>",
"   <p>",
"    Disadvantages of minilaparotomy include a higher complication rate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/2\">",
"     2",
"    </a>",
"    ], greater need for postoperative analgesia, longer recovery time, and a larger surgical incision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pomeroy method",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Pomeroy technique can be completed through a suprapubic incision, a colpotomy incision, or a subumbilical incision (in the immediate postpartum period). The incision is placed approximately one centimeter below the site at which the elevated uterine fundus hits the anterior abdominal wall in nonpregnant women.",
"   </p>",
"   <p>",
"    The fallopian tube is identified and grasped in the isthmic portion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/31\">",
"     31",
"    </a>",
"    ] with a Babcock clamp (",
"    <a class=\"graphic graphic_figure graphicRef75414 \" href=\"UTD.htm?16/23/16752\">",
"     figure 1",
"    </a>",
"    ). The \"knuckle\" of tube is then double ligated with 0 or 2-0 plain catgut suture (",
"    <a class=\"graphic graphic_figure graphicRef51325 \" href=\"UTD.htm?30/55/31600\">",
"     figure 2",
"    </a>",
"    ). The open blade of a Metzenbaum scissors is used to puncture the mesosalpinx within the knuckle. The ligated segment of the fallopian tube is then excised (",
"    <a class=\"graphic graphic_figure graphicRef64088 \" href=\"UTD.htm?1/26/1441\">",
"     figure 3",
"    </a>",
"    ) after which the muscularis retracts, causing protrusion of the tubal lumen. The ligated ends should be inspected for hemostasis and the presence of the tubal lumen confirmed. The same procedure is completed on the contralateral side.",
"   </p>",
"   <p>",
"    The plain catgut suture resorbs in three to four days, allowing the tubal lumina to separate (",
"    <a class=\"graphic graphic_figure graphicRef76868 \" href=\"UTD.htm?12/30/12769\">",
"     figure 4",
"    </a>",
"    ). Using a suture material that takes longer to resorb or one that is permanent increases the chance of fistula formation and sterilization failure.",
"   </p>",
"   <p>",
"    The tubal segments from the right and left tubes are labeled and sent in separate containers for histologic analysis. The pathologist should be able to document complete resection of a tubal segment (",
"    <a class=\"graphic graphic_picture graphicRef72510 \" href=\"UTD.htm?26/40/27271\">",
"     picture 1",
"    </a>",
"    ). It is the surgeon's responsibility to review the pathologist's report to make certain that both tubal lumina were transected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pitfalls",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slippage of the suture ligatures with retraction of the tube is the most common complication of the Pomeroy method. This risk is minimized by placement of two sutures and exerting traction only on the distal suture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Parkland (modified Pomeroy) method",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Parkland method is similar to the Pomeroy, but the segment of tube is ligated at two points, instead of jointly as a \"knuckle\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/32\">",
"     32",
"    </a>",
"    ]. The fallopian tube is identified and elevated in the isthmic portion with a Babcock clamp. An opening is made in an avascular portion of the mesosalpinx; 0 or 2-0 plain catgut sutures are passed through the opening. The proximal and distal portions of the tube are ligated; many surgeons doubly ligate the proximal portion. Care is taken not to put unnecessary traction on the tubal stumps, as this may lead to bleeding in the mesosalpinx. The intervening segment of tube is excised. The ligated ends are inspected for hemostasis and the presence of the tubal lumen is confirmed. The same procedure is completed on the contralateral side.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Irving method",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Irving technique was developed for sterilization at the time of cesarean section [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/33\">",
"     33",
"    </a>",
"    ]. It has an extremely low failure rate of less than 1 per 1000 cases, but is generally associated with greater intraoperative blood loss. The original description buried the proximal tubal stump within the myometrium and buried the ligated distal tubal segment in the broad ligament, but the latter procedure does not appear to increase effectiveness and is generally omitted.",
"   </p>",
"   <p>",
"    Following completion of the cesarean section, the fallopian tube is grasped with a Babcock clamp (",
"    <a class=\"graphic graphic_figure graphicRef57776 \" href=\"UTD.htm?23/38/24161\">",
"     figure 5",
"    </a>",
"    ). A hemostat is passed through an avascular portion of the mesosalpinx near the ampullary-isthmic junction (",
"    <a class=\"graphic graphic_figure graphicRef65422 \" href=\"UTD.htm?8/47/8945\">",
"     figure 6",
"    </a>",
"    ). Two 0 synthetic absorbable sutures are passed through this opening and the tube is doubly ligated (",
"    <a class=\"graphic graphic_figure graphicRef77247 \" href=\"UTD.htm?29/30/30176\">",
"     figure 7",
"    </a>",
"    ). A portion of the tube can be removed and sent for histologic confirmation, if desired (",
"    <a class=\"graphic graphic_figure graphicRef56281 \" href=\"UTD.htm?5/58/6049\">",
"     figure 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A hemostat is then used to pierce a hole approximately 1 cm deep in the posterior myometrium (",
"    <a class=\"graphic graphic_figure graphicRef67793 \" href=\"UTD.htm?24/38/25185\">",
"     figure 9",
"    </a>",
"    ). The sutures attached to the proximal tubal segment are threaded into a curved needle and passed via a grooved needle guide through the base of the myometrial hole to exit the uterine surface 1 to 2 cm apart (",
"    <a class=\"graphic graphic_figure graphicRef82066 \" href=\"UTD.htm?8/17/8466\">",
"     figure 10",
"    </a>",
"    ). These two sutures are tied together and the tubal stump is buried in the uterine muscularis. An absorbable suture can be used to reapproximate the uterine serosa (",
"    <a class=\"graphic graphic_figure graphicRef54438 \" href=\"UTD.htm?4/43/4785\">",
"     figure 11",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A similar procedure can be accomplished at laparoscopy. A plain catgut suture should be used for the laparoscopic procedure to achieve rapid resorption of the suture material [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Uchida method",
"    </span>",
"    &nbsp;&mdash;&nbsp;This technique is probably the most complex method of tubal sterilization. Its advantage is that it has an extremely low failure rate; Uchida reported no failures after completing more than 20,000 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A suprapubic incision is made (subumbilical if postpartum) and the fallopian tube is grasped with a Babcock clamp and brought into the operative field. A 25-gauge needle is used to inject saline into the subserosal layer in an area approximately 2 cm distal to the uterine cornu. The saline functions to balloon the serosa away from the muscularis (",
"    <a class=\"graphic graphic_figure graphicRef59391 \" href=\"UTD.htm?9/4/9281\">",
"     figure 12",
"    </a>",
"    ). The tubal serosa is then incised longitudinally to free a 2 to 3 cm segment of serosa. Two pieces of plain 0 or 2-0 absorbable suture are passed under the freed segment of tube and tied at both ends of the isolated tubal segment. Both sutures are held with hemostats while the isolated tubal segment is excised and inspected to make certain that the tubal lumen has been interrupted (",
"    <a class=\"graphic graphic_figure graphicRef68109 \" href=\"UTD.htm?19/12/19652\">",
"     figure 13",
"    </a>",
"    ). The specimen is sent for histologic confirmation.",
"   </p>",
"   <p>",
"    The proximal suture is then cut to allow the tube to retract into the mesosalpinx and tension is placed on the distal segment to elevate it above the mesosalpinx. A 3-0 synthetic absorbable suture is used to reapproximate the serosa so that the proximal stump is buried within the mesosalpinx and the distal stump is exteriorized. The distal tube and fimbria can also be excised, if desired (",
"    <a class=\"graphic graphic_figure graphicRef79037 \" href=\"UTD.htm?33/54/34659\">",
"     figure 14",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pitfalls",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complication is bleeding. Retraction of the distal segment can occur and can be prevented by placing traction on the distal segment, or by placing a suture around the distal tubal stump and attaching it to the serosa before closure of the serosa is completed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other tubal sterilization techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other techniques have been described for tubal sterilization. They are less frequently performed and less effective.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Madlener technique crushes a loop of the ampullary portion of the tube with a hemostat. The tube is then ligated with nonabsorbable suture material without excision of a tubal segment (",
"      <a class=\"graphic graphic_figure graphicRef55371 \" href=\"UTD.htm?42/48/43779\">",
"       figure 15",
"      </a>",
"      ). The failure rate of this technique is higher as a result of fistula formation beneath the permanent suture material, therefore the Madlener approach should",
"      <strong>",
"       NOT",
"      </strong>",
"      be employed.",
"     </li>",
"     <li>",
"      The Oxford technique divides the fallopian tube at the ampullary-isthmic junction and carries the proximal segment under the round ligament where it is secured. The distal tube is then tied on the opposite side of the round ligament (",
"      <a class=\"graphic graphic_figure graphicRef60411 \" href=\"UTD.htm?27/6/27750\">",
"       figure 16",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The Kroener technique (fimbriectomy) involves grasping the fimbriated end of the fallopian tube with a Babcock clamp, clamping the mesosalpinx and outer third of the tube, and doubly ligating it with synthetic absorbable suture [",
"      <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/37\">",
"       37",
"      </a>",
"      ]. The tube is then excised to make certain that the entire fimbriated end of the tube (and a portion of ampulla) is removed (",
"      <a class=\"graphic graphic_figure graphicRef69535 \" href=\"UTD.htm?23/63/24560\">",
"       figure 17",
"      </a>",
"      ). The most common complication is incomplete excision of the fimbriae, which can result in sterilization failure. This form of sterilization should",
"      <strong>",
"       not",
"      </strong>",
"      be used, as more effective alternatives are available.",
"     </li>",
"     <li>",
"      The Aldridge procedure buries the fimbriated end of the tube in the broad ligament with a series of nonabsorbable sutures that incorporate the serosal and muscular layers of the tube and ligament. The tube remains uninterrupted (",
"      <a class=\"graphic graphic_figure graphicRef66609 \" href=\"UTD.htm?23/36/24132\">",
"       figure 18",
"      </a>",
"      ). In theory, reversal would simply require opening the broad ligament.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     LAPAROSCOPIC STERILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic sterilization is the most common surgical method for interval sterilization. Advantages include the opportunity to visually explore the abdomen for occult disease, a small incision, and rapid recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/2\">",
"     2",
"    </a>",
"    ]. However, unexpected intraoperative findings or complications may necessitate conversion to laparotomy on occasion.",
"   </p>",
"   <p>",
"    The most commonly used methods of laparoscopic tubal occlusion are Falope ring or Hulka clip application and electrocoagulation. Severe cardiac or pulmonary disease, bleeding diathesis, or adhesive disease and massive obesity are relative contraindications for a laparoscopic procedure; such patients should be discussed with an anesthesiologist before surgery.",
"   </p>",
"   <p>",
"    An open or closed laparoscopy technique may be employed, neither is superior for routine procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=see_link\">",
"     \"Overview of conventional gynecologic laparoscopic surgery\"",
"    </a>",
"    .) For all laparoscopic procedures, the woman is placed in the lithotomy position, the bladder emptied, and a speculum inserted into the vagina. The cervix is cleaned with a prewarmed povidone-iodine solution. A Hulka uterine manipulator is inserted into the uterine cavity and attached to the anterior cervical lip. If the uterus is retroverted, the manipulator is placed along the uterine axis and then rotated 180 degrees (",
"    <a class=\"graphic graphic_figure graphicRef72458 \" href=\"UTD.htm?25/11/25777\">",
"     figure 19",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Bipolar electrocoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar electrodesiccation is safer than unipolar electrocoagulation and is preferred for this reason [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. The operating forceps of the bipolar system carries both the active and return electrode. The jaws are completely isolated from one another so that high-frequency current passes through one jaw and is retrieved and returned to the generator through the other jaw. Thus, the current selectively passes through the grasped tissue and has to travel only a short distance between the jaws and forceps. The theoretical danger of sparking is consequently eliminated. The bipolar forceps must be compatible with the generator and current settings should be appropriate for the procedure (eg, a cutting current with a power setting of 25 to 35 W).",
"   </p>",
"   <p>",
"    After the laparoscope is inserted, the pelvis is examined and any pelvic pathology noted. At times it will be necessary to free adhesions around the tube to fully visualize the operative site. The fallopian tube is grasped and maneuvered until the fimbriated end can be identified. This step is critical for verifying that the tube is the structure that will be desiccated, not the round or utero-ovarian ligament.",
"   </p>",
"   <p>",
"    The tube is grasped with bipolar forceps approximately 2 to 3 cm from the uterine cornu and placed on tension to ensure that the forceps are not in contact with any other structures (",
"    <a class=\"graphic graphic_figure graphicRef51476 \" href=\"UTD.htm?41/14/42209\">",
"     figure 20",
"    </a>",
"    ). Current is applied until an ammeter, optical meter, sound meter, or visual inspection shows the tissue grasped has been completely desiccated and can no longer transmit an electrical current. Most failures are a result of incomplete destruction of the endosalpinx (",
"    <a class=\"graphic graphic_picture graphicRef80209 \" href=\"UTD.htm?0/19/309\">",
"     picture 2",
"    </a>",
"    ), which can be avoided with the use of these devices.",
"   </p>",
"   <p>",
"    The tube is then regrasped and desiccated at immediately adjacent sites (",
"    <a class=\"graphic graphic_figure graphicRef64160 \" href=\"UTD.htm?29/19/30000\">",
"     figure 21",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76950 \" href=\"UTD.htm?18/14/18658\">",
"     figure 22",
"    </a>",
"    ) to coagulate 3 cm of contiguous tube. We suggest that the desiccation begin distally and move proximally so that the uterus can function as a heat sink. It is not necessary to transect the tube following desiccation. In fact, this appears to increase the risk of fistula formation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/43\">",
"     43",
"    </a>",
"    ]. The same procedure is repeated on the opposite side.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Banding procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Falope ring (Falope Ring Band, Cabot Medical, Langhorne, PA) is made of a nonreactive silicone rubber that incorporates a solution of 5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    sulfate to permit radiologic identification. The ring is 2.2 mm thick with an outer diameter of 3.6 mm and an inner diameter of 1 mm (",
"    <a class=\"graphic graphic_picture graphicRef71138 \" href=\"UTD.htm?14/50/15139\">",
"     picture 3",
"    </a>",
"    ). It possesses a specific elastic power with a recovery of 90 to 100 percent, if not stretched to more than 7 mm.",
"   </p>",
"   <p>",
"    One or two Falope rings are placed on a conical device that stretches them sufficiently to permit transfer to the tubal band applicator device. This device has two concentric cylinders whose movement is controlled by a single ring grip (",
"    <a class=\"graphic graphic_picture graphicRef68822 \" href=\"UTD.htm?15/28/15808\">",
"     picture 4",
"    </a>",
"    ) which allows the surgeon to extend the grasping prongs beyond the inner cylinder (",
"    <a class=\"graphic graphic_picture graphicRef73220 \" href=\"UTD.htm?26/15/26864\">",
"     picture 5",
"    </a>",
"    ), grasp the tube, and bring it inside the cylinder.",
"   </p>",
"   <p>",
"    The preloaded ring applicator is placed through the operating channel of an operating laparoscopic or through a suprapubic puncture. The grasping forceps is extended, and the fallopian tube is grasped approximately 2 to 3 cm distal to the uterotubal junction (",
"    <a class=\"graphic graphic_figure graphicRef62868 \" href=\"UTD.htm?32/8/32897\">",
"     figure 23",
"    </a>",
"    ). The tube should not be grasped next to the uterus because lack of tubal mobility may cause a laceration of the tube or formation of an inappropriate knuckle of tube. The distal third of the tube also should not be grasped, since incomplete tubal occlusion may occur due to the large tubal diameter in this area. The applicator is designed to draw a 2.5-cm tubal segment into the inner cylinder, a large diameter tube may not allow a complete knuckle of tube to be pulled through the ring.",
"   </p>",
"   <p>",
"    Once the tube is drawn into the inner sleeve, the handle is squeezed slowly causing the outer cylinder to push the ring over the tubal segment that has been drawn within the inner cylinder (",
"    <a class=\"graphic graphic_figure graphicRef78095 \" href=\"UTD.htm?20/17/20752\">",
"     figure 24",
"    </a>",
"    ). If the tubal ring has been applied correctly, a 1.0-cm high knuckle of tube will be seen above the ring and both the distal and proximal tubal segments can be observed entering the tubal ring (",
"    <a class=\"graphic graphic_figure graphicRef58138 \" href=\"UTD.htm?9/27/9663\">",
"     figure 25",
"    </a>",
"    ). The ring functions to occlude the blood supply to the tubal knuckle and, over a period of several days, necrosis takes place and the tubal segments separate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Pitfalls",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubal transection can occur if the tube is drawn into the inner cylinder too quickly; this is usually accompanied by a clicking sound. If this occurs, bands can be placed on the proximal and distal tubal segments or electrocoagulation can be used to destroy both the proximal and distal tubal segments.",
"   </p>",
"   <p>",
"    A tubal band may also fall off the applicator before it has been applied to the tube. If this occurs, the band can be retrieved (if visualized) or left in the abdominal cavity (if not).",
"   </p>",
"   <p>",
"    Large tubes (eg, hydrosalpinx) require a modification in technique to assure complete occlusion. The tube is grasped and retracted toward the applicator [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/44\">",
"     44",
"    </a>",
"    ]. It is then released and regrasped 1 cm proximal and distal to the original area and retracted partially into the applicator. This will bend the edematous tube so it can be grasped in its normal position and retracted fully into the applicator. With hydrosalpinx, one can use cautery to incise and drain the tube prior to sterilization procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clips",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Hulka-Clemens clip (Hulka-Clemens, Richard Wolf, Rosemont, IL) and the Filshie clip (Coopersurgical, Lake Forest, CA) are used for tubal occlusion. The Hulka-Clemens clip consists of two toothed jaws made of lexan plastic, joined by a metal hinge pin. The lower jaw possesses a distal hook. A gold-plated spring maintains the clip in an open position. When completely advanced, the spring closes and locks the jaws (",
"    <a class=\"graphic graphic_picture graphicRef50616 \" href=\"UTD.htm?13/19/13620\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An operating laparoscope specific for clip application may be used or the clip applier can be placed through a secondary trocar site. The applicator is 7 mm in diameter with a three-ring configuration at the handle. At the end of the applicator, there is a fixed lower jaw to accommodate the clip. When the handle is retracted, a mobile upper jaw permits placement of the open clip and, when advanced, closes the clip. A center piston locks the spring upon completion. Until that point, the jaws may be opened and closed as many times as needed (",
"    <a class=\"graphic graphic_picture graphicRef53061 \" href=\"UTD.htm?31/45/32464\">",
"     picture 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The Filshie clip is equally effective and easier to apply [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. It is a composite",
"    <span class=\"nowrap\">",
"     titanium/silicone",
"    </span>",
"    rubber clip that is bent around the Fallopian tube by means of an applicator [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/48\">",
"     48",
"    </a>",
"    ]. The rubber expands to keep the lumen blocked as tubal necrosis occurs. The tube eventually divides and the stumps heal closed. The 12-month pregnancy probability is 1.1 to 1.7 per 1000 women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/47,49,50\">",
"     47,49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Pitfalls",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Hulka clip was designed to be applied at a right angle to the isthmic portion of the tube about 2 to 3 cm from the cornu and across the complete diameter (",
"    <a class=\"graphic graphic_figure graphicRef63446 \" href=\"UTD.htm?31/25/32159\">",
"     figure 26",
"    </a>",
"    ). If the clip is placed at a more distal tubal segment, there is a higher chance that the clip will not be effective due to the increased volume of tissue and the larger tubal lumen that must be occluded. Once secured in place and released from the applicator, its position should again be verified (",
"    <a class=\"graphic graphic_figure graphicRef80841 \" href=\"UTD.htm?17/4/17474\">",
"     figure 27",
"    </a>",
"    ). If the clip is not properly placed, a second clip can be applied adjacent to the first (",
"    <a class=\"graphic graphic_figure graphicRef82185 \" href=\"UTD.htm?9/41/9872\">",
"     figure 28",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The peritoneum grows to cover the Filshie clips so they are anchored when the tubes divide, but it is theorized that if this process is slow, the clips may fall off. Six to 25 percent of clips become detached and eventually encased in dense adhesions; rarely migration results in organ penetration, pain, or other morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Use of local anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthesia offers important advantages over general anesthesia, such as avoidance of risks associated with general anesthesia, decreased anesthesia time, lower cost [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/52\">",
"     52",
"    </a>",
"    ], rapid recovery, earlier awareness of complications, and less nausea and vomiting. Less suitable candidates for sterilization under local anesthesia are those with known adhesive disease or massive obesity, since these women may require longer operative time and more tissue dissection, and the woman who is excessively anxious.",
"   </p>",
"   <p>",
"    The largest series using this technique included 250,136 procedures performed by a single operator in mobile clinics in India [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/53\">",
"     53",
"    </a>",
"    ]. The author reported the number of women sterilized was generally 40 to 50 per hour, the mortality rate was 4.8 per 100,000 procedures (not all attributable to the procedure), and the major complication rate (requiring laparotomy) was 3.2 per 100,000 procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     General technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper preoperative and intraoperative medication are critical to success. Pain can be diminished by using adequate preoperative medication and sedation, a good fascial and field block, and gentle uterine and pelvic organ manipulation. The doses and timing of drug administration are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef79011 \" href=\"UTD.htm?14/15/14587\">",
"     table 1",
"    </a>",
"    ). Care should be taken not to over-sedate the patient, as this may lead to loss of the gag reflex and airway control. During the procedure it is helpful to talk to the woman to provide reassurance and tell her when she might feel uterine movement or experience discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. The procedure is otherwise similar to those performed under general or spinal anesthesia.",
"   </p>",
"   <p>",
"    A 25-gauge one inch long needle is used to inject 5 mL of 0.5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    hydrochloride (HCL) into the infraumbilical skin (",
"    <a class=\"graphic graphic_figure graphicRef65880 \" href=\"UTD.htm?29/5/29777\">",
"     figure 29",
"    </a>",
"    ). Once the skin has been anesthetized, a 22-gauge 3.5 inch long spinal needle is used to create a diamond-shaped fascial block: 1 mL of 0.5 percent bupivacaine HCl is injected at each corner and in the center of the diamond, which will be the point of fascial entry (",
"    <a class=\"graphic graphic_figure graphicRef74917 \" href=\"UTD.htm?32/10/32929\">",
"     figure 30",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The skin incision is made using a number 11 scalpel and a hemostat is used to enlarge the incision slightly. The periumbilical trocar is inserted using either an indirect or direct technique and the abdomen insufflated with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    or carbon dioxide [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/57\">",
"     57",
"    </a>",
"    ] at a rate of 1 liter per minute. The uterus is slowly manipulated to expose the left and then the right fallopian tubes. Five milliliters of 0.5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    HCl are sprayed over and under both tubes and round ligaments [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/58\">",
"     58",
"    </a>",
"    ] to reduce postoperative pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sterilization procedure is accomplished using electrocoagulation, Falope rings, or Hulka clips. If electrocoagulation is used, the current is applied in an intermittent fashion to prevent heat buildup and pain. A randomized trial comparing outcome after electrocoagulation or silastic ring application found that silastic rings were preferable: this group had a shorter operating time, required less intraoperative anesthesia, and reported a similar degree of postoperative pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/54\">",
"     54",
"    </a>",
"    ]. It is important to occlude the tube with the ring and avoid tubal transection, which may cause hemorrhage.",
"   </p>",
"   <p>",
"    The woman is asked to cough or bear down (Valsalva Maneuver) following the procedure to remove as much abdominal gas as possible. The trocar valve should only be open when the patient is actually increasing her intra-abdominal pressure so atmospheric air does not enter the abdomen and cause peritoneal irritation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COLPOTOMY STERILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of laparoscopy led to a virtual disappearance of the vaginal route for tubal sterilization. The reported increase of postoperative pelvic infections following vaginal sterilization when compared to laparoscopic methods also contributed to the decreased use of this technique [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. However, subsequent studies showed comparable rates of morbidity with laparoscopic and vaginal sterilization when prophylactic antibiotics were used routinely [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vaginal approach is particularly useful in very obese patients, women with an umbilical hernia, or those with a previous umbilical hernia repair. Relative contraindications include multiple pelvic surgical procedures, endometriosis, known pelvic adhesive disease, or uterine immobility on examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The woman is placed in the dorsal lithotomy or knee-chest position. A right-angle or Dever retractor is used to expose the cervix, which is grasped on its posterior lip with a single-tooth tenaculum (",
"    <a class=\"graphic graphic_figure graphicRef61396 \" href=\"UTD.htm?23/43/24242\">",
"     figure 31",
"    </a>",
"    ). The posterior cul-de-sac (pouch of Douglas) is exposed and a colpotomy incision is performed using Mayo scissors (",
"    <a class=\"graphic graphic_figure graphicRef71175 \" href=\"UTD.htm?14/42/15012\">",
"     figure 32",
"    </a>",
"    ). The tips of the scissors are placed in the peritoneal opening and spread to enlarge the incision. The anterior retractor is then placed posterior to the cervix, just inside the incision, and is elevated (",
"    <a class=\"graphic graphic_figure graphicRef50184 \" href=\"UTD.htm?18/34/18977\">",
"     figure 33",
"    </a>",
"    ). This maneuver results in retroflexion of the uterus. The fallopian tube is grasped with a Babcock clamp and brought into the operative field (",
"    <a class=\"graphic graphic_figure graphicRef59942 \" href=\"UTD.htm?5/0/5122\">",
"     figure 34",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The sterilization can be accomplished using bands, electrocautery, or clips [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/63\">",
"     63",
"    </a>",
"    ]. However, the most common method described is the use of the Pomeroy technique (",
"    <a class=\"graphic graphic_figure graphicRef71728 \" href=\"UTD.htm?9/4/9280\">",
"     figure 35",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/64\">",
"     64",
"    </a>",
"    ]. The colpotomy incision is closed using interrupted figure-of-eight sutures or a single running suture of an absorbable material.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pitfalls",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common problem encountered intraoperatively is difficulty exposing the fallopian tubes. Placing the anterior retractor too deeply into the incision will antevert the uterus rather than cause uterine retroflexion. Suprapubic pressure can be used to facilitate uterine retroversion. A moist sponge on a stick can be used to displace bowel if it obscures the tubes.",
"   </p>",
"   <p>",
"    Pelvic infection is the most serious postoperative complication. Therefore, a single dose of a prophylactic antibiotic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    1 gram IV) should be administered approximately 30 minutes before the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     HYSTEROSCOPIC STERILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysteroscopic sterilization procedures have been introduced. Current procedures are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12665?source=see_link\">",
"     \"Hysteroscopic sterilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality rate of tubal sterilization in the United States is 1 to 4 deaths per 100,000 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/2\">",
"     2",
"    </a>",
"    ] and in developing countries 4.7 per 100,000 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/65\">",
"     65",
"    </a>",
"    ]. These rates are lower than those for pregnancy-associated maternal mortality and are mostly due to anesthetic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications such as wound infection, hematoma, and perforation of the uterus, bladder, or intestine occur in 0.4 to 1 percent of procedures. A prospective, multicenter cohort study of 9475 women who underwent interval laparoscopic tubal sterilization reported the overall intraoperative and postoperative complication rate was less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/66\">",
"     66",
"    </a>",
"    ]. Independent predictors of an increased risk of having one or more complications were diabetes mellitus, general anesthesia, previous abdominal or pelvic surgery, and obesity.",
"   </p>",
"   <p>",
"    Major complications are related to general anesthesia, sepsis, and hemorrhage. Serious sepsis generally results from unrecognized thermal bowel injury during unipolar coagulation. Myocardial infarction and pulmonary embolus also contribute to perioperative mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=see_link\">",
"     \"Overview of conventional gynecologic laparoscopic surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=see_link\">",
"     \"Management of hemorrhage in gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is uncommon after tubal sterilization. The risk appears to be related to age and the type of procedure, but every gynecologist should be familiar with the risk of failure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. In a large, long-term study of 10,685 women who underwent tubal sterilization and were followed for 8 to 14 years, 143 sterilization failures were identified (",
"    <a class=\"graphic graphic_table graphicRef54215 \" href=\"UTD.htm?13/33/13851\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/67\">",
"     67",
"    </a>",
"    ]. The cumulative 10-year probability of pregnancy was 18.5 per 1000 procedures; it was highest after clip sterilization, and lowest after unipolar coagulation and postpartum partial salpingectomy (36.5, 7.5, and 7.5 per 1000 procedures, respectively). The risk of pregnancy was highest among women sterilized at a young age (&lt;28 years) with bipolar coagulation and clip application (54.3 and 52.1 per 1000 procedures, respectively).",
"   </p>",
"   <p>",
"    A Canadian study of the 10 year cumulative probability of pregnancy after 311,960 sterilization procedures reported a rate of 18.5 per 1000 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/13\">",
"     13",
"    </a>",
"    ]. The lower rate of failure in this series may be related to greater use of the Filshie clip in Quebec than in the US.",
"   </p>",
"   <p>",
"    Failure rates after tubal sterilization, vasectomy, and insertion of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    intrauterine device are similar, but tubal sterilization is associated with higher morbidity than the other methods [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Ectopic pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When pregnancy does occur, the risk that it will be an ectopic pregnancy is increased over that in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/69\">",
"     69",
"    </a>",
"    ]. One-third of post sterilization failures are ectopic. In the same cohort studied above [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/67\">",
"     67",
"    </a>",
"    ], the 10-year cumulative probability of ectopic pregnancy was 7.3 per 1000 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/70\">",
"     70",
"    </a>",
"    ]. Again, the risk was related to age and the type of procedure performed. Women who were under age 30 years at the time of sterilization were almost twice as likely as older women to have a subsequent ectopic pregnancy. Bipolar coagulation resulted in the highest probability of ectopic pregnancy (17.1 per 1000 procedures at 10 years after sterilization), postpartum partial salpingectomy the lowest (1.5 per 1000 procedures at 10 years after sterilization).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Reasons for sterilization failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Series of laparoscopic sterilization procedures performed on women who had previously been sterilized have found [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resection methods failed most frequently because of spontaneous reanastomosis or fistula formation. Pregnancies following fimbriectomy occurred because a remnant of fimbria ovarica was left and spontaneous reanastomosis occurred.",
"     </li>",
"     <li>",
"      Bipolar coagulation failures demonstrated intact serosa, coagulated muscularis, and a viable endosalpinx.",
"     </li>",
"     <li>",
"      Unipolar sterilization failures were found to have fistulas.",
"     </li>",
"     <li>",
"      Tubal ring failures showed lack of separation of the tubal segments with fistula formation.",
"     </li>",
"     <li>",
"      Operator failure occurred when the occluding device was placed on the round ligament. Proper identification of the fallopian tube is crucial to prevent inadvertent ligation of the round ligament or mesosalpingeal veins. Operator error also may include suboptimal location of the tubal occlusion, incomplete closure of a clip or incomplete encapsulation of the tube and lumen, or transection of the tube by a clip or coagulation thereby increasing the likelihood of spontaneous regeneration of the tubal lumen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Technical failures or failures associated with the equipment or the inability to complete the procedure by laparoscopy can also occur. Risk factors associated with technical failure include obesity, prior use of an intrauterine device, previous pelvic surgery, or preexisting gynecologic pathology or congenital anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Chromotubation",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is a method of transcervical injection of dye to assess tubal patency [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/75\">",
"     75",
"    </a>",
"    ]. A potential advantage of chromotubation at the time of sterilization is that if there is dye spill, corrective action can be taken to ensure tubal occlusion. However, a study of 500 consecutive women found there was no difference in the overall failure rate whether the patient did or did not undergo this procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/76\">",
"     76",
"    </a>",
"    ]. We do not recommend it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Other long-term issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large prospective studies have assessed the risk of hysterectomy after tubal sterilization. These have not shown an increased risk overall, but have reported a slightly higher rate of subsequent hysterectomy in women sterilized before age 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/18,77-81\">",
"     18,77-81",
"    </a>",
"    ]. The explanation in not clear, but may indicate a greater acceptance of surgical therapy for gynecologic complaints in this population.",
"   </p>",
"   <p>",
"    Virtually all studies have shown a reduced risk of ovarian cancer in women who have undergone tubal sterilization, with odds ratios of 0.3 to 0.9 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/2,82\">",
"     2,82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"     \"Epithelial ovarian cancer: Pathology\"",
"    </a>",
"    .) There is also a reduction in hospitalization for pelvic inflammatory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/83,84\">",
"     83,84",
"    </a>",
"    ], although the procedure does not protect against sexually transmitted diseases. A possible mechanism is that tubal sterilization limits the potential for upward migration of carcinogens and bacteria through the vagina, cervix, and fallopian tubes into the peritoneal cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women should be reassured that there is",
"    <strong>",
"     no",
"    </strong>",
"    evidence that bleeding or uterine cramping is increased due to sterilization [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. This was illustrated in a five year prospective study that compared 9514 women who underwent tubal sterilization and 573 women whose partners underwent vasectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/8\">",
"     8",
"    </a>",
"    ]. Women who underwent sterilization were more likely to have a reduction in the number of days of bleeding (odds ratio 2.4; 95 percent CI 1.1 to 5.2), the amount of bleeding (OR 1.5; 95 percent CI 1.1 to 2.0), and menstrual pain (OR 1.3; 95 percent CI 1.0 to 1.8); the incidence of intermenstrual bleeding and menstrual cycle length were similar in both groups. However, women who were sterilized described more cycle irregularity (OR 1.6; 95 percent CI 1.1 to 2.3).",
"   </p>",
"   <p>",
"    Sexual function appears to be unchanged or improved in women following sterilization [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. As an example, in a prospective study of over 4500 women who underwent interval tubal sterilization, almost all women reported no change in (80 to 82 percent), or increased (17 to 18 percent), sexual desire or pleasure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few data on other late effects of tubal ligation. Two observational studies, which included fewer than 100 women, suggested that surgical sterilization might be a risk factor for development of hot flashes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Postablation tubal sterilization syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postablation tubal sterilization syndrome refers to the development of severe, cyclic, unilateral or bilateral pelvic pain usually occurring five to ten months after an endometrial ablation performed in a woman with a previous tubal sterilization procedure. This is a newly described entity still under study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link\">",
"     \"An overview of endometrial ablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     MEDICOLEGAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to document operative findings carefully if you are asked to perform a repeat sterilization after a sterilization failure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/74\">",
"     74",
"    </a>",
"    ]. Photographs should be taken, if possible. The tube should be resected and sent to pathology to determine whether a fistula has formed. In addition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If an occluding method was used, the lengths of both segments of tube should be measured and the portion of the tube destroyed should be identified.",
"     </li>",
"     <li>",
"      If an electrocoagulation procedure was done, a Mallory trichrome stain can be performed to document the extent of previous coagulation.",
"     </li>",
"     <li>",
"      If a Hulka clip was applied, its placement should be documented. Two to 3 cm from the cornu and at a 90-degree angle to the tubal axis is correct placement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, avascular necrosis of tissue inside a clip or ring allows the tube to separate and may be associated with migration of the ring or clip from its original correct anatomic position [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/74,90,91\">",
"     74,90,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     TEACHING/LEARNING LAPAROSCOPIC STERILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incorrectly performed tubal sterilization will lead to a higher failure rate. Therefore, a certain knowledge base is necessary to ensure that the operator is familiar with the prescribed methods of sterilization [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. In one study, residents who were required to view an instructional videotape, read an accompanying monograph, and demonstrate their knowledge by completing a written test had a lower rate of sterilization failure among their patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/38\">",
"     38",
"    </a>",
"    ]. Of interest, when this same multiple choice test was administered to a group of practicing",
"    <span class=\"nowrap\">",
"     obstetrician/gynecologists",
"    </span>",
"    who routinely perform the procedure, none performed at the level required of the residents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/42/15018/abstract/94\">",
"     94",
"    </a>",
"    ]. This suggests that a formalized teaching module is helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/51/23346?source=see_link\">",
"       \"Patient information: Sterilization for women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/28/7620?source=see_link\">",
"       \"Patient information: Permanent sterilization procedures for women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thorough discussion of the risks, benefits, and alternatives to permanent sterilization should take place and informed consent obtained.",
"     </li>",
"     <li>",
"      Surgical sterilization is safe (complication rate less than 1 percent) and effective (overall 10-year probability of pregnancy 18.5 per 1000 procedures, but varies with type of procedure).",
"     </li>",
"     <li>",
"      Pregnancies occurring after tubal ligation are more likely to be ectopic. The rate of ectopic pregnancy is higher than that in women using other forms of contraception, but lower than in women not using any form of contraception.",
"     </li>",
"     <li>",
"      The procedure should be considered permanent. Reversal may be successful, but requires major surgery, is costly, and may not be covered by medical insurance. Regret after sterilization may be related to young age, conflicted feelings at the time of surgery, or a subsequent change in marital status.",
"     </li>",
"     <li>",
"      Laparoscopic sterilization techniques and sterilization by minilaparotomy have comparable safety and efficacy. The choice of method should be based upon the clinical situation and patient and physician preference.",
"     </li>",
"     <li>",
"      Sexual",
"      <span class=\"nowrap\">",
"       desire/function",
"      </span>",
"      and menses are not affected by the procedure; posttubal sterilization syndrome is not a real entity.",
"     </li>",
"     <li>",
"      Women who have undergone tubal ligation are less likely to develop ovarian cancer and pelvic inflammatory disease, but may have a slightly higher rate of future hysterectomy.",
"     </li>",
"     <li>",
"      Women with preexisting gynecologic conditions that are often treated hormonally, such as menorrhagia or irregular menses, may be better served by hormonal contraception.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/1\">",
"      Westhoff C, Davis A. Tubal sterilization: focus on the U.S. experience. Fertil Steril 2000; 73:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/2\">",
"      ACOG Practice bulletin no. 133: benefits and risks of sterilization. Obstet Gynecol 2013; 121:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/3\">",
"      Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993; 270:2813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/4\">",
"      DeStefano F, Huezo CM, Peterson HB, et al. Menstrual changes after tubal sterilization. Obstet Gynecol 1983; 62:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/5\">",
"      Bhiwandiwala PP, Mumford SD, Feldblum PJ. Menstrual pattern changes following laparoscopic sterilization with different occlusion techniques: a review of 10,004 cases. Am J Obstet Gynecol 1983; 145:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/6\">",
"      Bhiwandiwala PP, Mumford SD, Feldblum PJ. Menstrual pattern changes following laparoscopic sterilization: a comparative study of electrocoagulation and the tubal ring in 1,025 cases. J Reprod Med 1982; 27:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/7\">",
"      Gentile GP, Kaufman SC, Helbig DW. Is there any evidence for a post-tubal sterilization syndrome? Fertil Steril 1998; 69:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/8\">",
"      Peterson HB, Jeng G, Folger SG, et al. The risk of menstrual abnormalities after tubal sterilization. U.S. Collaborative Review of Sterilization Working Group. N Engl J Med 2000; 343:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/9\">",
"      Grubb GS, Peterson HB, Layde PM, Rubin GL. Regret after decision to have a tubal sterilization. Fertil Steril 1985; 44:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/10\">",
"      Henshaw SK, Singh S. Sterilization regret among U.S. couples. Fam Plann Perspect 1986; 18:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/11\">",
"      Phillips JM, Hulka JF, Hulka B, Corson SL. 1979 AAGL membership survey. J Reprod Med 1981; 26:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/12\">",
"      Allyn DP, Leton DA, Westcott NA, Hale RW. Presterilization counseling and women's regret about having been sterilized. J Reprod Med 1986; 31:1027.",
"     </a>",
"    </li>",
"    <li>",
"     Trussell, J, Guilbert, E, Hedley, A. Sterilization failure, sterilization reversal, and pregnancy after sterilization reversal in Quebec. Obstet Gynecol 2003; 101; 677.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/14\">",
"      Divers WA Jr. Characteristics of women requesting reversal of sterilization. Fertil Steril 1984; 41:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/15\">",
"      Winston RM. Why 103 women asked for reversal of sterilisation. Br Med J 1977; 2:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/16\">",
"      Jamieson DJ, Kaufman SC, Costello C, et al. A comparison of women's regret after vasectomy versus tubal sterilization. Obstet Gynecol 2002; 99:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/17\">",
"      Wilcox LS, Chu SY, Eaker ED, et al. Risk factors for regret after tubal sterilization: 5 years of follow-up in a prospective study. Fertil Steril 1991; 55:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/18\">",
"      Vessey M, Huggins G, Lawless M, et al. Tubal sterilization: findings in a large prospective study. Br J Obstet Gynaecol 1983; 90:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/19\">",
"      WHITACRE FE, LOEB WM, LOEB L. The time for postpartum sterilization; report of 150 cases; bacteriologic studies on the postpartum uterus. Am J Obstet Gynecol 1946; 52:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/20\">",
"      Rozier JR. Immediate postpartum tubal ligation. An intraumbilical approach. Am J Obstet Gynecol 1973; 117:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/21\">",
"      Lu T, Chun D. A long term follow-up study of 1,055 cases of postpartum tubal ligation. J Obstet Gynaecol Br Emp 1967; 74:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/22\">",
"      Black WP, Sclare AB. Sterilization by tubal ligation--a follow-up study. J Obstet Gynaecol Br Commonw 1968; 75:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/23\">",
"      Green LR, Laros RK Jr. Postpartum sterilization. Clin Obstet Gynecol 1980; 23:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/24\">",
"      MacKay AP, Kieke BA Jr, Koonin LM, Beattie K. Tubal sterilization in the United States, 1994-1996. Fam Plann Perspect 2001; 33:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/25\">",
"      Lipscomb GH, Spellman JR, Ling FW. The effect of same-day pregnancy testing on the incidence of luteal phase pregnancy. Obstet Gynecol 1993; 82:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/26\">",
"      Grubb GS, Peterson HB. Luteal phase pregnancy and tubal sterilization. Obstet Gynecol 1985; 66:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/27\">",
"      Sherman PA, Burigo JA. Comparison of laparoscopic Falope-Ring and minilaparotomy sterilization. Obstet Gynecol 1984; 63:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/28\">",
"      Kulier R, Boulvain M, Walker D, et al. Minilaparotomy and endoscopic techniques for tubal sterilisation. Cochrane Database Syst Rev 2002; :CD001328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/29\">",
"      Penfield AJ. Minilaparotomy for female sterilization. Obstet Gynecol 1979; 54:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/30\">",
"      Lee RB, Boyd JA. Minilaparotomy under local anesthesia for outpatient sterilization: a preliminary report. Fertil Steril 1980; 33:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/31\">",
"      Cheng MC, Wong YM, Rochat RW, Ratnam SS. Sterilization failures in Singapore: an examination of ligation techniques and failure rates. Stud Fam Plann 1977; 8:109.",
"     </a>",
"    </li>",
"    <li>",
"     Peterson, HB, Pollack, AE, Warshaw, JS. Tubal sterilization. In: Telinde's Operative Gynecology, 8th ed, Rock, JA, Thompson, JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 1997. p.529.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/33\">",
"      Irving, FC. A new method of insuring sterility following cesarean section. Am J Obstet Gynecol 1924; 8:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/34\">",
"      Fox MD, Long CA, Meeks GR, et al. Laparoscopic Pomeroy tubal ligation as a teaching model for residents. J Reprod Med 1994; 39:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/35\">",
"      Murray JE, Hibbert ML, Heth SR, Letterie GS. A technique for laparoscopic pomeroy tubal ligation with endoloop sutures. Obstet Gynecol 1992; 80:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/36\">",
"      Uchida H. Uchida tubal sterilization. Am J Obstet Gynecol 1975; 121:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/37\">",
"      Kroener WF Jr. Surgical sterilization by fimbriectomy. Am J Obstet Gynecol 1969; 104:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/38\">",
"      Stovall TG, Ling FW, Lipscomb GH, et al. A model for resident surgical training in laparoscopic sterilization. Obstet Gynecol 1994; 83:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/39\">",
"      PALMER R. [Not Available]. Gynecol Obstet (Paris) 1947; 46:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/40\">",
"      Rioux JE, Quesnel G, Blanchet J, et al. [Laparoscopy: tubal sterilization: 1000 cases and general evaluation of the method]. Union Med Can 1973; 102:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/41\">",
"      Yuzpe AA, Loffer FD, Pent D. Laparoscopic tubal sterilization by the \"burn only\" technic. Obstet Gynecol 1977; 49:106.",
"     </a>",
"    </li>",
"    <li>",
"     Soderstrom, RM. Electrical safety in laparoscopy. p. 306. In Philips JM (ed): Endoscopy in Gynecology. American Association of Gynecologic Laparoscopists Downey, CA, 1967.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/43\">",
"      Black WP. Sterilization by laparoscopic tubal electrocoagulation: an assessment. Am J Obstet Gynecol 1971; 111:979.",
"     </a>",
"    </li>",
"    <li>",
"     Poliakoff, SR, Yoon, IB, King, TM. A four year experience with the Yoon Ring. In Phillips JM (ed): Endoscopy in Gynecology. American Association of Gynecologic Laparoscopists, Downey, CA, 1978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/45\">",
"      Penfield AJ. The Filshie clip for female sterilization: a review of world experience. Am J Obstet Gynecol 2000; 182:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/46\">",
"      Kohaut BA, Musselman BL, Sanchez-Ramos L, Kaunitz AM. Randomized trial to compare perioperative outcomes of Filshie clip vs. Pomeroy technique for postpartum and intraoperative cesarean tubal sterilization: a pilot study. Contraception 2004; 69:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/47\">",
"      Dominik R, Gates D, Sokal D, et al. Two randomized controlled trials comparing the Hulka and Filshie Clips for tubal sterilization. Contraception 2000; 62:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/48\">",
"      Filshie GM, Casey D, Pogmore JR, et al. The titanium/silicone rubber clip for female sterilization. Br J Obstet Gynaecol 1981; 88:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/49\">",
"      Sokal D, Gates D, Amatya R, Dominik R. Two randomized controlled trials comparing the tubal ring and filshie clip for tubal sterilization. Fertil Steril 2000; 74:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/50\">",
"      Kovacs GT, Krins AJ. Female sterilisations with Filshie clips: what is the risk failure? A retrospective survey of 30,000 applications. J Fam Plann Reprod Health Care 2002; 28:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/51\">",
"      Daucher JA, Weber AM. Chronic abdominal pain after laparoscopic sterilization clip placement. Obstet Gynecol 2006; 108:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/52\">",
"      Handa, VL, Berlin, M, Washington, AE. A comparison of local and general anesthesia for laparoscopic tubal sterilization. J Women Health 1994; 3:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/53\">",
"      Mehta PV. A total of 250,136 laparoscopic sterilizations by a single operator. Br J Obstet Gynaecol 1989; 96:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/54\">",
"      Lipscomb GH, Stovall TG, Ramanathan JA, Ling FW. Comparison of silastic rings and electrocoagulation for laparoscopic tubal ligation under local anesthesia. Obstet Gynecol 1992; 80:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/55\">",
"      Fishburne JI Jr. Office laparoscopic sterilization with local anesthesia. J Reprod Med 1977; 18:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/56\">",
"      Penfield AJ. Laparoscopic sterilization under local anesthesia. 1200 cases. Obstet Gynecol 1977; 49:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/57\">",
"      Lipscomb GH, Summitt RL Jr, McCord ML, Ling FW. The effect of nitrous oxide and carbon dioxide pneumoperitoneum on operative and postoperative pain during laparoscopic sterilization under local anesthesia. J Am Assoc Gynecol Laparosc 1994; 2:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/58\">",
"      Lipscomb GH, Summitt RL Jr, McCord ML, Ling FW. Serum bupivacaine levels during laparoscopic sterilization using local anesthesia. J Am Assoc Gynecol Laparosc 1994; 2:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/59\">",
"      Benhamou D, Narchi P, Mazoit JX, Fernandez H. Postoperative pain after local anesthetics for laparoscopic sterilization. Obstet Gynecol 1994; 84:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/60\">",
"      LEE JG Jr, RANDALL JH, KEETTEL WC. Tubal sterilization; a review of 1,169 cases. Am J Obstet Gynecol 1951; 62:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/61\">",
"      Miesfeld RR, Giarratano RC, Moyers TG. Vaginal tubal ligation--is infection a significant risk? Am J Obstet Gynecol 1980; 137:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/62\">",
"      Smith RP, Maggi CS, Nolan TE. Morbidity and vaginal tubal cautery: a report and review. Obstet Gynecol 1991; 78:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/63\">",
"      Hartfield VJ. Female sterilization by the vaginal route: a positive reassessment and comparison of 4 tubal occlusion methods. Aust N Z J Obstet Gynaecol 1993; 33:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/64\">",
"      Hartfield VJ. Daycare Pomeroy sterilisation by the vaginal route. N Z Med J 1977; 85:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/65\">",
"      Khairullah Z, Huber DH, Gonzales B. Declining mortality in international sterilization services. Int J Gynaecol Obstet 1992; 39:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/66\">",
"      Jamieson DJ, Hillis SD, Duerr A, et al. Complications of interval laparoscopic tubal sterilization: findings from the United States Collaborative Review of Sterilization. Obstet Gynecol 2000; 96:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/67\">",
"      Peterson HB, Xia Z, Hughes JM, et al. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol 1996; 174:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/68\">",
"      Chi IC, Laufe LE, Gardner SD, Tolbert MA. An epidemiologic study of risk factors associated with pregnancy following female sterilization. Am J Obstet Gynecol 1980; 136:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/69\">",
"      McCausland A. High rate of ectopic pregnancy following laparoscopic tubal coagulation failures. Incidence and etiology. Am J Obstet Gynecol 1980; 136:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/70\">",
"      Peterson HB, Xia Z, Hughes JM, et al. The risk of ectopic pregnancy after tubal sterilization. U.S. Collaborative Review of Sterilization Working Group. N Engl J Med 1997; 336:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/71\">",
"      Soderstrom RM. Sterilization failures and their causes. Am J Obstet Gynecol 1985; 152:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/72\">",
"      Thompson BH, Wheeless CR. Failures of laparoscopy sterilization. Obstet Gynecol 1975; 45:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/73\">",
"      Chi I, Mumford SD, Laufe LE. Technical failures in tubal ring sterilization: Incidence, perceived reasons, outcome, and risk factors. Am J Obstet Gynecol 1980; 138:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/74\">",
"      Varma R, Gupta JK. Failed sterilisation: evidence-based review and medico-legal ramifications. BJOG 2004; 111:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/75\">",
"      Aubert JM, Garcia A. Improving Falope-Ring application in laparoscopy training. J Reprod Med 1987; 32:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/76\">",
"      Lipscomb GH, Stovall TG, Summitt RL Jr, Ling FW. Chromopertubation at laparoscopic tubal occlusion. Obstet Gynecol 1994; 83:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/77\">",
"      Cohen MM. Long-term risk of hysterectomy after tubal sterilization. Am J Epidemiol 1987; 125:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/78\">",
"      Stergachis A, Shy KK, Grothaus LC, et al. Tubal sterilization and the long-term risk of hysterectomy. JAMA 1990; 264:2893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/79\">",
"      Goldhaber MK, Armstrong MA, Golditch IM, et al. Long-term risk of hysterectomy among 80,007 sterilized and comparison women at Kaiser Permanente, 1971-1987. Am J Epidemiol 1993; 138:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/80\">",
"      Hillis SD, Marchbanks PA, Tylor LR, Peterson HB. Higher hysterectomy risk for sterilized than nonsterilized women: findings from the U.S. Collaborative Review of Sterilization. The U.S. Collaborative Review of Sterilization Working Group. Obstet Gynecol 1998; 91:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/81\">",
"      Taffe J, Green A, Dudley E, Dennerstein L. Tubal ligation, hysterectomy and D&amp;C: evidence from the Melbourne Women's Midlife Health Project. Gynecol Obstet Invest 2000; 50:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/82\">",
"      Narod SA, Sun P, Ghadirian P, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001; 357:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/83\">",
"      Abbuhl SB, Muskin EB, Shofer FS. Pelvic inflammatory disease in patients with bilateral tubal ligation. Am J Emerg Med 1997; 15:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/84\">",
"      Edelman DA. Pelvic inflammatory disease and contraceptive practice. Adv Contracept 1986; 2:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/85\">",
"      Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/86\">",
"      Costello C, Hillis SD, Marchbanks PA, et al. The effect of interval tubal sterilization on sexual interest and pleasure. Obstet Gynecol 2002; 100:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/87\">",
"      Smith A, Lyons A, Ferris J, et al. Are sexual problems more common in women who have had a tubal ligation? A population-based study of Australian women. BJOG 2010; 117:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/88\">",
"      Visvanathan N, Wyshak G. Tubal ligation, menstrual changes, and menopausal symptoms. J Womens Health Gend Based Med 2000; 9:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/89\">",
"      Carranza-Lira S, Murillo-Uribe A, Mart&iacute;nez-Trejo N, Santos-Gonz&aacute;lez J. Influence of previous bilateral partial tubal resection on symptoms, hormones, lipids, and bone density in postmenopausal women. Contraception 1997; 56:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/90\">",
"      Twigg J, Evans J. Spontaneous tubal re-canalisation: a late complication of Falope ring sterilisation. J Fam Plann Reprod Health Care 2001; 27:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/91\">",
"      Lok IH, Lo KW, Ng JS, et al. Spontaneous expulsion of a Filshie clip through the anterior abdominal wall. Gynecol Obstet Invest 2003; 55:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/92\">",
"      Stovall TG, Ling FW, Henry GM, Ryan GM Jr. Method failures of laparoscopic tubal sterilization in a residency training program. A comparison of the tubal ring and spring-loaded clip. J Reprod Med 1991; 36:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/93\">",
"      Stovall TG, Ling FW, O'Kelley KR, Coleman SA. Gross and histologic examination of tubal ligation failures in a residency training program. Obstet Gynecol 1990; 76:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/42/15018/abstract/94\">",
"      Lipscomb GH, Stovall TG, Ling FW. Basic laparoscopic knowledge among gynecologic laparoscopists. Am J Obstet Gynecol 1994; 171:1455.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3307 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_42_15018=[""].join("\n");
var outline_f14_42_15018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Regret after sterilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Timing of sterilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Luteal phase pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sterilization method",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MINILAPAROTOMY STERILIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pomeroy method",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pitfalls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Parkland (modified Pomeroy) method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Irving method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Uchida method",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pitfalls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other tubal sterilization techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      LAPAROSCOPIC STERILIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Bipolar electrocoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Banding procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Pitfalls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clips",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Pitfalls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Use of local anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      General technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COLPOTOMY STERILIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pitfalls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      HYSTEROSCOPIC STERILIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Reasons for sterilization failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Chromotubation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Other long-term issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Postablation tubal sterilization syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      MEDICOLEGAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      TEACHING/LEARNING LAPAROSCOPIC STERILIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3307\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3307|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/23/16752\" title=\"figure 1\">",
"      Pomeroy tubal ligation A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/55/31600\" title=\"figure 2\">",
"      Pomeroy tubal ligation B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/26/1441\" title=\"figure 3\">",
"      Pomeroy tubal ligation C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/30/12769\" title=\"figure 4\">",
"      Pomeroy tubal ligation D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/38/24161\" title=\"figure 5\">",
"      Irving tubal ligation A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/47/8945\" title=\"figure 6\">",
"      Irving tubal ligation B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/30/30176\" title=\"figure 7\">",
"      Irving tubal ligation C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/58/6049\" title=\"figure 8\">",
"      Irving tubal ligation D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/38/25185\" title=\"figure 9\">",
"      Irving tubal ligation E",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/17/8466\" title=\"figure 10\">",
"      Irving tubal ligation F",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/43/4785\" title=\"figure 11\">",
"      Irving tubal ligation G",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/4/9281\" title=\"figure 12\">",
"      Uchida tubal ligation A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/12/19652\" title=\"figure 13\">",
"      Uchida tubal ligation B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/54/34659\" title=\"figure 14\">",
"      Uchida tubal ligation C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/48/43779\" title=\"figure 15\">",
"      Madlender tubal ligation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/6/27750\" title=\"figure 16\">",
"      Oxford tubal ligation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/63/24560\" title=\"figure 17\">",
"      Kroener fimbriectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/36/24132\" title=\"figure 18\">",
"      Aldridge sterilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/11/25777\" title=\"figure 19\">",
"      Placement uterine manipulator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/14/42209\" title=\"figure 20\">",
"      Bipolar sterilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/19/30000\" title=\"figure 21\">",
"      Bipolar sterilization B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/14/18658\" title=\"figure 22\">",
"      Bipolar sterilization C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/8/32897\" title=\"figure 23\">",
"      Tubal ring sterilization A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/17/20752\" title=\"figure 24\">",
"      Tubal ring sterilization B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/27/9663\" title=\"figure 25\">",
"      Tubal ring sterilization C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/25/32159\" title=\"figure 26\">",
"      Hulka clip sterilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/4/17474\" title=\"figure 27\">",
"      Correct placement of Hulka clip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/41/9872\" title=\"figure 28\">",
"      Placement of second clip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/5/29777\" title=\"figure 29\">",
"      Infraumbilical skin block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/10/32929\" title=\"figure 30\">",
"      Diamond field block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/43/24242\" title=\"figure 31\">",
"      Vaginal tubal sterilization A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/42/15012\" title=\"figure 32\">",
"      Vaginal tubal sterilization B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/34/18977\" title=\"figure 33\">",
"      Vaginal tubal sterilization C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/0/5122\" title=\"figure 34\">",
"      Vaginal tubal sterilization D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/4/9280\" title=\"figure 35\">",
"      Vaginal tubal sterilization E",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3307|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/40/27271\" title=\"picture 1\">",
"      Cross section transected tube",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/19/309\" title=\"picture 2\">",
"      Cross section intact tube",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/50/15139\" title=\"picture 3\">",
"      Tubal bands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/28/15808\" title=\"picture 4\">",
"      Tubal ring with piston grip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/15/26864\" title=\"picture 5\">",
"      Grasping prongs of applicator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/19/13620\" title=\"picture 6\">",
"      Hulka Clemens clip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/45/32464\" title=\"picture 7\">",
"      Spring loaded clip applicator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3307|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/15/14587\" title=\"table 1\">",
"      Analgesia for sterilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/33/13851\" title=\"table 2\">",
"      Sterilization failure rates",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=related_link\">",
"      An overview of endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12665?source=related_link\">",
"      Hysteroscopic sterilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=related_link\">",
"      Management of hemorrhage in gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=related_link\">",
"      Overview of conventional gynecologic laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/28/7620?source=related_link\">",
"      Patient information: Permanent sterilization procedures for women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/51/23346?source=related_link\">",
"      Patient information: Sterilization for women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=related_link\">",
"      Reproductive surgery for female infertility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_42_15019="Neuro vs myopathy vs NMJ";
var content_f14_42_15019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of findings in neuropathy, myopathy, and NMJ disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neuropathy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Myopathy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neuromuscular junction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Typical distribution",
"       </td>",
"       <td>",
"        Distal &gt; proximal",
"       </td>",
"       <td>",
"        Proximal &gt; distal",
"       </td>",
"       <td>",
"        Diffuse (oculomotor and bulbar early)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reflexes",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Normal to decreased",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sensory involvement",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Asimos, AW. Weakness: A Systematic Approach to Acute, Non-traumatic, Neurologic and Neuromuscular Causes. Emergency Medicine Practice 2002; 4:1. Copyright &copy; 2002 EB Practice, LLC. All rights reserved. file://www.ebmedicine.net.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_42_15019=[""].join("\n");
var outline_f14_42_15019=null;
var title_f14_42_15020="Common teratogens";
var content_f14_42_15020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common teratogens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of teratogen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical phenotype",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"8\">",
"        Chemical",
"       </td>",
"       <td>",
"        Retinoic acid",
"       </td>",
"       <td>",
"        Hydrocephalus, microtia, CNS migrations defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thalidomide",
"       </td>",
"       <td>",
"        Limb reduction defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valproic acid",
"       </td>",
"       <td>",
"        Neural tube defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"       </td>",
"       <td>",
"        Dysmorphic features, nail hypoplasia, heart defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lithium",
"       </td>",
"       <td>",
"        Ebstein anomaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ACE inhibitors",
"       </td>",
"       <td>",
"        Renal and skull defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Misoprostol",
"       </td>",
"       <td>",
"        Fetal death, vascular disruptions (eg, terminal transverse limb defects)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DES",
"       </td>",
"       <td>",
"        Cervical cancer in female progeny",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Physical",
"       </td>",
"       <td>",
"        Ionizing radiation",
"       </td>",
"       <td>",
"        Fetal death, growth retardation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperthermia",
"       </td>",
"       <td>",
"        Microcephaly, ID, seizures",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Biological",
"       </td>",
"       <td>",
"        Cytomegalovirus",
"       </td>",
"       <td>",
"        Microcephaly, ID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxoplasmosis",
"       </td>",
"       <td>",
"        Microcephaly, ID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rubella",
"       </td>",
"       <td>",
"        Microcephaly, ID",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Maternal",
"       </td>",
"       <td>",
"        Diabetes",
"       </td>",
"       <td>",
"        CHD, NTD, sacral anomalies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenylketonuria",
"       </td>",
"       <td>",
"        Microcephaly, CHD, ID",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CHD: congenital heart disease; ID: intellectual disability; NTD: neural tube defects.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_42_15020=[""].join("\n");
var outline_f14_42_15020=null;
var title_f14_42_15021="Diuresis in minimal change";
var content_f14_42_15021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Time course of natriuresis during recovery from minimal change disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 248px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fractional excretion of sodium (FENa, percent), plasma creatinine concentration (PCr, mg/dL), plasma renin activity, and plasma albumin concentration (PAlb, g/dL) in patients with minimal change disease both before therapy and at the time of peak diuresis during corticosteroid-induced remission. The FENa rose, in association with reductions in the plasma creatinine concentration and plasma renin activity, and a minimal elevation in the plasma albumin concentration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Koomans, HA, Boer, WH, Dorhout Mees, EJ, Nephron 1987; 47:173.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_42_15021=[""].join("\n");
var outline_f14_42_15021=null;
var title_f14_42_15022="Candesartan prehypertension";
var content_f14_42_15022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Candesartan in prehypertension in TROPHY",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 263px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the TROPHY trial, 806 patients with prehypertension (systolic BP 130-139 mmHg and/or diastolic BP 80-89 mmHg) were randomly assigned to candesartan or placebo for two years; all patients were then continued on placebo therapy for another two years. The systolic pressure was significantly reduced in the candesartan group during the two years of active therapy, but returned to placebo levels within nine months of cessation of candesaran. Although not shown, similar findings were noted with the diastolic pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Julius, S, Nesbitt, SD, Egan, BM, et al, N Engl J Med 2006; 354:1685.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_42_15022=[""].join("\n");
var outline_f14_42_15022=null;
var title_f14_42_15023="Diabetic neuroarthropathy II";
var content_f14_42_15023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diabetic neuroarthropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph of the tibia and fibula in the same patient as the previous pictures. The patient had a spontaneous fracture of the right tibia and fibula three years previously, which had healed with bowing (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of LD Hordon, MD and Verna Wright, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_42_15023=[""].join("\n");
var outline_f14_42_15023=null;
